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ABSTRACT
Immobilization of white rhinoceros (Ceratotherium simum) is a fundamental 
procedure used in the conservation of this threatened megaherbivore and allows 
for the capture, translocation and treatment of individuals. Immobilization also 
allows scientific investigation, which facilitates protection of this species. The 
potent opioids, including etorphine, are the only class of drugs which allow for a 
rapid and reversible immobilization, which is essential in the capture of 
rhinoceros. However, immobilization is associated with changes in respiratory 
and cardiovascular function which can result in high morbidity and mortalities. I 
therefore investigated the cardiorespiratory pathophysiological effects of 
etorphine and azaperone; pharmacological agents most often used in rhinoceros 
immobilization, and examined the effectiveness of butorphanol, a mixed agonist- 
antagonist opioid, in limiting these adverse effects. Reducing morbidity and 
mortality risks through an increased understanding and moderation of drug- 
induced cardiorespiratory changes in immobilized rhinoceros will contribute to 
future successes in managing this species.
In my first study, ten healthy captive white rhinoceros including four males and 
six females ranging in age from 3.5 to 15 yr were immobilized for a total of 13 
procedures with etorphine plus azaperone, and administered butorphanol 
intravenously immediately after initial blood collection and physiological 
assessment. Respiratory and cardiovascular parameters, body temperature and 
arterial blood gases were monitored for 100 min. The results confirmed that 
severe hypoxaemia, hypercapnia, tachycardia and an increased alveolar-arterial 
(A-a) oxygen gradient occur in immobilized rhinoceros. Giving butorphanol 
appeared to decrease heart rate, increase arterial oxygen tension, and decrease the 
A-a gradient and respiratory rate. However as the study was observational, it 
could not be confirmed that these changes were caused by butorphanol. Despite 
the initial improvements in blood oxygen levels, the rhinoceros remained severely 
hypoxaemic and hypercapnic for the remainder of the procedure.
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To further investigate the cardiorespiratory effects of butorphanol in immobilized 
rhinoceros, a randomised cross-over study design was used. Six healthy sub-adult 
male white rhinoceros were subjected to four drug interventions: 1) etorphine 
intramuscularly; 2) etorphine plus azaperone intramuscularly; 3) etorphine 
intramuscularly and post-induction butorphanol intravenously; and 4) etorphine 
plus azaperone intramuscularly, and post-induction butorphanol intravenously. 
The results from this study demonstrated that hypoxaemia and hypercapnia in 
etorphine-immobilized rhinoceros were not predominantly a result of a decrease 
in respiratory minute volume, as has been proposed in previous studies. Rather, an 
increase in metabolic oxygen consumption and carbon dioxide production, 
associated with muscle tremors, is suggested as the primary cause. In addition, a 
high alveolar-arterial oxygen gradient may have contributed to hypoxaemia and 
possibly also hypercapnia in immobilized rhinoceros. Although, decreased minute 
ventilation was not the fundamental cause of hypoxaemia and hypercapnia, low 
arterial oxygen partial pressure (PaCb) and high arterial carbon dioxide partial 
pressure (PaCC>2) did not stimulate ventilation, probably as a consequence of 
opioid-induced central and peripheral chemoreceptor inhibition. Butorphanol 
administered post-induction in etorphine-immobilized rhinoceros resulted in a 
moderate improvement in blood gases, although hypoxaemia and hypercapnia 
persisted. My results support the idea that improvements in PaC>2 and PaC02 after 
butorphanol administration resulted from reduced muscle tremors, metabolic 
oxygen consumption and carbon dioxide production rather than improved minute 
ventilation.
Cardiovascular changes in etorphine-immobilized rhinoceros included 
hypertension and tachycardia. The inclusion of azaperone with etorphine in the 
immobilizing drug combination reduced blood pressure to below normotensive 
values; however, heart rate remained elevated. The administration of butorphanol 
was followed by a reduction in heart rate with no clinical effect on blood 
pressures in etorphine-immobilized rhinoceros. Similarly, butorphanol did not 
change blood pressure but reduced tachycardia in individuals immobilized with 
etorphine plus azaperone.
VIn summary, butorphanol administration reduced hypoxaemia and hypercapnia in 
immobilized white rhinoceros as a result of decreased muscle tremors and oxygen 
consumption. Reduced oxygen consumption may mitigate hypoxic and 
hypercapnic mortality risks associated with immobilization, especially in 
rhinoceros compromised due to old age, nutritional stress or disease. My findings 
indicate that butorphanol administration allows rhinoceros to be immobilized for 
extended periods, which facilitates clinical procedures in injured individuals or 
managing orphaned calves. The reduction in tachycardia suggests that 
butorphanol may have a myocardial oxygen-sparing effect and may lower the risk 
of an adverse outcome associated with immobilization.
My recommendations for the immobilization of white rhinoceros to reduce the 
morbidity and mortality risks associated with etorphine-induced respiratory and 
cardiovascular changes include azaperone administration in combination with the 
potent opioid. The inclusion of azaperone reduces hypertension in etorphine- 
immobilized rhinoceros. However, 1 suggest that lower azaperone doses be 
considered compared to those used in my studies to moderate the decrease in 
blood pressure and possible complications associated with reduced tissue 
perfusion. Butorphanol should be administered intravenously to etorphine plus 
azaperone-immobilized-rhinoceros as soon as possible after induction to limit 
increased opioid-induced metabolic effects and improve hypoxaemia and 
hypercapnia. The administration of butorphanol also has the advantage of 
reducing tachycardia with a potential myocardial oxygen sparing effect in 
immobilized-rhinoceros. Butorphanol should be administered in repeated doses (5 
to 10 x etorphine dose in mg) until limb muscle tremoring is reduced and possibly 
halted, and an elevated heart rate slows to less than 100 beats per minute or 
slower.
Future research should focus on improving alveolar gas exchange and reducing 
the sympathomimetic and hypermetabolic effects of the potent opioids in 
immobilized-rhinoceros, and not only just improving ventilation and blood 
pressure.
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1CHAPTER 1
Introduction
2South Africa, as in many other countries around the world, has in recent history 
suffered significant losses in numbers, distribution, and diversity of its wild 
mammals. The arrival of European colonists and increased agricultural 
requirements drastically changed animals’ habitats. Loss of suitable habitat, 
frequently compounded by excessive hunting and the introduction of non- 
indigenous diseases such as the Rinderpest panzootic of the late 19th century, 
resulted in the local extinction of some species (Joubert 2007; Thomson 2006). 
Hunting pressure is believed to have resulted in the extinction of the historical 
population of blue antelope (Hippotragus leucophaeus) (Kerley et al. 2009).
In the late-1800s, it was realized that without some form of protection, the natural 
heritage of the country would suffer irreparable damage, and this resulted in the 
proclamation of the area between the Sabie and Crocodile Rivers as a game 
reserve in 1889. This was the first step in the process which led to the 
establishment of the Kruger National Park in 1926 (Joubert 2007). Since this 
initial beginning, numerous national parks and provincial game reserves have 
been established throughout the country. There has also been a dramatic increase 
in the number of private game farms, many of which are used for commercial 
purposes including photographic safaris, hunting and breeding of endangered 
species (Van der Merwe & Saayman 2003). Although there has been an increase 
in land areas supporting wildlife, many of these are isolated either by distance, 
fences or, in some cases, regulatory disease control measures.
Requirements for species reintroductions into former ranges, management of non­
contiguous populations, capture and translocation of animals for commercial 
purposes, and captive breeding of “high-value” species has resulted in the 
development of wildlife chemical capture techniques (La Grange, Du Toit & Van 
Rooyen 2016). In mega-herbivores, including the southern white rhinoceros 
(Ceratotherium simum simurti), these techniques are based on the use of etorphine, 
a potent opioid, combined with either a tranquillizer or sedative. Although these 
drug combinations are commonly used in white rhinoceros immobilization, 
significant respiratory depression and cardiovascular perturbations occur
3(Boardman et al. 2014; Haw et al. 2014, 2015; Miller et al. 2013; Wenger et al. 
2007). As the white rhinoceros is listed as near threatened, with a dramatic 
escalation in poaching in recent years, it is essential that methods for mitigating 
these negative physiological consequences are investigated to improve the safety 
of capture procedures (Boardman et al. 2014; Emslie 2011). This chapter reviews 
the requirements for chemical restraint in white rhinoceros, historical 
development of currently used immobilizing drug combinations, and introduces 
the cardiorespiratory side-effects in immobilized rhinoceros and interventions 
used to manage them.
1.1 History of white rhinoceros chemical immobilization
Chemical capture of white rhinoceros is an essential procedure used for the 
conservation and management of this species (Haw et al. 2014). The initial 
impetus for developing capture and transport techniques, including immobilizing 
drug cocktails, was the requirement in the early 1960s to reintroduce this mega­
herbivore back into its former historical range from a single remaining population 
in South Africa (Condy 1964).
By 2004, the translocation of white rhinoceros had resulted in 293 additional 
separate populations with an estimated total population in excess of 10,000 
animals being established in South African state and municipal reserves, in other 
African countries, on private land and in zoological gardens across the globe 
(Friedman & Daly 2004; Rookmaaker 2000). According to the World Wildlife 
Fund (n.d.), the population had increased to over 20,000 individuals by 2014.
More recently, chemical immobilization has been used to combat a marked 
increase in poaching with rhinoceros captured for the removal of horns, 
implantation of identifying microchips or translocation to safer areas (Boardman 
et al. 2014; Bush et al. 2004; Kock et al. 1995). Chemical restraint is also 
essential for veterinary examination of individuals, performing medical 
procedures, reproductive interventions and collection of biological samples (Haw 
et al. 2015; Heard, Olsen & Stover 1992; Miller et al. 2013; Waltzer et al. 2000; 
Wenger et al. 2007). All southern white rhinoceros alive today are ultimately
4derived from stock originating in Hluhluwe-iMfolozi Park, KwaZulu-Natal. By 
the end of the 19th century, it is estimated this single population had been reduced 
to about 200 animals (Rookmaaker 2000). By the early 1960s, there were 
approximately 650 rhinoceros which occurred in this park or roamed on adjacent 
Crown land. These animals were vulnerable to ever-increasing land invasions by 
squatters and a lack of food due to potential drought. To safeguard these 
rhinoceros, it was decided that approximately 400 animals should be removed and 
translocated elsewhere (Harthoorn 1962).
The drug combinations used in immobilizing the first rhinoceros were based on 
diethyl-thiambutene (Themalon), a synthetic opioid, in various combinations with 
morphine, 1-hyoscine (Scopolamine), phencyclidine (Sernyl), and chlorpromazine 
(Largactil) (Anton-Stephens 1954; Brown & Laikin 2011; Cohen 1962; Haigh 
1990; Harthoorn 1962). Mean induction times were 15 to 20 minutes (min), and 
distances travelled between drug administration and immobilization ranged 
between 274 meters and 5.6 kilometers in the twelve animals initially darted. 
These times and distances would be considered unacceptable by today’s 
standards; however, all animals survived (Harthoorn 1962). Other disadvantages 
were that the Themalon had to be dissolved just prior to use and large volumes 
necessitated the use of large darts for an adult rhinoceros (Haigh 1990). Despite 
these early challenges, eight juvenile rhinoceros were subsequently captured in 
1962 with the same dose of Themalon, Scopolamine and Largactil and 
successfully translocated to Zimbabwe (Condy 1964).
The advent of etorphine (M99), a semi-synthetic molecule derived from thebaine, 
with a marked increase in potency compared to Themalon, allowed for use of 
much smaller volumes in the immobilization of large herbivores. The increase in 
potency, compared to morphine, is due to its molecular structure which has a 
greater affinity for opioid receptors and increased lipid solubility, allowing it to 
pass more effectively through the blood-brain-barrier (Haigh 1990). Etorphine is 
now the most commonly used opioid in the chemical immobilization of 
rhinoceros; although, it has been used in combination with various sedatives and
5tranquillizers (Burroughs et al, 2012b; Portas 2004). Early reports indicate the 
successful use of etorphine alone in the immobilization of captive rhinoceros for 
medical examination and treatment (Heard et al. 1992; Le Blanc et al 1987). 
Carfentanil, the most potent of the opioids, has been used to immobilize 
rhinoceros in the past; however, it is not commercially available in southern 
Africa (Portas 2004; Raath 1999).
By 1993, the drug cocktails used by the then Natal Parks Board had evolved from 
Themalon-based combinations to using etorphine and fentanyl in a ratio of 1: 10 
(mg) with hyoscine added. Fentanyl, a synthetic opioid, was included as it 
resulted in quicker and smoother inductions, and reduced muscle tremoring and 
rigidity in the immobilized animal. Hyoscine, a parasympatholytic, was purported 
to induce mydriasis with temporary blindness causing the animal to stop running 
sooner (Haigh 1990; Rogers 1993). Rogers (1993) also suggested that azaperone, 
a butyrophenone tranquillizer, could be incorporated into the immobilizing drug 
mixture, and some operators included hyaluronidase or dimethyl sulfoxide 
(DMSO) to improve drug absorption and reduce induction times. Hyaluronidase is 
an enzyme which breaks down hyaluronic acid between cells and DMSO is a 
carrier agent which promotes drug absorption (Burroughs, Meltzer & Morkel. 
2012a; Plumb 2008). Around this time in the Kruger National Park, etorphine plus 
azaperone was becoming the combination of choice. Hyoscine was not used due 
to the possible deleterious side-effects of parasympatholytic drugs, including 
tachycardia and extended gastrointestinal stasis (Brown & Laikin 2011; Hattingh, 
Knox & Raath 1994; Raath 1999).
In the mid-1990s, 141 free-ranging rhinoceros were immobilized in Zimbabwe as 
part of a conservation study using etorphine alone or combinations of etorphine 
with xylazine, fentanyl or detomidine. Hyaluronidase was added to all 
combinations to reduce induction times (Kock et al. 1995). Xylazine and 
detomidine are alpha (01)2 - receptor agonists resulting in sedation (Burroughs et 
al. 2012a). A significant difference between the immobilization of these animals 
and those in the early days of capture was a reduced average induction time of
6about 6 min compared to 15 to 20 min (Harthoorn 1962; Kock et al. 1995). 
Induction times greater than 6 min were considered to be a medical emergency 
due to the risks of hyperthermia and metabolic acidosis, associated with 
prolonged running. Etorphine plus detomidine was found to be the preferred 
combination as it resulted in a rapid and smooth induction, superior muscle 
relaxation, and absence of muscle rigidity and limb paddling. Heart rates in 
rhinoceros immobilized with etorphine and detomidine were also significantly 
lower compared to those in rhinoceros immobilized with the other drug 
combinations. However, it was noted that all combinations produced some degree 
of cardiovascular and respiratory system compromise (Kock et al. 1995).
In 2000, Radcliffe, Shannon & Childs (2000) reported the use of butorphanol, a 
mixed synthetic agonist-antagonist opioid, combined with azaperone for the 
chemical restraint of captive rhinoceros. The combination resulted in varying 
levels of neuroleptanalgesia, with some rhinoceros remaining standing and others 
becoming recumbent. The combination also allowed for minor surgical 
procedures. However, total volumes of both drugs were beyond the capacity of 
available darts and this combination was not tried on free-ranging individuals. 
Butorphanol has also been used in combination with etorphine, acepromazine and 
detomidine for chemical restraint with supplementary doses of both ketamine and 
xylazine administered intravenously (IV) in captive rhinoceros to facilitate 
reproductive evaluation, semen collection, and artificial insemination (Waltzer et 
al. 2000).
In the last ten years, etorphine plus azaperone has become the drug combination 
routinely used in the immobilization of boma-adapted and free-ranging white 
rhinoceros of both sexes and all ages (Boardman et al. 2014; Burroughs et al. 
2012b; Bush et al. 2004; Haw et al. 2014; Miller et al. 2013). Etorphine is 
commonly used as it has potent immobilizing effects so low volumes can be 
administered by dart. Azaperone has a synergistic effect and is added to the 
combination to reduce induction time and improve immobilization quality 
(Boardman et al. 2014; Portas 2004; Wenger et al. 2007). Onset of effects is rapid
7following drug administration and free-ranging rhinoceros darted from a 
helicopter become recumbent within approximately 4 to 7 min, and boma-housed 
rhinoceros within 5 to 6 min (Haw et al. 2015; Miller et al. 2013). Free-ranging 
rhinoceros are frequently given higher doses to ensure induction times are not 
prolonged (Miller et al. 2013). Midazolam, a benzodiazepine sedative which 
produces excellent muscle relaxation, has recently been investigated as an 
immobilizing drug cocktail adjunct (Van Zijll Langhout et al. 2016).
Potent opioids, such as etorphine, are the only class of drugs capable of inducing 
rapid and reversible immobilization in white rhinoceros (Haw et al. 2015). 
However, marked respiratory depression is a common side-effect and may lead to 
hypoxaemia, hypercapnia, acidaemia and complications associated with decreased 
tissue oxygenation (Boardman et al. 2014; Haw et al. 2014; Haw et al. 2015; 
Miller et al. 2013; Wenger et al. 2007). Cardiovascular effects of this potent 
opioid are less studied but include tachycardia and hypertension (Hattingh et al. 
1994; Heard et al. 1992; LeBlanc et al. 1987; Raath 1999; Waltzer et al. 2000). 
These potentially fatal complications have been managed in the past by the 
administration of partial opioid antagonists and tracheal oxygen insufflation 
(Burroughs et al. 2012b; Bush et al. 2004; Radcliffe & Morkel 2007; Radcliffe et 
al. 2000). Opioid partial antagonists that have been used include diprenorphine, 
nalbuphine and, more commonly, nalorphine (Bush et al. 2004; Portas 2004;
Raath 1999; Wenger et al. 2007). Due to limited and variable responses, and a 
lack of availability of some of these agents, especially nalorphine, butorphanol 
has recently become widely used as a partial antagonist to improve respiratory 
function (Haw et al. 2014; Miller et al. 2013).
The following chapters will review the physiology of respiration and 
cardiovascular control mechanisms, how these are influenced by etorphine and 
azaperone, and the management of cardiopulmonary side-effects, due to 
immobilization with the use of butorphanol emphasized.
81.2 Respiratory system
Breathing provides the body with oxygen for aerobic metabolism and eliminates 
carbon dioxide produced during the metabolism of organic compounds (Taylor & 
Weibel 1981). It requires continuous movement of skeletal muscles and consumes 
approximately 7% of metabolic output in animals at rest (Feldman, Del Negro & 
Gray 2013). Rhythmic contractions of the diaphragm, intercostal and abdominal 
muscles cause changes in lung volume and movement of air in and out of the 
respiratory airways (Bianchi, Danavit-Saubie & Champagnat 1995). The 
diaphragm, a defining characteristic of mammals, is an unusually powerful muscle 
involved in changing thoracic volume which allows for the high levels of 
ventilation required with increases in metabolism (Feldman et al. 2013; Feldman 
& Negro 2006).
1.2.1 Respiratory system control
Inspiration in the non-exercising animal is an active process with contraction of 
the diaphragm and external intercostal muscles to inflate the lungs, and expiration 
is passive as these muscles relax and the ribs return to their original position due 
to elastic recoil. As activity increases and consequently the metabolic demands, so 
expiration also becomes active with contraction of abdominal and internal 
intercostal muscles (Feldman et al. 2013). The brainstem produces efferent 
signals which generate and control the movements of breathing via motor neurons 
which innervate the various muscles involved in breathing (Bianchi et al. 1995; 
Rekling & Feldman 1998). These outputs are modulated by central and peripheral 
chemoreceptors which sense pH changes and blood oxygen and carbon dioxide 
levels, conscious inputs from the brain cortex, and sensory neurons within the 
lungs, muscles and blood vessels (Mitchell & Johnson 2003; Pattinson 2008).
The respiratory neural control system not only has to be highly robust as breathing 
is a continuous homeostatic process but also sufficiently flexible to accommodate 
rapid fluctuations in metabolic demand and other short-term perturbations 
including postural changes, suckling, swallowing, sniffing, chewing and
9vocalization (Bianchi et al. 1995; Mitchell & Johnson 2003; Smith et al. 2007). 
The system also needs to be sufficiently flexible to accommodate changed 
circumstances such as persistent hypoxia, injury, disease and aging (Mitchell & 
Johnson 2003).
The rhythm of inspiration and expiration is generated by a pontine-medullary 
respiratory network which coordinates the activity of spinal and cranial motor 
neurons (Smith et al. 2007). These neurons include the phrenic nerve which 
innervates the diaphragm, branches of the vagus nerve which supply the 
pharyngeal muscles and bronchial smooth muscle, recurrent laryngeal nerves of 
the larynx, and nerves arising from the spinal column which innervate the 
intercostal and abdominal muscles (Bianchi et al. 1995; Konig, Liebich & 
Cerveny 2009). Pharyngeal muscles are important in maintaining upper airway 
patency and laryngeal muscles regulate the diameter of the airway and resistance 
to airflow during inspiration and expiration (Haji, Takeda & Okazaki 2000). The 
glossopharyngeal nerve, hypoglossal nerve and branches of the facial and 
trigeminal nerves also take part in regulating muscle activity of the upper- 
respiratory tract during breathing (Bianchi & Gestreau 2009; Bianchi et al. 1995; 
Konig et al. 2009).
There are three essential phases of respiration: inspiration, in which respiratory 
muscles contract; post-inspiration, in which inspiratory muscles progressively 
stop contracting and adductor muscles of the upper airway reduce inhalation; and 
late expiration in which expiratory muscles contract. In breathing at rest, 
expiration can be passive and there will not be motor outputs (Bianchi & Gestreau 
2009; Haji et al. 2000; Koo & Eikermann 2011; Smith et al. 2007). The three 
phases correspond to phasic activity of respiratory neurons within the ventral 
respiratory column (VRC) located in the medulla. The VRC is modulated by the 
pons (Bianchi & Gestreau 2009; Haji et al. 2000; Koo & Eikermann 2011; Smith 
et al. 2007). It is believed that a rhythm generator is responsible for switching 
between the different respiratory phases, and a pattern generator shaping neuron 
activity (Haji et al. 2000).
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Three areas arranged rostro-caudally are found in the VRC: Botzinger complex 
(BotC), pre-Botzinger complex (pre-BotC) and rostral ventral respiratory group 
(rVRG) (Smith et al. 2007). A neuronal kernel consisting of a network of 
excitatory neurons with pacemaker properties located in the pre-BotC is believed 
to generate an inspiratory rhythm and is essential in normal breathing (Feldman et 
al. 2013; Smith et al. 2000). The hybrid pacemaker-network model of respiratory 
rhythm generation suggests that these pacemaker cells receive tonic excitatory 
inputs and are interconnected, creating synchronized discharges and establishing a 
basic oscillation. Inhibitory synaptic connections with the kernel regulate the 
shape, duration and interval between discharges to create the dynamic range of 
inspiratory and expiratory network activity required in respiration (Rekling & 
Feldman 1998; Smith et al. 2000). It is uncertain if only the pre-BotC pacemaker 
is responsible for generating respiratory rhythm or it is part of a collective of 
pacemaker neurons (Koo & Eikermann 2011). Motor output patterns of the 
phrenic nerve originate from and are driven by the pre-BotC (Smith et al. 2007). 
The BotC is a major source of expiratory activity in the respiratory network and 
provides phasic inhibition of pre-BotC inspiratory activity. Pontine activation of 
the BotC during inspiration provides strong modulation of the VRC and seems 
critical in rhythm and pattern generation (Smith et al. 2007)
With increased physical activity, there is a transition from passive to active 
expiration to increase ventilation in response to metabolic demands and it has 
been proposed that a group of neurons is responsible for driving expiration. 
Stimulation of a region, termed the retro-trapezoid nucleus/parafacial respiratory 
group (RTN/pFRG), nearby the pre-BotC, results in active expiration (Feldman et 
al. 2013). It is proposed the RTN/pFRG (expiration) interacts with the pre-BotC 
neurons (inspiration) as a coupled oscillator system in the regulation of respiratory 
rhythm (Feldman & Del Negro 2006; Koo & Eikermann 2011). Although the 
mechanism of activation is unknown, the RTN is involved in central 
chemoreception that regulates respiration depending on carbon dioxide levels in 
the blood (Smith et al. 2007). In expiration, regardless of the signal origin, there is 
a rapid decline in phrenic nerve activity, inspiratory airflow stops and expiratory
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airflow begins (Feldman et al. 2013). The pontine respiratory group, which 
includes the parabrachialis medialis and Kolliker-Fuse nucleus, is believed to be 
associated with respiratory volume control (Dahan, Aarts & Smith 2010).
Hypercapnia is the primary driver of respiration and the ventilatory response to 
hypoxia is considered a vital backup reflex. Respiratory rhythmogenesis and 
regulation of tonic drive to respiratory motor outputs is moderated by hypercapnic 
stimulation of central chemosensitive structures. A 1mm Hg partial pressure 
increase in carbon dioxide increases ventilation by 20% to 30% (Koo & 
Eikermann 2011). Multiple chemosensing areas located mostly within the brain 
stem make up the central chemoreceptor, and include the nucleus tractus solitarus 
(NTS), midline medullary raphe, pre-BotC and RTN/pFRG (medulla), locus 
coerulus (pons), and fastigial nucleus (cerebellum) (Haji et al. 2000; Pattinson 
2008). The contribution of these different areas in chemosensing may vary 
depending on the age and state (e.g., sleep-awake, rest-exercise) of an animal 
(Feldman et al. 2013). The mechanisms underlying central chemosensitivity are 
not fully understood. It is hypothesized that a distinct population of astrocytes 
sense changes in pH and control the activity of nearby chemosensitive neurons, 
including the RTN/pFRG, through the release of adenosine triphosphate (ATP) 
which in turn modulates respiration (Feldman et al. 2013). A decrease or increase 
in pH of the brain interstitial fluid, which bathes the central chemoreceptor 
increases or decreases ventilation, respectively. As carbon dioxide moves freely 
through the blood-brain barrier into the cerebrospinal fluid (CSF), increases in 
arterial carbon dioxide tension result in a decrease in pH following the formation 
of carbonic acid which dissociates into hydrogen and bicarbonate ions. As the 
CSF communicates directly with the interstitial fluid, this increase in acidity 
stimulates breathing (Robinson 2007).
Peripheral chemoreceptors, especially the carotid bodies, sense changes in arterial 
oxygen levels and relay this information to those areas of the brain regulating 
respiration (Prabhakar 2000). Carotid body Type 1 (glomus) cells are the primary 
sensors of hypoxia, resulting in impulses that travel via the carotid sinus branch of
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the glossopharyngeal nerve, which terminates almost exclusively in the NTS (Haji 
et al. 2000; Koo & Eikermann 2011; Pattinson 2008,). A direct link between the 
NTS and RTN facilitates modulation of respiration.
In humans, the carotid bodies are essential in mediating the hypoxic ventilatory 
response (Pattinson 2008). Hypoxia is thought to cause the release of an 
excitatory neurotransmitter from glomus cells, which results in an increased 
sensory discharge from afferent nerve endings with a haem and/or redox-sensitive 
enzyme and/or a K+ channel protein being the primary oxygen sensor. It is likely 
that additional sensory mechanisms become involved as the severity of hypoxia 
increases. It is proposed that inhibitory transmitters also released by glomus cells 
prevent over-excitation and assist in maintaining a sustained response during 
prolonged periods of hypoxia (Prabhakar 2000). Glomus cells also sense carbon 
dioxide and the response to hypoxia is influenced by arterial levels of carbon 
dioxide; a synergistic response between hypercapnia and hypoxia occurs 
(Pattinson 2008; Prabhakar 2000). In dogs, increased carbon dioxide in the carotid 
arteries excites expiratory neurons influencing the expiratory phase of respiration 
(Haji et al. 2000).
The Hering-Breuer reflex (HBR) prevents over-inflation of the lungs and 
primarily controls transition from inspiration to expiration. This reflex relies on 
slowly adapting stretch receptors in pulmonary tissue which are activated by lung 
inflation and transmit information to brainstem neurons controlling the duration of 
inspiration and expiration (Haji et al. 2000; Koo & Eikermann 2011). An active 
HBR limits inspiratory duration and tidal volume, and increases respiratory 
frequency (Koo & Eikermann 2011).
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1.2.2 Respiratory effects of immobilizing drugs
1.2.2.1 Opioids
Opioids include both opiates, which are derivatives of opium, and drugs that are 
synthetic or semi-synthetic agents but also act on opioid receptors. Opioids have 
been used extensively as analgesics in human medicine dating back several 
millennia, and since the early 20th century, by veterinarians, in treating a variety 
of conditions including colic in horses, coughs, and for analgesia (Feng et al. 
2012; Kukanich & Papich 2009).
Opioids act on an endogenous opioidergic system and their effects are mediated 
through three major opioid receptor families, mu-opioid receptor (MOR); delta- 
opioid receptor (DOR); and kappa-opioid receptor (KOR). A fourth receptor type 
is also recognized, nociception or orphanin FQ receptor or the opioid receptor-like 
orphan receptor. A sigma receptor has been suggested in the past but has since 
been disregarded due to a lack of sensitivity to the opioid antagonist naloxone 
(Feng et al. 2012; McDonald & Lambert 2005). Synthetic opioids have a 
relatively high selectivity to MOR, DOR and KOR, which are similar in their 
primary structures, function and intracellular signaling mechanisms (Feng et al. 
2012).
There is significant pharmacological evidence which supports the concept of 
multiple opioid receptor subtypes (MOR1.3, DOR 1.2, and KOR1.3) and that these 
subtypes are responsible for different clinical effects, e.g. MORi-subtype 
produces analgesia and MOR2-subtype produces respiratory depression. However, 
the molecular evidence for identification of subtype-specific genes to support this 
sub-classification of receptors is lacking (Dietis, Rowbotham & Lamber 2011; 
Feng et al. 2012).
Opioid receptors are classified as seven transmembrane spanning G-protein 
coupled receptors. Binding of opioid receptors results in the inhibition of adenylyl
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cyclase and a reduction in intracellular levels of cyclic adenosine mono-phosphate 
(cAMP). This reduction causes changes in neuronal cell polarization, reduction in 
impulse transmission and inhibition of neurotransmitter release (Boom et al.
2012; McDonald & Lambert 2005). Other intracellular signal pathways may be 
triggered resulting in activation or inhibition of various cellular proteins and 
signaling mechanisms, which could explain the multiple biological outcomes 
associated with opioid administration (Boom et al. 2012). It is possible that 
opioids have effects on receptors other than opioid receptors. Fentanyl has been 
shown to inhibit muscarinic (M)-receptor activation by acetylcholine, resulting in 
vasodilation (Koo & Eikermann 201 1).
Opioid receptors not only exist in the nervous system but also in peripheral 
organs, and the distribution of receptors and receptor types may vary between 
organs and different animal species (Feng et al. 2012). Opioid receptors are 
located in multiple components of the respiratory system. Both MORs and DORs 
are found in the respiratory control centres of the medulla and pons, and higher 
respiratory centres in the insula, thalamus and anterior cingulate cortex. Opioid 
receptors are also found in the vagal nerves and carotid bodies of the peripheral 
chemoreceptors, and mechanosensory receptors in the epithelium, submucosa and 
muscular layers of the airways (Koo & Eikermann 2011; Pattinson 2008).
MORs are located in the pre-BotC and administration of opioids suppresses pre- 
BotC activity (Boom et al. 2012; Pattinson 2008,). Those neurons are 
preferentially inhibited during inspiration (Koo & Eikermann 2011). Opioid 
activity at the parabrachialis medialis and Kolliker-Fuse nuclei in the pons is also 
thought to influence output from the pre-BotC and contribute to irregular 
respiratory rhythm. Activity of the RTN/pFRG is not influenced by the presence 
of opioids and studies suggest this group of neurons takes over respiratory rhythm 
generation when the pre-BotC becomes depressed, and contributes to the 
alteration in respiratory rhythm (Pattinson 2008). Opioids result in profound 
depression of the respiratory response to increased arterial carbon dioxide level 
(hypercapnic ventilatory response); a response primarily modulated by the central
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chemoreceptors. Peripheral chemoreceptor carotid body activity is inhibited by 
opioids and increased ventilation in response to hypoxia (hypoxic ventilatory 
response) is suppressed. The hypercapnic ventilatory response may also be 
influenced as glomus cells sense carbon dioxide (McDonald & Lambert 2005; 
Pattinson 2008). It has also been suggested that opioids may inhibit the NTS. 
which receives afferent inputs from the carotid bodies (Pattinson 2008).
As well as blunting the response of central and peripheral receptors to 
hypercapnia and hypoxia, opioids also decrease the central drive to the muscles 
which drive respiration and dilator muscles of the upper airways (Koo & 
Eikermann 2011). Opioid administration is associated with an increase in chest 
wall and abdominal muscle rigidity, and a decrease in phrenic nerve and 
diaphragmatic muscle activity, which contribute to a decrease in ventilation (Koo 
& Eikermann 2011). Inhibition of the hypoglossal motor neuron and reduced 
innervation of the genioglossus muscle can result in potentially fatal upper airway 
obstruction. Opioids influence the function of vagal laryngeal abductor and 
pharyngeal constrictor motor neurons, further contributing to upper airway 
resistance. Activity of the tongue can be suppressed centrally (Koo & Eikermann 
2011). Bronchoconstriction due to opioids may limit airflow within the respiratory 
tree and influence alveolar ventilation (Koo & Eikermann 2011).
Studies in “knockout’1 mice lacking MOR have confirmed that this group of 
receptors is largely responsible for mediating opioid-induced respiratory 
depression (Dahan et al. 2010). Opioids have less of a depressant respiratory 
effect at DOR and no effect when KOR is activated (McDonald & Lambert 2005; 
Feng et al. 2012). It also appears that interactions between the opioid receptors 
influence the extent of respiratory depression. For example, opioid activities at 
DOR and MOR are synergistic in suppressing respiration with no interaction 
occurring with the activation of both KOR and MOR (Feng et al. 2012). 
Pharmacological receptor binding studies have ascribed respiratory depression to 
the MOR2-subtype, and opioid-induced analgesia to the MORi-subtype; however, 
as indicated earlier, molecular cloning studies have only identified a single
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encoding gene for each of the main opioid receptor groups (Boom et al. 2012; 
Haji et al. 2000; McNally & Akil 2002).
Clinically, respiratory depression due to opioids is characterized by a bradypnoea 
and an irregular rhythm with a decrease in minute and tidal volumes resulting in 
hypercapnia and hypoxaemia (Boom et al. 2012; West 2008). Changes in 
respiratory rhythm and pattern tend to occur at lower opioid doses and a reduction 
in tidal volume as the dose increases (Pattinson 2008). At high opioid doses, 
apnoea and death may result (Feng et al. 2012).
Etorphine
Etorphine is an opioid agonist at MOR, DOR and KOR and is used extensively in 
the chemical capture of both captive and free-ranging herbivores (Branson & 
Gross 2001; Burroughs et al. 2012b; Haigh 1990; Yaksh & Wallace 2011). 
Etorphine is the only opioid currently used in the chemical capture of free-ranging 
white rhinoceros (Branson & Gross 2001). The principle side-effect of etorphine 
in immobilized wildlife is respiratory depression with both rate and minute 
volume affected (Haigh 1982). However, the degree of depression is dependent on 
species, dose rate and other drugs administered in combination (Burroughs et al. 
2 0 12b).
The high potency of etorphine compared to other opioids, allows for a sufficient 
dose to be delivered by dart in the immobilization of a wide variety of animals 
including the mega-herbivores. However, there are considerable differences in 
sensitivity between species with elephants, hippopotamus and rhinoceros 
considered more sensitive and equids less sensitive to etorphine. Doses per unit 
body mass of etorphine that result in immobilization in antelope vary widely 
between species (Burroughs et al. 2012b; Haigh 1990). Etorphine is seldom 
administered on its own, and usually combined with synergistic drugs to reduce 
the time from administration to recumbency and improve the quality of 
immobilization. Alpha2-adrenergic agonists (xylazine, detomidine and 
medetomidine) and butyrophenones (azaperone) have been used in combination
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with etorphine in the chemical capture of white rhinoceros (Haigh 1990; Kock et 
al. 1995; Miller et al. 2013; Wenger et al. 2007).
Butornhanol
Butorphanol is a synthetic mixed opioid agonist-antagonist analgesic agent which 
is pharmacologically related to the agonist-antagonist drugs pentazocine and 
buprenorphine (Gillis, Benfield & Goa 1995; Commiskey, Fan & Rockhold 2005; 
WHO Expert Committee on Drug Dependence 2006). The drug was originally 
used as an antitussive agent in dogs and more recently, it has been approved as an 
analgesic in cats and horses (Grimm & Lamont 2007).
Butorphanol binds to the three principle opioid receptors, MOR, DOR and KOR 
with an affinity ratio of 1:4:25, and produces complex effects due to either MOR 
antagonist or low-efficacy MOR agonist and KOR agonist activities (Commiskey 
et al. 2005; Haw et al. 2015; Vivian et al. 1999). The seemingly variable effects 
of butorphanol may in part be due to differences in affinities for and efficacies at 
the different opioid receptors (Vivian et al. 1999). Opioid receptor binding studies 
suggest that butorphanol has a moderate affinity and no activity at MOR, and high 
affinity and moderate activity at KOR (McCrackin et al. 1994).
Early studies suggested that butorphanol, as a mixed opioid agonist-antagonist, 
did not produce significant respiratory depressant effects due to a 'plateau or 
ceiling effect’; however, there is now contradictory evidence which suggests 
marked respiratory perturbations can occur (WHO Expert Committee on Drug 
Dependence, 2006). Respiratory effects of butorphanol are variable depending on 
species, dosage and presence of other drugs. For example, butorphanol in 
monkeys resulted in respiratory depression (Vivian et al. 1999); a dose of 0.4 
mg/kg IV did not alter cardiorespiratory function in the horse (Sellon et al. 2001); 
in detomidine-sedated horses, the addition of butorphanol decreased ventilation 
(Miller et al. 2013); in dogs, the central chemoreceptor threshold to carbon 
dioxide was raised (Plumb 2008); butorphanol (0.3 mg/kg IM) in rabbits reduced
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respiratory rate but there were no significant changes in arterial blood gas tensions 
(Schroeder & Smith 2011).
Butorphanol has been used in the past 10 years to selectively antagonize the 
marked respiratory depression that occurs in etorphine-immobilized white 
rhinoceros (Haw et al. 2014; Wenger et al. 2007). MOR2-subtype mediates 
respiratory depression and stimulation of KOR induces sedation as well as spinal 
analgesia (McCrackin et al. 1994). Etorphine as a pure opioid agonist acts on 
MOR (MORi and MOR2) and KOR resulting in respiratory depression and 
immobilization of the animal (Yaksh & Wallace 2011). Therefore, it was 
hypothesized that butorphanol would selectively antagonize the MOR2-subtype 
and thereby limit the adverse respiratory effects of etorphine; however, sedation in 
the immobilized rhinoceros would not be reversed due to the agonist activity at 
KOR (McCrackin et al. 1994; Wenger et al. 2007).
1.2.2.2 Butyrophenones
Azaperone and haloperidol are butyrophenones used as tranquillizers in wildlife. 
Azaperone is a short-acting drug, lasting 2 to 3 hours, and is frequently 
administered in combination with etorphine in the immobilization of rhinoceros. 
Haloperidol’s duration of clinical effect is up to 18 hours; however, due to the 
formation of precipitates, it cannot be mixed with etorphine (Burroughs et al. 
2012b; Swan 1993). Azaperone modifies behaviour in animals primarily by 
central dopamine (D) receptor blockade. Azaperone has been shown to bind with 
D2-receptors; however, it is uncertain if it binds with other dopamine receptors 
(Leysen & Gommeren 2008). This tranquillizer also has low binding affinities for 
other receptor types including a r , histamine (H)i-, 5-hydroxytryptamine- (5-HT-) 
and M3- receptors (Burroughs et al. 2012a; Lemke 2007).
Dopamine receptors are classified as Di-like receptors which include the D r and 
D5- subtypes, and D2-like receptors which include the D2-, D3- and D4- subtypes 
(Sugita et al. 2015). Dopamine binding at Dj-like receptors increases intracellular 
cAMP synthesis via stimulation of D-sensitive adenylate cyclase whereas D2-like
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receptors do not stimulate adenylate cyclase activity (Kolesnikova & 
Serebrovskaya 1998). D| receptors are found in multiple structures of the brain 
including the nucleus tractus solitarus (NTS) and locus coerulus of the central 
chemoreceptor and parabrachial nuclei of the pons (Haji et al. 2000; Iwase et al. 
2013; Pattinson 2008). The parabrachial complexes are thought to participate in 
respiratory volume control and respiratory phase transition (Dahan et al. 2010; 
Iwase et al. 2013; Koo & Eikermann 2011). D2-receptors are similarly found in 
various areas of the brain; however, they appear to have limited effects on the 
central respiratory neuronal network (Tsuchiya et al. 2011). Both Dp and 0 2- 
receptors are present in carotid bodies (Iwase et al. 2013, Tsuchiya et al. 2011).
Endogenous dopamine is believed to have significant respiratory modulation 
effects in both central respiratory neurons and peripheral carotid bodies (Lalley 
2008). Dopamine appears to be important in regulating respiration both at rest and 
during periods of exercise (Iwase et al. 2013). Several D-receptors are implicated, 
with binding of dopamine to Dp and D4-receptors slowing respiratory rhythm, 
and Dpreceptor activation centrally increasing the respiratory response to 
hypercapnia (Lalley 2008). D2-receptors may play a role in peripheral 
chemoreceptor function during periods of hypoxia (Tsuchiya et al. 2011).
It is reported that dopaminergic mechanisms are important in modulating 
respiration both centrally and peripherally (Hsiao, Lahiri & Mokashi 1989); 
however the role of dopamine in respiratory regulation is not conclusive.
Research indicates differences in outcomes between in vivo and in vitro studies, 
depending on dopamine dosage and route of administration, specific D-agonists or 
antagonists used, and species (Kolesnikova & Serebrovskaya 1998). For example, 
Hedner et al. (1982) concluded that in the CNS, dopamine has a tonic function in 
stimulating respiration, based on intracerebroventricular or systemic 
administration of D-agonists and antagonists in halothane-anaesthetized rats. 
However, Eldridge & Millhorn (1981) reported that CNS D-agonist activity may 
decrease respiratory frequency in rats. In cats, it has been reported that central 
antagonism of D-receptors decreases the respiratory response to hypoxia
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(Smatresk, Pokorski & Lahiri 1983). In part, the differences between studies may 
be explained by variations in D-receptor subtype within brain areas and between 
central and peripheral chemoreceptors; and the ability of certain D-agonists and 
antagonists to pass through the blood-brain-barrier (Zapata & Zuazo 1982).
Exogenously administered dopamine, which does not readily cross the blood- 
brain-barrier, appears to have an inhibitory function in peripheral chemoreceptors 
in the cat, dog, and goat, depressing ventilation in these species (Haji et al. 2000; 
Smatresk et al. 1983). This catecholamine has also been shown to negatively 
influence respiration in humans (Smatresk et al. 1983). The activity of dopamine 
at D2-receptors is believed to inhibit the hypoxic and hypercapnic responses of 
peripheral chemoreceptors in man and animals (Bascom et al. 1991). In contrast, 
in vitro studies suggest that dopamine is an excitatory neurotransmitter in the 
carotid bodies and natural stimuli such as hypoxaemia, hypercapnia or acidaemia 
result in dopamine release and increased activity of the carotid sinus nerve 
(Kolesnikova & Serebrovskaya 1998). It has been suggested that this excitatory 
effect is also mediated by D2-receptors, which illustrates the apparent complexity 
of dopamine functions in the peripheral chemoreceptors. It is possible that the 
observed differences in responses to endogenous and exogenous dopamine are 
due to D2- receptors with variable affinities for dopamine which occur extra-, pre-, 
or post-synaptically in carotid body glomus tissue. Depending on location, these 
receptors may also have different functions including autoregulation of dopamine 
release, explaining why relatively large doses of exogenous dopamine have an 
inhibitory effect (Kolesnikova & Serebrovskaya 1998).
Reports on respiratory effects due to butyrophenones are largely limited to 
haloperidol as it has been used to investigate the role of dopamine in modulating 
respiration (Hedner et al. 1982; Hsiao et al. 1989; Smatresk et al. 1983; Zapata & 
Zuazo 1982). Haloperidol is a lipophilic D-antagonist which can penetrate the 
blood-brain barrier and is frequently used for medium duration (8 - 1 2  hours) 
tranquillization in wildlife (Burroughs et al. 2012a; Hsiao et al. 1989).
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Butyrophenones appear to result in transient improvements in respiratory function 
with increases in respiratory minute volume, tidal volume and, or, respiratory rate. 
However, these improvements are variable between species with no response to 
haloperidol observed in humans, an increase in respiratory rate in dogs and cats, 
and improved ventilation in awake hypoxic goats and anaesthetized rabbits 
(Smatresk et al. 1983; Zapata & Zuazo 1982). Reflex respiratory adjustments to 
changes in blood gases, for example, fluctuations in arterial carbon dioxide partial 
pressure, are believed to limit the duration of haloperidol-induced respiratory 
improvements (Zapata & Zuazo 1982). Butyrophenones appear to augment 
peripheral chemosensory drive by blocking inhibitory D-receptors which are 
normally tonically activated by the continuous release of endogenous dopamine. 
This effect may be reinforced by the unmasking of excitatory D-receptors in the 
glomus tissues which are no longer inhibited by endogenous dopamine (Zapata & 
Zuazo 1982). Results in anaesthetized cats suggest that although haloperidol 
stimulates carotid chemoreceptor activity, it reduces the ventilatory response to 
hypoxia but not to hypercapnia (Hsiao et al. 1989; Smatresk et al. 1983). It was 
concluded that haloperidol prevents the central integration of peripheral 
chemoreceptor activity, despite being increased, resulting in an attenuated 
hypoxic respiratory response. The central respiratory response to increased carbon 
dioxide is unchanged following haloperidol administration (Smatresk et al. 1983).
Activation of respiratory system Hi-receptors has been shown to increase 
pulmonary resistance and influence ventilation distribution (Ahmed et al. 1980).
In rats, the depletion of central 5-HT results in a substantial and sustained 
hyperventilation and 5-HT precursors depressed respiratory rate, resting 
respiratory minute volume and ventilation response to PaCOi in cats (Armtjo & 
Florez 1974; Olson, Dempsey & McCrimmon 1979). M3-receptors on airway 
smooth muscle mediate the contraction of airways in animals and humans (Fryer 
& Jacoby 1998).
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Azaperone
Azaperone is an antagonist at D-receptors and has some activity blocking 
peripheral ai-receptors (Burroughs et al. 2012a). Azaperone is partially 
metabolized to azaperol, which has 4 -3 0  times reduced pharmacological activity 
(Mestorino et al. 2013). Azaperone is frequently combined with etorphine as an 
opioid synergist in the immobilization of wildlife and in recent years, this drug 
combination has been used extensively in white rhinoceros (Portas 2004). 
Azaperone is reported as having little effect on pulmonary function (Lemke 
2007). In domestic equids, azaperone results in insignificant changes to arterial 
blood pH, and oxygen and carbon dioxide tensions; however, changes in 
respiratory rate are equivocal with both an increase or a decrease reported (Lees & 
Serrano 1976; Serrano & Lees 1976). Improvements in ventilation may occur in 
pigs, horses, and humans due to azaperone and it has been suggested that 
azaperone may inhibit respiratory depression due to opioids and general 
anaesthetics (Radcliffe et al. 2000).
1.2.3 Respiratory effects of immobilizing drugs in white rhinoceros
Early reports in the literature indicate that opioid-immobilized white rhinoceros 
experienced adverse respiratory effects. Keep (1971) first proposed respiratory 
depression resulting from etorphine in rhinoceros; increased respiration was 
consistently observed in etorphine-immobilized rhinoceros following the 
administration of the opioid antagonist cyprenorphine. A report on an adult 
captive bull white rhinoceros immobilized with 2.8 mg etorphine indicated a 
resulting respiratory rate of 15 to 20 breaths per min (LeBlanc, 1987). This rate is 
similar to 16 to 23 breaths/min reported for standing, unrestrained captive white 
rhinoceros, however, the dose of etorphine used by LeBlanc (1987) was low 
compared to those currently used in adult male rhinoceros (Burroughs et al.
2012b; Citino & Bush 2007). Heard et al. (1992) reported a much lower 
respiratory rate, 2 to 6 breaths/min, in a captive adult female animal administered 
multiple etorphine doses, both IM and IV (total dose 2.75 mg), over 165 min. This 
immobilized individual was also hypercapnic (PaCCL = 69 mm Hg) and 
hypoxaemic (PaC>2 = 61 mm Hg). Hypoventilation, ventilation/perfusion
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mismatching, shunting and lung atelectasis were proposed as possible 
contributing factors.
Arterial blood gas values similar to those in captive rhinoceros were recorded in 
early reports for free-ranging animals darted from a helicopter and immobilized 
with a combination of etorphine and azaperone (PaCC>2 = 68 mm Hg; PaCE = 57 
mm Hg). Etorphine-induced respiratory depression was proposed as the cause of 
the abnormal blood gas values, since a similar effect had been recognized in other 
species (Hatting and Knox 1994). Kock et al. (1995) evaluated several drug 
combinations in the capture of 141 free-ranging white rhinoceros, including 
etorphine alone or in combination with fentanyl, xylazine or detomidine. The 
inclusion of azaperone with etorphine in the drug mixture was not assessed. 
Respiratory frequency was considered normal (8 to 12 breaths/min) for an 
immobilized rhinoceros; however, this was lower than for a non-immobilized 
animal (16 to 23 breaths/min) (Citino & Bush 2007). Respiration was also 
subjectively evaluated as shallow in animals immobilized with etorphine alone or 
the combinations. In some rhinoceros, especially large cows and bulls, there was 
a progressively worsening hypoxaemia, detected by cyanosis of arterial blood 
samples. All drug combinations resulted in mortalities (total = 5) including a 
single death in an animal immobilized with etorphine alone. It was concluded that 
hypoventilation and hypoxaemia contributed to the mortalities. Other contributing 
factors may have been pressure on the diaphragm associated with a large digestive 
tract, pulmonary shunting and progressive lung atelectasis. Etorphine-induced 
sympathetic stimulation resulting in peripheral vasoconstriction, tachycardia and 
muscle tremors may also have contributed to the apparent hypoxaemia (Kock et 
al. 1995).
In a review article, Portas (2004) suggested that respiratory depression in 
immobilized white rhinoceros was common and etorphine dose-dependent. A list 
of potential causes of hypoxaemia and hypercapnia included hypoventilation, 
pulmonary shunting, ventilation-perfusion mismatching, lung atelectasis and
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thoracic muscular rigidity. Portas (2004) proposed that increased thoracic 
muscular rigidity reduced respiratory excursions.
Bush et al. (2004) reported that free-ranging white rhinoceros darted with 
etorphine and azaperone from a helicopter, then administered nalorphine and/or 
doxapram IV once immobilized, experienced severe hypoxaemia (35 ± 9 mm Hg) 
and moderate hypercapnia (62 ± 12 mm Hg). They postulated that the low arterial 
oxygen partial pressure was due to the higher opioid doses required to reduce 
induction times under field conditions, sensitivity of rhinoceros to etorphine, 
physiological alterations associated with recumbency in a large animal, and 
development of a ventilation/perfusion mismatching. The immobilized rhinoceros 
were also acidotic (pH = 7.171 ± 0.073) due to a combination of both metabolic 
and respiratory acidosis. The metabolic acidosis was probably due to lactic acid 
accumulation as a result of muscle activity prior to and after the helicopter chase 
associated with darting, and hypoxaemia during recumbency. The administration 
of nalorphine, an opioid agonist-antagonist used to lighten opioid immobilization 
and improve respiration, was shown to have a negligible effect. Impaired 
pulmonary gas exchange was suggested by Fahlman, Foggin & Nyman (2004) as 
the cause of hypoxaemia and hypercapnia in free-ranging rhinoceros immobilized 
with etorphine, azaperone and detomidine.
In 2007, the first report on the use of butorphanol to mitigate the adverse 
cardiopulmonary effects associated with immobilizing drugs in white rhinoceros 
was published (Wenger et al. 2007). Butorphanol was added to the immobilizing 
drug combination of etorphine, azaperone and detomidine in the dart. It was 
hypothesized that butorphanol, a MOR antagonist and KOR agonist, would 
attenuate respiratory depression due to MOR activation associated with etorphine. 
However in the study, butorphanol was found to have no beneficial effects when 
compared to control animals and both groups showed respiratory and metabolic 
acidosis, hypoxaemia and hypercapnia. The study indicated that hypoventilation 
combined with an elevated alveolar to arterial oxygen partial pressure gradient 
(P(A-a)0 2) was the most probable cause of a low PaC>2. PaC>2 values were higher
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and P(A-a)C>2 gradients lower in calves compared to in older animals, and those in 
sternal compared to lateral recumbency. The differences between age groups may 
have reflected the variation in body size and, therefore, the size of the digestive 
tract, and the impact this may have had on pulmonary shunting (Wenger et al. 
2007).
Miller et al. (2013) compared cardiorespiratory effects in free-ranging rhinoceros 
between butorphanol added to the dart and butorphanol administered IV once 
etorphine-azaperone immobilized rhinoceros became recumbent. These animals 
were darted from the air after a brief chase. Rhinoceros administered butorphanol 
in the dart took longer to come to a standstill after darting; however, they did not 
run further compared to the animals in the butorphanol IV group. It was proposed 
that the intensity of exercise was less in these animals resulting in decreased lactic 
acidosis and hyperthermia. Rhinoceros given butorphanol in the dart also tended 
to remain standing once immobilized and this position, compared to lateral 
recumbency, is believed to have facilitated ventilation. Intravenous butorphanol 
administration reduced tachycardia and hypercapnia in the recumbent rhinoceros. 
However, the decrease in hypercapnia was not associated with an improvement in 
hypoxaemia, suggesting improved ventilation but possibly a decrease in oxygen 
diffusion. Alternative explanations given for the increased PaCC>2 and lack of 
change in PaCK were ventilation / perfusion mismatching associated with 
recumbency and increased tissue oxygen demand following the exertion of 
capture. It was also hypothesized that butorphanol may cause muscle relaxation 
and reduced carbon dioxide production in immobilized rhinoceros. It was 
concluded that butorphanol improved metabolic rather than respiratory parameters 
in immobilized rhinoceros (Miller et al. 2013).
Boardman et al. (2014) reported contradictory results in that butorphanol IV in 
etorphine-azaperone immobilized semi-captive rhinoceros (not chased and darted 
from a stationary vehicle) resulted in improved PaCC>2, PaCT and SaCT, and a 
reduction in pH. However, the rhinoceros were still more hypoxaemic (PaCT =
45.03 mm Hg) compared to rhinoceros prior to butorphanol administration in the
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studies by both Wenger et al. (2007) (PaC>2 = 58.9) and Miller et al. (2013) (PaCT 
= 50.95 mm Hg). The differences in arterial oxygen values between these studies 
were possibly due to increased body mass in supplementary-fed compared to free- 
ranging animals, differences in butorphanol to etorphine ratios administered IV or 
included in the dart, and reduced exertion in the rhinoceros as they were darted 
from a vehicle rather than a helicopter. This study also found that blood oxygen 
values (PaO? and SaC^) were marginally improved in immobilized rhinoceros 
placed in sternal compared to lateral recumbency due to an apparent improvement 
in pulmonary ventilation (Boardman et al. 2014).
Haw et al. (2014, 2015) reported on the effects of butorphanol IV in etorphine- 
azaperone immobilized rhinoceros either habituated to captivity or free-ranging. 
Both groups of animals were administered similar dosages of both immobilizing 
drugs and butorphanol. Captive rhinoceros developed severe hypoxaemia (PaCK = 
27 mm Hg), hypercapnia (PaCC>2 = 82 mm Hg) and acidosis (pH = 7.26) within 
20 min of darting. The authors suggested that the increased PaCCT indicated the 
hypoxaemia was predominantly due to hypoventilation. Other proposed factors 
contributing to the decrease in Pa02 included ventilation-perfusion mismatch, 
intrapulmonary shunts and increased alveolar dead space ventilation associated 
with recumbency. However, the primary cause of respiratory depression was 
believed to be due to opioid-induced respiratory depression. The administration of 
butorphanol IV improved both oxygen and carbon dioxide blood gas values 
suggesting an improvement in ventilation, although the animal remained 
hypoxaemic (PaC>2 = 60 mm Hg) and hypercapnic (PaCCT = 67 mm Hg) (Haw et 
al. 2014). In immobilized free-ranging rhinoceros, initial PaOo (35.4 mm Hg) 
values were similar to the captive animals; however, PaCC>2 (63 mm Hg) was not 
as elevated and yet the animals were more acidaemic (pH = 7.10). These results 
suggested that field-immobilized rhinoceros ventilated better than did their boma- 
immobilized counterparts, but developed a metabolic acidosis due to increased 
activity associated with helicopter darting. It was also hypothesized that an 
increase in psychological and physiological stress associated with this type of 
capture resulted in decreased diffusion of oxygen from ventilated alveoli to
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perfusing blood due to sympathetic-induced pulmonary hypertension, pulmonary 
oedema and congestion (Haw et al. 2015).
1.3 Cardiovascular system
The primary function of the cardiovascular system is the transport of metabolic 
substrates required by tissues and the removal of metabolic waste products. It is 
essential that the various organ systems receive sufficient oxygen, glucose, amino 
acids, fatty acids, water, essential electrolytes, and various hormones to meet 
metabolic demands. The by-products of cellular activity, including carbon 
dioxide, lactic acid and nitrogenous wastes, have to be removed, metabolized, 
recycled and in some cases excreted from the body. The system must be able to 
both continuously meet homeostatic requirements of all tissues and adapt rapidly 
to changes in organ perfusion requirements in times of increased metabolic 
activity (Stephenson 2007).
1.3.1 Cardiovascular system control
Perfusion pressure, difference between the mean aortic blood pressure and venous 
caval blood pressure, is the driving force which circulates blood through the 
systemic circulation. As central venous pressure in the vena cava near the right 
atrium of the heart is low (3-8 mm Hg), the mean arterial blood pressure and mean 
aortic blood pressure are often considered to be equivalent (Stephenson 2007). 
Mean aortic blood pressure is determined by cardiac output and total peripheral 
resistance (Guyenet 2006). Cardiac output is made-up of two components; stroke 
volume (blood volume ejected by the left ventricle each cardiac cycle) and heart 
rate (number of cardiac cycles per minute) (Muir 2007). Stroke volume is the 
difference between ventricular end-diastolic volume and ventricular end-systolic 
volume (Stephenson 2007).
Ventricular end-diastolic volume is influenced by ventricular preload, duration of 
diastole and ventricular compliance. The amount of ventricular filling that occurs 
during diastole determines preload or pressure within the ventricle, and depends
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on venous return to the heart. Cardiac venous return is influenced by factors such 
as compression of veins due to muscle activity, the pressure differential between 
the thorax and abdomen associated with respiration, and sympathetic constriction 
of large veins. These factors facilitate the return of blood to the heart within the 
venous system (Guyenet 2006; Stephenson 2007).
The duration of diastole will also influence the degree of ventricular filling. The 
ventricles relax and fill with venous blood during diastole; however, with 
increasing heart rates, the diastolic period is reduced, limiting the time available 
for ventricular filling. In humans, at heart rates higher than 160 beats / min, there 
is insufficient time for complete ventricular filling and a reduction in stroke 
volume, cardiac output and mean aortic blood pressure results. To ensure 
sufficient time for ventricular filling during periods of increased metabolic 
demands, the ventricles take less time to contract and contract with greater force 
due to increased sympathetic nervous system activity. The sympathetic system 
both innervates individual myocardial cells and the sino-atrial and atrial- 
ventricular nodes, and releases adrenaline and noradrenaline from the adrenal 
medulla into circulation. These catecholamines and noradrenaline released from 
sympathetic neurons act on myocardial beta (P)i -adrenergic receptors with 
positive chronotropic, inotropic, dromotropic and lusitropic outcomes. The net 
effect is the maintenance of diastole to allow for sufficient ventricular filling. 
Ventricular compliance is the ease with which the ventricle walls stretch to 
accommodate the preload, and a healthy heart is able to accommodate the normal 
end-diastolic ventricular volume (Stephenson 2007).
Ventricular-end systolic volume depends on the contractility of the ventricles, and 
an increase in contractility results in an increased stroke volume for any end- 
diastolic volume. As discussed above, sympathetic nerve activity increases 
ventricular contractility (Stephenson 2007).
Total peripheral resistance, a component of mean arterial pressure, is determined 
by vascular resistance to blood flow of which vessel radius, especially of
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arterioles, is the primary moderator. Arterioles contain smooth muscle, and by 
contraction or relaxation, alter resistance to blood flow within the systemic 
system. Vasoconstriction increases resistance and decreases blood flow and 
vasodilation has the opposite effect (Stephenson 2007).
Arteriolar resistance in controlled by two mechanisms; intrinsic mechanisms 
which are metabolic in origin and extrinsic mechanisms which are nerve and 
hormone dependent (Janssen & Smits 2002). The intrinsic mechanism dominates 
over the extrinsic mechanism in tissue critical to an animal’s survival 
(myocardium, brain and exercising skeletal muscle) (Stephenson 2007). Cellular 
metabolic products, such as potassium, carbon dioxide, adenosine and lactic acid, 
cause arteriolar smooth muscle to relax resulting in vasodilation with increased 
perfusion of metabolizing tissue cells (Muir 2007). This increased blood flow 
removes metabolic products, and delivers oxygen and metabolic substrates 
(Stephenson 2007).
The neurohumoral or extrinsic mechanism includes the autonomic (sympathetic 
and parasympathetic) nervous system, and adrenaline and noradrenaline released 
from the adrenal medulla. The autonomic nervous system tends to produce 
cardiovascular responses which can be large in magnitude but generally of short 
duration. The release of adrenaline and noradrenaline into circulation by the 
adrenal medulla has effects complimentary to those of sympathetic nervous 
stimulation but of longer duration (Muir 2007). The neurohumoral mechanism 
primarily controls blood flow to non-critical organs, and influences heart rate and 
stroke volume in regulating cardiac output.
Noradrenaline released from sympathetic neurons, and circulating adrenaline and 
noradrenaline released from the adrenal medulla, interact with adrenergic 
receptors differentially distributed in the various organs. Alpha] - and 012-  
adrenergic receptors occur on arterioles of all body organs and abdominal veins 
(Stephenson 2007). Alpha2-adrenergic effects predominate in veins compared to 
arteries (Muir 2007). Alphas- and a iD-adrenergic receptors are the prime
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mediators of sympathetic arterial smooth muscle contraction (Janssen & Smits 
2002). The major effect is to increase total peripheral resistance and maintain 
perfusion pressure to non-vasoconstricted organs (Stephenson 2007). The 
constriction of abdominal veins assists with venous blood return to the heart to 
increase ventricular preload.
Catecholamine stimulation of pi-receptors located on myocardial cells increases 
the rate and force of ventricular contraction, increasing heart rate, stroke volume 
and cardiac output (Janssen & Smits 2002). Beta2-adrenergic receptors in blood 
vessels are not innervated by the sympathetic nervous system, but rather respond 
to circulating catecholamines (Muir 2007). Adrenaline and noradrenaline activate 
P2-receptors on coronary and skeletal muscle arterioles increasing blood flow in 
both these tissues. Beta2-vasodilation takes preference over a-vasoconstriction 
(Stephenson 2007). The parasympathetic nervous system decreases heart rate and 
cardiac output through stimulation of M2-receptors located primarily in the sino­
atrial and atrio-ventricular nodes, and atria (Janssen & Smits 2002). This system 
also inhibits the release of noradrenaline from sympathetic neurons innervating 
the ventricles (Stephenson 2007). Stimulation of the parasympathetic nervous 
system has minimal effects on most peripheral blood vessels (Muir 2007).
Central cardiovascular control is integrated between multiple regions. 
Hypothalamic centres modulate cardiovascular responses in the fight-or-flight 
response, with body temperature changes, and during exercise. The cerebral 
cortex influences cardiovascular responses to exercise, emotion, ischaemia and 
hypoxia (Muir 2007). The nucleus tractus solitarius in the medulla is a principle 
centre for circulatory control and receives input from arterial baroreceptors, 
volume receptors and peripheral chemoreceptors. The arterial baroreceptors are 
the afferent component of the baroreflex (Guyenet 2006).
The baroreceptor reflex responds quickly and powerfully to counteract sudden 
changes in blood pressure. This reflex is responsible for maintaining moment-to- 
moment stability in blood pressure by adapting cardiac output and vascular
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resistance (Janssen & Smits 2002). Baroreceptors located in the walls of the 
carotid arteries and aortic arch sense changes in distension of the arterial walls 
due to fluctuations in blood pressure. The receptors send afferent impulses to the 
CNS via the vagus, carotid sinus and glossopharyngeal nerves, which reflexively 
alter cardiac output and vascular resistance (in non-critical organs) to maintain 
mean aortic blood pressure (Charkoudian et al. 2005; Stephenson 2007). 
Decreased distension of arterial walls due to falling blood pressure will decrease 
afferent baroreceptor activity (Guyenet 2006). In response, the CNS activates 
sympathetic activity, which increases cardiac output and causes vasoconstriction 
of arterioles, particularly in non-critical organs (kidney, splanchnic organs and 
resting skeletal muscle), and increasing total peripheral resistance. The cardiac 
sympathetic effects are augmented by a decrease in parasympathetic activity. The 
net result is an increase in blood pressure. The baroreceptor reflex response is 
reversed for an increase in blood pressure (Stephenson 2007). Baroreceptors 
become inoperative below 60 mm Hg, and above this pressure, afferent nerve 
activity progressively increases reaching a maximum at approximately 180 mm 
Hg (Muir 2007). The activation of peripheral chemoreceptors by hypoxia and 
hypercapnia increases sympathetic nerve activity to the heart and blood vessels 
(sympathetic chemoreflex) resulting in increases in blood pressure and heart rate. 
It is possible that central chemoreceptors also contribute to this response (Guyenet 
2006).
In cases of psychogenic stress resulting in the ‘‘fear, fight or flight” response, 
there is increased sympathetic and decreased parasympathetic activity, which will 
result in an increase in blood pressure due to increased heart rate, stroke volume, 
cardiac output and total peripheral resistance associated with vasoconstriction in 
non-critical organs. In these cases the baroreceptor reflex is reset so that blood 
pressure is regulated at an elevated level rather than trying to correct the increase 
in blood pressure (Stephenson 2007).
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1.3.2 Cardiovascular effects of immobilizing drugs
1.3.2.1 Opioids
Cardiovascular effects of endogenous or exogenous opioids are complex and can 
be difficult to define as they are mediated by receptors located centrally within the 
brain and peripherally by tissue-associated opioid receptors. Activity of opioid 
receptors may be modulated indirectly by other G protein-coupled receptors, and 
some opioid effects are mediated by receptor-independent mechanisms (Headrick, 
Pepe & Peart 2012). Opioid effects on the heart and vasculature can be due to 
interaction with receptors or direct interaction with myocardial cells or blood 
vessel smooth muscle (Pugsley 2004). Drug effects are further complicated by 
changes in opioid receptor expression due to alterations in physiological states 
(such as hypotension) and disease (such as hypertension) (Pugsley 2002).
Cardiovascular effects of centrally administered exogenous opioids are variable 
depending on species, dose, opioid analog receptor specificity, and the route and 
site of administration (Feuerstein 1985; Feuerstein & Siren 1987). Generally, 
opioids injected into the lateral cerebral ventricle result in hypertension and 
tachycardia; however, hypotension and bradycardia are observed following 
administration into the cisterna magna or the fourth cerebral ventricle (Feuerstein 
& Siren 1988). Responses vary depending on the exact location of the injection 
site and type of opioid administered (Sun et al. 1996). Microinjection of various 
opioids into hypothalmic nuclei located less than 1 mm apart can result in both 
pressor and depressor effects (Feuerstein & Siren 1988). Outcomes of 
intrahypothalamic injections may also vary with dose of opioid administered; 
increases in blood pressure and heart rate were observed with low doses of a 
MOR specific agonist and the reverse occurred with higher doses (Feuerstein & 
Siren 1988). Injection of endomorphins, with a high selectivity for MOR, into the 
subarachnoid space and central spinal fluid (CSF) of the spinal cord in rats 
elicited a decrease in systemic blood pressure and heart rate (Feng et al. 2012). 
Central opioid cardiovascular outcomes can be further complicated by concurrent
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changes in the respiratory system induced by the administration of this group of 
drugs. Controlling respiration through artificial ventilation can alter a 
cardiovascular depressor response to a pressor response following central 
encephalin analog administration in rats (Feuerstein 1985).
Opioid receptors within both the sympathetic and parasympathetic nervous 
systems appear to be involved in cardiovascular modulation (Feuerstein & Siren 
1987). The outcome of giving an opioidergic drug is influenced by the balance 
between these two components of the autonomic system at the time of 
administration (Headrick et al. 2012). Pressor effects and tachycardia due to 
specific MOR- and DOR-agonists in conscious rats is most likely due to 
activation of the sympathoadrenomedullary axis (Feuerstein & Siren 1987). 
Morphine-induced bradycardia, hypotension, reduced inotropy and cardiac output 
in rats, rabbits, and dogs can be blocked by severing the vagus nerve (Headrick et 
al. 2012). Blocking of opioid peptide receptors restores reduced heart rate and 
blood pressure due to acute vagal stimulation in dogs (Headrick et al. 2012).
MOR appear to be absent in the heart, although may be present on cardiac nerves 
or on cardiac vascular endothelial cells. Both KOR and DOR are found in the 
heart, with DOR in large numbers (Pugsley 2004). Distribution of receptor types 
varies within the heart between ventricles and atria; for example, both ventricular 
and atrial myocytes have DOR and KOR, although KOR binding occurs more in 
the right atrium compared to the left, and DOR appear to be concentrated in the 
atria and sino-atrial node (Feuerstein & Siren 1987; Headrick et al. 2012; Pugsley 
2004). KOR and DOR agonists have been shown to inhibit atrial but not 
ventricular activity, whereas MOR agonists reduce ventricular contractility 
without altering atrial function (Pugsley 2002).
Negative opioid inotropic effects can either be opioid peptide receptor dependent 
or independent (Headrick et al. 2012). Positive opioid inotropic effects have also 
been observed and it is hypothesized that activation of DOR on prejunctional 
cardiac vagal nerves or parasympathetic ganglia reduces the release of
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acetylcholine (Headrick et al. 2012; Pugsley 2002). MOR activation may decrease 
the rate of electrical impulses and sinoatrial and atrioventricular nodal function in 
the heart with a negative chronotropic outcome. By comparison. MOR and DOR 
stimulation can increase heart rate due to inhibition of vagal activity and 
baroreflex-mediated bradycardia. These effects on heart rate may be mediated by 
both central and peripheral modes of action (Headrick et al. 2012). In rats, it has 
been shown that central MOR activation, especially of the nucleus tractus 
solitarius, markedly impairs the baroreceptor control of sympathetic and 
cardiovascular function. Suppression of the baroreceptor reflex by stimulation of 
central opioid receptors is increased with low reflex activity and can be overcome 
as baroreceptor information reaching the brain increases (Gordon 1986; Gordon 
1990).
Studies suggest that opioids can have receptor independent actions on cardiac 
myocytes by blocking Na+, possibly K+ and potentially L-type Ca2+ channels 
influencing repolarization or depolarization of these cells (Pugsley 2002). Activity 
of opioid agonists and antagonists is relatively receptor specific at low 
concentrations, yet at high concentrations their activity becomes receptor 
independent (Pugsley 2002, Pugsley 2004).
Endogenous enkephalins inhibit, or reverse the chronotropic and inotropic effects 
of (3-adrenoceptor activity. This inhibition of catecholamine effects can occur 
directly on the cardiac myocytes and does not require neural involvement 
(Headrick et al. 2012). It has been shown in single isolate rat ventricular myocytes 
that opioid peptide stimulation at DOR modulates P-adrenergic responses and 
may be important in regulating myocardial responses to stress (Xiao et al. 1997).
Opioid effects on vascular smooth muscle are variable depending on species and 
between different vascular beds. In rats, contraction of the aorta, dilation of 
mesenteric arterioles, and no effect at muscular venules have been observed 
(Feuerstein & Siren 1987). These effects appear to be direct, involving various 
opioid receptor sub-types on smooth muscle or may be indirect (Feuerstein &
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Siren 1987). Vasodilation in humans and dogs following morphine administration 
is histamine-modulated (Headrick et al. 2012; Robertson, Muir & Sams 1981). 
Various studies indicate that the different pressor responses due to opioids depend 
not only on the opioid receptor targeted but also the dose of opioid given 
(Headrick et al. 2012).
Etorphine
Opioids at therapeutic analgesic doses have minimal cardiovascular effects in 
domestic animals; however, these may become more pronounced when 
administered at supra-therapeutic doses or when potent opioids are used such as in 
the immobilization of wildlife (Kukanich & Papich 2009; Leigh & Mathews 
2007). Cardiovascular responses to etorphine differ between species. In rats, dogs, 
cats, and monkeys, etorphine causes bradycardia and hypotension, although 
tachycardia and increased blood pressure has been reported in elephants (Daniel 
& Ling 1972; Haigh 1990). In artiodactyls, blood pressure tends to decrease with 
etorphine administration; bradycardia may occur especially at higher doses (Haigh 
1990). Etorphine and carfentanil, are reported to cause a prolonged hypertension 
and bradycardia in goats (Heard et al. 1996)
Increased cardiac output, total peripheral resistance and arterial blood pressure are 
consistent findings in opioid-immobilized perissodactyls including domestic and 
Mongolian horses, ponies, Grevy’s zebra, and white rhinoceros (Haigh 1982;
Haigh 1990; Heard et al. 1992; Lees & Hillidge 1975). Horses, administered 
etorphine remained tachycardic and hypertensive for 30 min (Bogan, MacKenzie 
& Snow 1978), with tachycardia present over a wide range of etorphine doses 
(with acepromazine) (Daniel & Ling 1972). Similarly, the same drug combination 
also caused a pronounced hypertension, of variable duration, in other horses (Lees 
& Hillidge 1975; Schlarmann et al. 1973). Increased sympathetic activity, due to 
direct and, or, indirect stimulation, is proposed as the cause of these 
cardiovascular changes with etorphine (Bogan et al. 1978; Heard et al. 1996; Lees 
& Hillidge 1975; Schlarmann et al. 1973). Indirect stimulants may include 
hypoxia and, or, hypercapnia due to impaired respiration, stress associated with
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research procedures, pain or a combination of factors (Heard et al. 1996; Lees & 
Hillidge 1975). Increased sympathetic activity may lead to direct myocardial 
stimulation, terminal arterial and arteriolar constriction, and, or, adrenal gland 
catecholamine release (Bogan et al. 1978; Heard et al. 1996; Lees & Hillidge 
1975; Schlarmann et al. 1973). This increased central sympathetic outflow has 
also been suggested as the cause of increased arterial pressure observed with 
intravenous administration of morphine in humans (Carter, Sauder & Ray 2002).
Butornhanol
Butorphanol is a potent analgesic providing mild sedation with a rapid onset of 
action and minimal adverse effects. In horses, it is commonly used to relieve 
moderate to severe pain (Orsini 1988; Wenger et al. 2007). Butorphanol causes 
minimal cardiovascular effects in humans and dogs (Robertson et al. 1981). 
Although butorphanol IV does not alter heart rate in human subjects, there are 
alterations of other indices of cardiovascular function, such as increases in cardiac 
and stroke volume index, left ventricular end diastolic pressure, and pulmonary 
arterial pressure. These changes suggest that butorphanol may increase cardiac 
workload (Gillis et al. 1995). In contrast, Plumb (2008) suggested that 
butorphanol may decrease heart rate secondary to an increase in parasympathetic 
tone, along with mild decreases in arterial blood pressure. In humans, butorphanol 
attenuates the baroreceptor receptor reflex control of heart rate in response to an 
increase in blood pressure, but not with decreased blood pressure. Possible 
explanations include hypercapnia associated with butorphanol administration 
altering baroreflex sensitivity to increased blood pressure, or central effects at the 
nucleus tractus solitaries which is the primary termination for baroreceptor 
afferent fibres (Wajima, Inque & Ogawa 1993).
In awake dogs, butorphanol (0.1 and 0.4 mg/kg) IV was reported to cause small 
but significant decreases in heart rate and mean arterial blood pressure, possibly 
due to a peripheral vasodilation (Trim 1983). Similar results have been reported in 
halothane-anaesthetized dogs administered butorphanol (0.2 mg/kg) IV where 
significant, although transient (< 15 min.) decreases in heart rate, mean and
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diastolic arterial blood pressure occurred. However, cardiac index, stoke volume, 
pulmonary artery wedge pressure and systemic vascular resistance did not change 
significantly (Greene, Hartsfield & Tyner 1990). In alpacas, butorphanol causes a 
mild decrease in systemic vascular resistance but no significant changes in other 
cardiovascular variables (Pereira et al. 2005).
Intravenous butorphanol (0.1-0.4 mg/kg) in horses at rest did not significantly 
change heart rate, mean and diastolic blood pressures or cardiac output (Robertson 
et al. 1981). However, in separate studies, 0.22 mg/kg and 0.1 mg/kg butorphanol 
IV to ponies and horses, respectively, resulted in increased heart rate which 
persisted for up to two hours in the horses. There were significant differences in 
the magnitude of change between individuals. It has been suggested that these 
cardiac effects were due to CNS stimulation (Knych et al. 2012).
Cardiovascular effects of butorphanol in equids appear to be dose-related. In 
halothane-anaesthetized ponies and horses, low doses of butorphanol (0.022 to 
0.05 mg/kg) did not produce changes in mean arterial blood pressure or heart rate; 
however, a larger dose (0.2 mg/kg) induced hypotension (Hofmeister, Mackey & 
Trim 2008). In horses sedated with detomidine, the addition of butorphanol 
reversed the increased systemic vascular resistance caused by a2-agonist. Other 
cardiovascular changes, including decreased heart rate and cardiac output, and 
increased systemic arterial pressure, were unaltered (Nyman et al. 2009)
1.3.2.2 Butyrophenones
Butyrophenones are antagonists at multiple receptors with the strongest affinity 
for D-receptors and weaker binding at adrenergic ai-adrenergic, 5-HT-, M3- and 
Hi- receptors (Lemke 2007). Clinically, butyrophenones are generally reported to 
increase heart rate, decrease contractility and slightly decrease blood pressure, 
with no change or an increase in cardiac output (Muir 2007). However, 
cardiovascular outcomes are variable due to multiple receptor affinities. Di-like 
and D2-like receptors exist in the cardiovascular system; however, there is limited 
understanding of their functions (Missale et al. 1998). In blood vessels, activation
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ofD 2-like receptors indirectly induces vasodilation by inhibiting noradrenaline 
release on postganglionic sympathetic nerve terminals and activation of Di-like 
receptors on vascular smooth muscle directly results in vasodilation primarily in 
the renal, mesenteric, cerebral and coronary circulations (McGrath & Wang 1994; 
Missale et al. 1998). In the adrenal medulla, Di-like receptor activation stimulates 
and Do-like receptor activation inhibits the release of catecholamines. Do-like 
receptor activations in peripheral sympathetic ganglia and nerve endings inhibit 
the release of noradrenaline (Missale et al. 1998). Both D|- and D2-like receptors 
including Dp, D2-, D4- and D5-receptors, occur in the epicardium, myocardium 
and endocardium of human atria and ventricles with variable distribution 
(Cavallotti et al. 2010). The administration of exogenous dopamine increases 
cardiac contractility (Pivonello et al. 2007).
Alpha)-adrenergic receptors compared to a2-adrenergic receptors, are the 
predominant a-receptor located on vascular smooth muscles. Activation of these 
receptors result in smooth muscle contraction which is more pronounced in 
arterial resistance vessels (small arteries and arterioles) compared to veins and 
results in increased peripheral resistance (Klabunde 2013). 5-HT can have 
profound and varied effects in the cardiovascular system: centrally 5-HT can 
inhibit noradrenaline release and sympathetic activity. 5-HT-receptors on 
cardiomyocytes have positive chronotropic and inotropic effects, and, depending 
on the species, effects on blood vessels can result in both vasoconstriction and 
vasodilation (Ni & Watts 2006). M3-acetylcholine receptors in the heart play a 
role in the parasympathetic control of cardiac function including regulation of 
heart rate and cardiac repolarization, and modulation of inotropic effects (Wang et 
al. 2007). In vascular tissue, the activation of H r and H2-receptors results in 
vasoconstriction and vasodilation, respectively; however in humans, vasodilation 
is the predominant effect (Ebeigbe & Talabi 2014). Simultaneous stimulation of 
these two histamine receptors in the heart results in positive inotropic and 
chronotropic effects, a negative dromotropic effect and increased automaticity 
(Krzan 1996).
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Azaperone
Azaperone, a D-receptor antagonist, is administered primarily as a tranquillizer in 
domestic animals and wildlife species; however, due to its blocking activity at 
peripheral ai-receptors, it is also used to moderate opioid-induced hypertension in 
immobilized megaherbivores (Burroughs et al. 2012a). In horses tranquillized 
with azaperone (0.4 and 0.8 mg/kg), a 30% reduction in mean arterial blood 
pressure, due to reduction in total peripheral resistance, developed for up to four 
hours. A proposed mechanism for this drop in blood pressure was the blockade of 
a-receptors and reduction in motor tone. The higher dose of azaperone (0.8 
mg/kg) resulted in a small increase in heart rate due to possible baroreceptor 
stimulation in response to the hypotension (Lees & Serrano 1976; Serrano & Lees 
1976). Decreases in heart rate and cardiac output were reported in young pigs 
administered 2.5 mg/kg azaperone intramuscularly, and a decrease in arterial 
pressure at a dose of 0.3 to 3.5 mg/kg in adult pigs (Lemke 2007). Van Woerkens 
et al. (1990) found that azaperone (5 mg/kg 1M) in conscious pigs reduced cardiac 
output by 10% and mean arterial pressure by 35%. The change in cardiac output 
was due to a decrease in stroke volume rather than heart rate. Blood flow to the 
brain was maintained despite the reduction in mean arterial blood pressure due to 
cerebral vasodilation (Van Woerkens et al. 1990). In addition to a pronounced a- 
adrenergic blocking effect, azaperone appears to reduce p2-antagonist action and 
retard sympathetic reflexes in pigs (Gregory & Wilkins 1986).
1.3.3 Cardiovascular effects of immobilizing drugs in white rhinoceros
Published reports on the cardiovascular effects of immobilizing drugs in white 
rhinoceros are limited. An early case report of a captive white rhinoceros (2000 
kg) immobilized with etorphine (2.8 mg) found initial systolic and diastolic blood 
pressures of 300 and 250 mm Hg, which gradually decreased and stabilized at 240 
and 200 mm Hg, respectively, for the remainder of a 120 minute procedure. Heart 
rate remained between 80 to 100 beats per minute (LeBlanc et al. 1987). This 
animal was hypertensive and tachycardic compared to mean blood pressures 
(systolic 160 mm Hg, diastolic 104 mm Hg) and mean heart rate (39 beats per 
minute) in captive conscious white rhinoceros standing at rest (Citino & Bush
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2007). Increased sympathetic activity was proposed as the cause of the pressure 
effects in the immobilized rhinoceros (LeBlanc et al. 1987). Heard et al. (1992) 
reported more moderate increases in arterial blood pressure and heart rate in a 28 
year old captive female white rhinoceros immobilized with an initial lower 
etorphine dose, with repeated doses over 210 min. Opioid-induced hypercapnia, 
hypoxaemia and pain associated with reproductive manipulation were suggested 
as contributing causes to the hypertension (Heard et al. 1992). Portas (2004) also 
suggested that etorphine-induced hypertension, secondary to increased cardiac 
output and peripheral resistance, is a common occurrence in white rhinoceros, and 
may be related to increased sympathetic activity. This may have contributed to the 
marked tachycardia (152 beats per minute) also reported for free-ranging white 
rhinoceros immobilized with etorphine only (Kock et al. 1995).
When etorphine was combined with azaperone to immobilize free-ranging 
rhinoceros, a lower mean arterial blood pressure (141 mm Hg) was measured 
compared to that in animals that received etorphine plus fentanyl (183 mm Hg) 
(Hattingh et al. 1994). It was hypothesized that the difference in blood pressure 
between treatments was due to the peripheral ai-adrenergic receptor properties of 
azaperone (Hattingh et al. 1994). Bush et al. (2004) found that free-ranging 
rhinoceros immobilized with a combination of etorphine and azaperone (ratio ± 
1:10-20, in mg) were hypertensive (systolic blood pressure 164 mm Hg, normal 
resting value 124 mm Hg (Citino & Bush 2007)) and tachycardic ( 107 beats per 
minute). However, compared to standing resting values for white rhinoceros, 
which were not available at the time, the immobilized rhinoceros were only 
mildly hypertensive, although heart rate was significantly elevated (Bush et al. 
2004, Citino & Bush 2007). The provision of supplementary oxygen did not alter 
blood pressure or heart rate in these animals (Bush et al. 2004).
In free-ranging rhinoceros immobilized with etorphine and azaperone, with 
butorphanol included in the dart or administered IV once the animals became 
immobilized, the initial tachycardia observed in both treatments decreased over 
time. It was suggested that the reduction in heart rate was due to butorphanol,
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although possible mechanisms for this effect were not discussed (Miller et al. 
2013). Boardman et al. (2014) also reported a significant decrease in heart rate 
(118 to 74 beats per minute) within 10 min after administration of butorphanol (10 
x etorphine dose in mg) IV in white rhinoceros immobilized with etorphine and 
azaperone. Systolic and diastolic blood pressures significantly declined (systolic 
162 to 139 mm Hg, diastolic 104 to 80 mm Hg). The changes in blood pressure 
were attributed to a prolonged onset of azaperone effects compared to those of 
etorphine (Boardman et al. 2014). Similarly, Hawc/a/. (2015) found that 
butorphanol (15 x etorphine dose in mg) IV and provision of supplementary 
oxygen resulted in significant decreases in heart rate (136 to 99 beats per min.) 
and mean arterial blood pressure (158 to 114 mm Hg) within four min of 
administration. There were no further changes in cardiovascular parameters for 
the remaining 14 min of the trial, and the animals remained tachycardic and 
normotensive (Haw et al. 2015).
1.4 Summary and thesis aims
Chemical immobilization is an essential procedure used in the management of 
free-ranging white rhinoceros including moving animals between isolated 
populations, re-introductions into previous ranges, disease investigation, anti­
poaching measures and treatment of injuries. Anaesthesia and sedation are also 
important procedures used in the husbandry and welfare of captive individuals. At 
present, white rhinoceros can only be immobilized with a potent opioid combined 
with a tranquillizer or sedative, and etorphine plus azaperone is most commonly 
used (Burroughs et al. 2012b).
Etorphine is the immobilizing opioid of choice for white rhinoceros as it is 
sufficiently potent to be included in a dart, results in rapid induction and is 
commercially available. Azaperone is included in etorphine-darts as it reduces 
induction time (dart in to immobilization) and limits opioid-induced hypertension 
in immobilized white rhinoceros. However, this drug combination results in 
changes to respiratory and cardiovascular clinical parameters which indicate
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significant physiological alterations in these two systems and may be associated 
with mortalities (Van Zij 11 Langhout et al. 2016; Kocke/ al. 1995).
Various procedures are used to limit the cardiorespiratory physiological 
alterations associated with etorphine-azaperone immobilization, which include 
minimizing immobilization duration, use of partial opioid antagonists (nalorphine 
and diprenorphine) and respiratory stimulants (doxapram), and nasal or tracheal 
oxygen insufflation (Buss et al. 2015). Butorphanol, a mixed opioid agonist- 
antagonist, has in recent years been evaluated as a possible antagonist to 
respiratory depression in immobilized rhinoceros (Boardman et al. 2014; Haw et 
al. 2014; Haw et al. 2015; Miller et al. 2013; Wenger et al. 2007). Anecdotal field 
evidence suggested that butorphanol improved respiratory function; however, 
study results are equivocal suggesting that either improved ventilation or 
metabolic shifts result in improved arterial partial pressure of oxygen, carbon 
dioxide or both (Boardman et al. 2014; Haw et al. 2014; Haw et al. 2015; Miller 
et al. 2013; Wenger et al. 2007). Personal field observations suggested that 
etorphine-azaperone immobilization could be maintained in rhinoceros for longer 
periods of time and an initial tachycardia decreased rapidly if butorphanol was 
administered intravenously.
The adverse respiratory parameters in immobilized white rhinoceros are well 
documented in scientific literature (Boardman et al. 2014; Haw et al. 2014; Haw 
et al. 2015; Miller et al. 2013; Wenger et al. 2007). Cardiovascular changes are 
less well recorded (Hattingh et al. 1994; Heard et al. 1992; LeBlanc et al. 1987; 
Raath 1999; Waltzer et al. 2000). Similarly, studies which investigate the origins 
of drug-specific physiological effects that influence the clinical parameters 
recorded are limited. The reason for a paucity of these types of studies is 
multifactorial (Haw et al. 2014 & 2015; Miller et al. 2013). In free-ranging 
rhinoceros darted from helicopters, the physiological drug effects are overlain by 
multiple other influences, including variable environmental factors (temperature 
and humidity), an adrenergic stress response and increased metabolic activity 
prior to immobilization, limited health status evaluation and drug dose rates based
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on an estimated body mass. In both free-ranging and captive rhinoceros, 
monitoring of respiratory and cardiovascular variables starts only once the animal 
is sufficiently immobilized to be safely approached. By this time, both etorphine 
and azaperone are influencing physiological responses, centrally and peripherally, 
and it is not possible to differentiate their individual specific effects.
Unraveling the respiratory and cardiovascular physiological drug effects of 
etorphine, azaperone and butorphanol is further complicated by the complexity of 
these two integrated biological systems. Enormous strides have been made in 
understanding the physiology of these systems, however, our understanding is 
incomplete and in some aspects, contradictory. Mathematical models based on 
current knowledge are used to best describe how respiratory rhythm is generated 
and modulated in the ventral respiratory column (Rekling & Feldman 1998; Smith 
et al. 2000). Coordinated motor neuron outputs arising centrally are generated to 
control the various muscle groups involved in breathing including those of the 
thorax, upper respiratory tract and the diaphragm. Modulation of the system is 
primarily due to carbon dioxide levels which are sensed by multiple 
chemosensing areas located within the brain stem making up the central 
chemoreceptor (Haji et al. 2000; Pattinson 2008). Peripheral chemoreceptors in 
carotid bodies play a supporting role which becomes more important with 
developing hypoxia. However, the mechanisms underlying chemosensitivity are 
not fully understood (Feldman et al. 2013). Modulation can also be conscious 
with inputs from the brain cortex. The mechanisms that generate and control 
respiration have to be sufficiently flexible and integrated to adjust rapidly to 
changes in metabolic demand, accommodate chronically altered conditions such 
as disease or persistent hypoxia, and allow for short-term perturbations such as 
postural changes, swallowing and vocalization (Bianchi et al. 1995; Mitchell & 
Johnson 2003; Smith et al. 2007).
The cardiovascular system is similar to the respiratory system in that it responds 
rapidly to changing circumstances including increases in metabolic requirements 
to ensure sufficient metabolic substrates are supplied to active tissues and waste
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products removed. The control of this system is complex and depends on two 
principle mechanisms; intrinsic control which is metabolic in origin, and extrinsic 
control, which is nerve and hormone dependent (Janssen & Smits 2002). Central 
cardiovascular control is integrated between multiple regions and receives input 
from baroreceptors and volume receptors within the vascular system. Peripheral 
chemoreceptors also contribute to cardiovascular control (Guyenet 2006). The 
system is also modulated by regions of the CNS which respond to changes in 
body temperature, exercise, emotion, ischemia and hypoxia (Muir 2007). During 
the “flight and fight” response, neurohumoral mechanisms primarily influence 
heart rate, stroke volume and blood flow to non-critical organs through the 
autonomic nervous system and release of catecholamines from the adrenal 
medulla (Stephenson 2007). Outcomes are dependent on direct autonomic 
innervation of tissues, and the type and distribution of both adrenergic and 
cholinergic receptors within the cardiovascular system.
The etorphine-azaperone immobilizing combination can influence the respiratory 
and cardiovascular systems both centrally and peripherally by both receptor and 
non-receptor associated mechanisms. Etorphine is a pure agonist at MOR, DOR 
and KOR receptors and its respiratory and cardiovascular effects will depend on 
the distribution of opioid receptors within these systems and the cellular functions 
they influence. Current understanding of opioid effects are clouded, in part, by 
pharmacological evidence which suggests the existence of a number of opioid 
receptor-subtypes; however molecular evidence does not support the notion of 
opioid receptor-subtypes (Dietis et al. 2011; Feng et al. 2012). Opioids influence 
the respiratory and cardiovascular systems both centrally and peripherally, 
activate various intracellular signal pathways, and can influence the activity of 
receptors other than opioid receptors (Boom et al. 2012; Koo & Eikermann 2011). 
The principle respiratory effect of opioids is a profound depression of neuronal 
rhythm generation and respiratory response to increasing arterial carbon dioxide 
levels; the peripheral chemoreceptor hypoxic response is also inhibited 
(McDonald & Lambert 2005; Pattinson 2008). Current understanding of opioid 
respiratory effects has resulted principally from extensive studies on human
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therapeutic opioid use and research done using rodent or domestic animal models. 
However, it is not known to what extent this current understanding applies to 
etorphine use in immobilizing rhinoceros.
The physiological basis of opioid-induced cardiovascular distresses appears to be 
less well understood when compared to those of the respiratory system. Central 
opioid influences are variable and outcomes can depend on the exact 
administration location, and receptor activity, affinity and dose of opioid being 
studied (Feuerstein & Siren 1988). Peripherally, opioid receptors are found in 
both parasympathetic and sympathetic nerves involved in cardiovascular control. 
In the heart, the distribution of opioid receptor types differs between ventricle and 
atria, and variable chronotropic and inotropic outcomes have been observed 
depending on opioid study methodologies (Feuerstein & Siren 1987; Headrick et 
al. 2012; Pugsley 2004). Opioids can also impair baroreceptor control of 
sympathetic and cardiovascular function (Gordon 1986; Gordon 1990). Opioids 
may alter cardiac function by receptor independent actions and possibly influence 
the catecholamine response at myocyte p-adrenergic receptors (Pugsley 2002;
Xiao et al. 1997).
Respiratory and cardiovascular physiological influences of azaperone are poorly 
understood. It is an antagonist at several receptors (D-, ai-, 5-HT-, M3- and H r) 
suggesting that it may potentially have multiple effects on the respiratory and 
cardiovascular systems. The primary activity of azaperone is the blockade of D- 
receptors and dopaminergic mechanisms modulate respiration both centrally and 
peripherally; although the specific effects are not conclusive (Hsiao et al. 1989). 
Similarly, the role of D-receptors in controlling cardiovascular functions is not 
well understood (Missale et al. 1998). However, azaperone is reported to 
antagonize ai-adrenergic receptors and decrease peripheral resistance which is 
believed to moderate hypertension in etorphine-immobilized rhinoceros (Hattingh 
et al. 1994; Klabunde 2013; Lemke 2007).
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Butorphanol’s physiological effects are possibly the least understood of the drugs 
used in white rhinoceros immobilization. In humans and domestic animals, 
butorphanol is administered as the principle opioid for its agonist and analgesic 
effects; however, in immobilized rhinoceros, it is used to partially antagonize the 
agonist effects of etorphine. The use of this mixed opioid agonist-antagonist in 
this manner would appear to be unique in published literature and reports on 
physiological outcomes are limited (Boardman et al. 2014; Haw et al. 2014; Haw 
et al. 2015; Miller et al. 2013; Wenger et al. 2007). Butorphanol administered on 
its own tends to depress respiration. Initially it was thought that this depression 
was limited due to a ceiling effect; however, it has been shown that it can be 
marked. Reports suggest that its respiratory effects are variable depending on 
dose, species and presence of other drugs (Vivian et al. 1999; WHO Expert 
Committee on Drug Dependence 2006). In the horse, a domestic perissodactyl 
used as a physiological equivalent for comparison with rhinoceros, butorphanol’s 
cardiovascular effects are not well defined and variable pressor effects have been 
documented.
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The research objectives and aims of this thesis are:
Objective 1
Determine the effects of etorphine and etorphine plus azaperone on respiration in 
immobilized white rhinoceros.
Aims:
1.1 Determine the effects of etorphine-azaperone on clinical respiratory 
parameters in immobilized rhinoceros.
1.2 Determine the effects of etorphine on clinical respiratory parameters in 
immobilized rhinoceros.
1.3 Evaluate which clinical respiratory parameters can be attributed to 
etorphine-induced respiratory physiological alterations in immobilized 
rhinoceros.
Objective 2
Determine through which mechanisms butorphanol alters respiratory depression 
in etorphine or etorphine plus azaperone immobilized white rhinoceros.
Aims:
2.1 Determine the effects of intravenous butorphanol administration on 
clinical respiratory parameters in etorphine-azaperone immobilized 
rhinoceros.
2.2 Determine the effects of intravenous butorphanol administration on 
clinical respiratory parameters in etorphine-immobilized rhinoceros.
2.3 Evalute which clinical respiratory parameter changes can be attributed to 
intravenous butorphanol administration in etorphine-immobilized 
rhinoceros.
Objective 3
Determine the effects of etorphine and etorphine plus azaperone on the 
cardiovascular system in immobilized white rhinoceros.
Aims:
3.1 Determine the effects of etorphine-azaperone on clinical cardiovascular 
parameters in immobilized rhinoceros.
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3.2 Determine the effects of etorphine on clinical cardiovascular parameters in 
immobilized rhinoceros.
3.3 Evalute which clinical cardiovascular parameters can be attributed to 
etorphine-induced cardiovascular physiological alterations.
Objective 4
Determine through which mechanisms butorphanol alters cardiovascular 
parameters in etorphine and etorphine plus azaperone immobilized white 
rhinoceros.
Aims:
4.1 Determine the effects of intravenous butorphanol administration on 
clinical cardiovascular parameters in etorphine-azaperone immobilized 
rhinoceros.
4.2 Determine the effects of intravenous butorphanol administration on 
clinical cardiovascular parameters in etorphine-immobilized rhinoceros.
4.3 Evalute which clinical cardiovascular parameter changes can be attributed 
to intravenous butorphanol administration in etorphine-immobilized 
rhinoceros.
To reduce confounding variables associated with field capture, all study trials 
were conducted in wild-caught white rhinoceros adapted to holding facilities, and 
included animals of known body mass and health status. Trials were also 
conducted at the same time of day with minimal disturbance to the rhinoceros 
prior to darting.
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CHAPTER 2
Evaluation of cardiorespiratory, blood gas, and lactate values during 
extended immobilization of white rhinoceros (C eratotherium  sim um ).
Buss, P., Olea-Popelka, F., Meyer, L., Hofmeyr, J., Mathebula, N., Kruger, 
M., Bruns, A., Martin, L. & Miller, M.
(2015)
Journal of Zoo and Wildlife Medicine 46(2), 224-233
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EVALUATION OF CARDIORESPIRATORY, BLOOD GAS, AND 
LACTATE VALUES DURING EXTENDED IMMOBILIZATION OF 
WHITE RHINOCEROS (C E R A TO TH E R IU M  SIM U M )
Peter Buss. B.V.Sc., M..Med.Vet.. Francisco Olea-Popelka, D.V.M., Pli.D., Leith Meyer. B.V.Sc., 
Plt-D., Jennifer Ifofineyr, B. Tech. (Vet), B.Sc.Hon., Nomkliosi Mathebula, B.Tech. (Vet), M arius 
Kruger, B.Sc.Ilon., M.Sc., Angela Brims, D.V.M., Laura Martin, D.V..\l„ and Michele Miller, D.V.M., 
Ph.D.
Abstract: Ten white rhinoceros (Ceratotheriuni simtun) were immobilized for a total of 13 procedures in holding 
facilities in Kruger National Park using etorphinc, azaperone, and hyaluronidasc to assess the effect o f extended 
immobilization on serial cardiorespiratory, blood gas, and lactate values. Butorphanol was administered 
intravenously following initial blood collection and physiologic assessments -0). Respiratory and cardiovascular 
parameters, body temperature, and arterial blood gases were monitored at 10-min intervals for a total of 100 min. 
Initial parameters at the time of recumbency revealed severe hypoxemia, hypercapnia, tachycardia, an increased 
alveolar-arterial (A-a) gradient, and mildly elevated lactate levels. At 10 min and 20 min, there were significant (P 
< 0.0S) changes in the following physiologic parameters: heart rate decreased [96 and 80 bcats/min, respectively, 
vs. 120 bcats/min], arterial partial pressure of oxygen (PaO.) increased [48 and 45 mm Hg. respectively vs 30 mm 
Hg], arterial hemoglobin oxygen saturation increased [79% and 74%, respectively, vs. 47%], A-a gradient 
decreased [29.13 and 30.00 mm Hg, respectively, vs. 49.19 mm Hg], and respiratory rate decreased [5 and 5 
breaths/min vs. 7 breaths/min]. Blood lactate levels also decreased from 154 mM/L to 1.50 and 0.89 mM/L, 
respectively. Despite initial improvements in blood oxygen levels at t = 10 and 20 min, the rhinoceros remained 
severely hypoxemic for the remainder of the procedure (median PaO. = 50.5 mm Hg, 95% confidence interval, 
43.8-58.1). Median values for respiratory rate (5 breaths/min) and arterial partial pressure of carbon dioxide 
(PaCOj; 68.5 mm Hg) did not change significantly for the remaining 80 min. Median lactate, base excess, 
bicarbonate, and pH values improved between 20 and 100 min despite the persistent hypercapnia, indicating that 
the animals adequately compensated for respiratory and lactic acidosis. White rhinoceros were immobilized for 
100 min with no negative effects, a desirable outcome if procedures require extended chemical immobilization 
without oxygen supplementation.
Key words: Blood gas, butorphanol, cardiorespiratory, Ccrmotherium simum, white rhinoceros.
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INTRODUCTION
Free-ranging white rhinoceros (Ceratotheriuni 
simum) are routinely immobilized with etorphinc, 
a potent opioid, combined with the butyrophe- 
none tranquilizer azaperone for medical and 
management procedures.”  Tachycardia, hypo- 
pnea, hypoxemia, and hypercapnia with respira­
tory and metabolic acidosis are well-documented 
side effects o f  the drug combination in this 
spedcs.1*-1’-2* These potentially fatal complica­
tions are managed by minimizing the time an 
animal is kept immobilized before a complete 
opioid antagonist is administered.' Partial opioid 
antagonists, including nalorphine and diprenor- 
phine; nasal or tracheal oxygen insufflation; and 
respiratory stimulants such as doxapram have 
also been used to counteract these negative effects 
with limited and variable degrees of success.1- 21-”  
A t times there is a requirement to keep an animal 
immobilized in the field for a prolonged period of 
time (>20 min), such as during the treatment of
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injuries caused by poaching, including the remov­
al o f snares and bullet w ounds.F requently  these 
operations are helicopter based and are per­
formed without the advantages of inhalation 
anesthesia, oxygen insufflation, o r mechanical 
ventilation.2*1 Etorphine, the primary immobiliz­
ing agent, is a p, k , and A opioid peptide (MOP, 
KOP, and DOP, respectively) receptor agonist.11 
Butorphanol, a synthetic opioid reported to have 
KOP receptor agonist and MOP receptor antag­
onist effects, has anecdotally been used to im ­
prove ventilation in opioid-immobilized white 
rhinoceros.21" The objective of this descriptive 
study was to record and evaluate the cardiorespi­
ratory, blood gas, and lactate values in white 
rhinoceros immobilized for an extended time 
period (100 min) with no oxygen support and a 
single dose of butorphanol. The lack of a control 
group in this clinical study prevents the rendering 
o f definitive conclusions about the effects of 
butorphanol; however, it does raise a number of 
potential research questions to be pursued in 
future analytical studies.
MATERIALS AND METHODS
Study area and sample population
The study animals were white rhinoceros cap­
tured in Kruger National Park (24'59'44.50'S, 
3I°35'11.17'E; altitude 317 m), South Africa, and 
placed into holding facilities for management 
purposes. The management and immobilization 
of the rhinoceros were conducted according to the 
South African Parks Standard Operating Proce­
dures for the Capture, Transportation and Main­
tenance in Holding Facilities o f Wildlife. These 
animals were part o f another study that required a 
prolonged period of immobilization.
Ten animals were used in this descriptive study; 
three individuals were immobilized twice on 
separate occasions. Rhinoceros ranged in age 
from 3.5 to 15 yr and included four males and 
six females. Prior to being included in this trial, all 
animals had adapted to captivity and were eating 
and defecating normally. Animals were deemed 
healthy based on behavior, dietary intake, body 
condition, and physical examination.
Each rhinoceros received a combination of 
etorphine (9.8 mg/ml; Novartis, Kempton Park 
1619, South Africa), azaperone (40 mg/ml; Jans­
sen Pharmaceutical Ltd., Halfway House 1685, 
South Africa), and hyaluronidase (5,000 IU/vial; 
Kyron Laboratories, Benrosc 2011, South Africa) 
delivered into the muscles o f the nuchal hump 
remotely using a 3.0-ml plastic dart with a 60-mm
uncollared needle propelled by a compressed air 
rifle (DAN-INJECT, International S.A., Skukuza 
1350, South Africa). Doses were based on stan­
dardized age categories: 3 to  4 years =  2.5 mg 
etorphine, 20 mg azaperone, and 5,000 IU hyal­
uronidase; 4 to 5 years = 3.0 mg etorphine, 40 mg 
azaperone, and 5,000 1U hyaluronidase; and >5 
years = 4 mg etorphine, 40 mg azaperone, and 
5,000 IU hyaluronidase. Darting took place early 
in the morning prior to feeding or cleaning of 
enclosures to ensure minimal disturbance or 
stimulation of the animals.
All animals were recumbent within 10 min after 
darting and were blindfolded as soon as they 
could be safely approached and placed in sternal 
recumbency. Each rhinoceros’s body position was 
alternated between sternal 3nd lateral recumben­
cy at 20-min intervals to ensure adequate ventila­
tion of both lung fields and perfusion o f limbs, 
respectively.
At t = 0, once the rhinoceros were handled for 
the first time, an initial blood sample was 
obtained. Butorphanol (50 mg/ml; Kyron Labo­
ratories) was administered intravenously at 10 
times the etorphine dose (mg) into an auricular 
vein immediately following the collection o f  
samples and assessment o f cardiorespiratory 
parameters at t =  0. Arterial blood samples were 
collected, and heart rate, respiratory rate, and 
rectal temperature were measured every 10 min 
starting at t = 0, for a total duration of 100 min. 
Initial handling of recumbent rhinoceros was 
designated time 0 min (t = 0). The first sample 
collected after the administration of butorphanol 
was obtained at 10 min (t = 10). This single 
butorphanol dose was selected since it is com­
monly used in field immobilization o f free- 
ranging while rhinoceros and because subjective 
results suggest it improves cardiorespiratory 
functions.12
At the end of the procedure, naltrexone (40 m g/ 
ml; Kyron Laboratories) was administered intra­
venously at 33.3 to 57 times the etorphine dose 
(mg), and the animal was kept under observation 
until it had fully recovered.
Sample collection and assays
Arterial samples were collected from the medial 
auricular artery in a 1 -ml heparinized syringe and 
immediately analyzed using a portable blood gas 
analyzer (iSTAT®l Handheld Ginical Analyzer, 
Heska Corporation, Loveland, Colorado 80538, 
USA) using the CG4+ cartridge (iSTAT CG4+ 
cartridges, Heska Corporation). Arterial partial 
pressure o f oxygen (PaO j ,  arterial partial pres-
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Table I. Mean, standard deviation, median, interquartile range, and number of observations for each 
cardiopulmonary parameter at sampling periods 0, 10, and 20 min.‘
Sample 
lime (min) Distribution
Respiratory rate 
(breaths/mm)
Heart rale 
(bcats/min)
Rectal
temperature ( C)
BE*,
(mmol/L)
HCO, 
(mm Hg)
Mean 7.62 121.46 36.60 9.46 35.25
SD 2.22 16.52 0.76 3.36 3.61
Median 7.00 120.00 36.70 8.00 33.50
IQR 6.00, 8.00 112.00, 130.00 36.15,37.09 7.00, 12.00 32.70, 37.40
n 13 13 12 13 13
10 Mean 6.31 86.31 36.71 9.31 35.52
SD 2.50 21.62 0.84 4.63 4.39
Median 5.00 96.00 36.75 9.00 35.20
IQR 5.00, 7.00 68.00, 100.00 36.25, 37.40 5.00, 14.00 31.70, 39.90
n 13 13 12 13 13
20 Mean 5.92 80.31 36.64 10.15 36.12
SD 2.72 16.60 0.75 4.88 4.73
Median 5.00 80.00 36.60 11.00 37.40
IQR 4.00, 8.00 68.00, 94.00 36.40, 37.20 7.00, 15.00 33.10,40.30
it 13 13 13 13 13
* IQR indicates interquartile ran®: (25<h-75lh percentile): BE^, base excess: HCO,, bicarbonate; SaO„ arterial hemoglobin 
oxygen saturation: PaO-. arterial partial pressure of oxygen' PaCO,. arterial partial pressure of carbon dioxide: A-a gradient, 
alseolar- arterial gradient.
sure of carbon dioxide (PaCO:), pH, and lactate 
were measured by the machine; PaO;, PaCO:, and 
pH were corrected for body temperature. Base 
excess (BE«j), bicarbonate (HCOJ), and arterial 
hemoglobin oxygen saturation (SaO J were values 
calculated by the blood gas analyzer. Heart rate 
was determined by auscultation of the heart or 
palpation o f the medial auricular artery. Respira­
tory rate was measured by visual assessment of 
thoracic-abdominal excursions and air movement 
at the nares. The Alveolar -  arterial (A-a) oxygen 
gradient was calculated using the formula 
FIO;(Pb-PH:o) -  Paco; -  Pao.-, as reported by 
Meyer et a l.“  A measured mean barometric 
pressure (Pb) of 739 mm Hg and an inspired 
oxygen fraction (Flo.) o f 21 mm Hg were used in 
all calculations. The water vapor pressure of 
saturated air in the alveoli (P„;o) was calculated 
as 4.58 exp [(17.27Tb)/(237.3 + Th). Body temper­
ature (T J was measured by placing a thermome­
ter deep into the rectum against the rectal wall. It 
was assumed that alveolar partial pressure of 
carbon dioxide was equilibrated with PaCO: .'‘
Data analysis
STATA (Stata Statistical Software: Release 11, 
College Station, Texas 77840, USA) was used for 
the statistical analysis. Means, standard devia­
tions, medians, and first (Q l) and third (Q3) 
quartile were calculated for descriptive purposes 
for rhinoceros at different sampling points (10- 
min intervals). As a result o f the relatively small
sample size obtained for this study, nonparamet- 
ric statistical tests were used to compare median 
values at different sampling points (over 100 
min). Initially, the data were screened using the 
Kruskal-Wallis test to assess if  median values for 
different cardiorespiratory, blood gas, A-a gradi­
ent, and lactate values differed over sampling 
points (over 100 min). Secondly, a pairwise 
comparison of adjacent intervals (i.e., 0 to 10, 30 
to 40, 70 to 80 min, etc.) was conducted to assess 
differences in median cardiorespiratory, blood 
gas, A-a gradient, and lactate values within a 10- 
min period using the Wilcoxon rank sum tesL All 
sampling points were compared to the baseline 
values at t = 0 (before the administration of 
butorphanol). To account for repeated measure­
ments (lack of independence among samples 
taken from the same rhinoceros at different 
sample poinLs and the three rhinoceros sampled 
twice), a mixed linear regression model using 
ranks was used to evaluate the effect o f time on 
the cardiorespiratory, blood gas, A-a gradient, 
and lactate values over time, including the sample 
intervals (every 10 min), as a fixed effect and using 
t -  0 as the reference value. Based on the initial 
results and distribution of data (indicating that 
most clinically relevant changes in cardiorespira­
tory, blood gas, A-a gradient, and lactate values 
occurred during the first 20 min and then tended 
to stabilize), the analysis (mixed linear regression 
using ranks as described above) was repeated in 
order to formally assess changes on cardiorespi-
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Table 1. Extended.
SaO, (% )
Lactate
(mmoI/L)
Corrected
pH
Coirecled 
PaCO, (mm Hg)
Corrected 
PaO, (mm Hg)
A-a gradient 
(mm Hg)
51.46 2.88 7.34 65.33 30.83 49.35
18.13 1.72 0.04 11.71 9.36 10.26
47.00 2.48 7.34 60.95 30.00 49.19
44.00, 64.00 1.87. 3.46 7.33, 7.36 58.85, 68.45 25.00,37.50 39.59,58.95
13 13 12 12 12 12
74.77 2.10 7.32 69.05 47.31 29.07
17.18 1.87 0.04 10.03 11.00 6.95
79.00 1.50 7.32 64.80 48.00 29.13
76.00. 82.00 1.09, 1.91 7.31, 7.35 60.90, 76.10 42.00, 54.00 26.90, 33.28
13 13 13 13 13 13
73.92 1.13 7.33 68.89 47.00 29.53
14.44 0.71 0.04 9.04 12.63 13.82
74.00 0.89 7.34 68.40 45.00 30.00
66.00, 84.00 0.60, 1.44 7.29, 7.36 67.70, 70.80 39.00, 53.00 23.04, 32.83
13 12 13 13 13 13
ratory, blood gas, A-a gradient, and lactate values 
after 20 min using t = 20 as the reference value. To 
summarize the data for the last 80 min of the 
immobilization procedure (between 20 and 100 
min), the bootstrap method was used to obtain 
the median (and median 95% confidence interval 
(Cl]) for each parameter. Box plot graphs were 
used to present the distribution of data for 
selected parameters over the 100-min period. 
Statistical significance was set at P < 0.05 for all 
statistical tests.
RESULTS
Median cardiorespiratory values for rhinoceros 
at initial sampling (t = 0) were as follows: 
respiratory rate = 7 breaths per min (breaths/ 
min), PaO, = 30 mm Hg, SaO, = 47%, PaCO, = 
60.95 mm Hg, A-a gradient -  49.19, mm H gand 
heart rate = 120 bcats/min. Median arterial blood 
pH was 7.34, BE*,= 8 mM /L, HCOj =33.5 mM / 
L, lactate = 2.48 m M /L, and rectal temperature = 
36.7°C (Table 1). Rhinoceros also initially exhib­
ited muscle tremors and limb rigidity. The mean 
induction time from darting to recumbency for all 
rhinoceros in the study was 5.71 min (95% C l, 
4.69-6.72).
At t = 10 and t = 20 there were a number of 
statistically significant changes in median values 
of physiologic parameters when compared to t = 0  
(Table 1). Subjective observations also showed 
improved muscle relaxation, with a reduction in 
tremors. PaO, (48 and 45 mm Hg, respectively) 
and SaO, (79% and 74%, respectively) both 
increased significantly at t = 10 and t = 20 min (P
< 0.0001), and A-a gradient (29.13 and 30.00 mm 
Hg, respectively) decreased significantly at the 
same time points (P < 0.001). Heart rate de­
creased significantly to 96 beats/m in at 10 min 
and 80 beats/m in at 20 min, compared to 120 
beats/m in at t = 0 (P < 0.001). Compared to 
values at t = 0 (2.48 mM /L), lactate levels were 
lower at t = 10 (1.50 mM/L, P  = 0.019) and t =20 
(0.89 m M /L  P < 0.001). Respiratory rate de­
creased from 7 breaths/min at t = 0 to 5 breaths/ 
min at t = 10 (P = 0.005) and remained at 5 
breaths/min at t = 20 (P < 0.0001). At t = 10, a 
significant difference was observed in median pH 
(7.32) when compared to the value at t = 0 (7.34). 
There were no significant changes at t  = 10 and t = 
20 in median rectal temperatures, BE^, H CO j, 
and PaCO. compared to the corresponding values 
at t = 0.
During the latter periods of immobilization 
(20-100 min), median values for respiratory rate 
and PaCO. (Fig. 1) did not change significantly, 
although both SaO. and PaO. remained at higher 
levels compared to the values at t = 0 (Fig. 2). 
Compared to t =20 (74%), SaO, was significantly 
(P < 0.05) different at t = 50, 60, 70, 90, and 100, 
with median oxygen saturation levels at 88%, 
89%, 84%, 91%, and 85%, respectively. PaO: 
values followed the same trend as SaO.. PaOj 
was significantly (P < 0.05) different at t = 50,60, 
90, and 100, with median values at 57, 61, 59, 
and 52 mm Hg, respectively, compared to values 
at t = 20 (45 mm Hg). A-a gradients at t =  50, 60, 
and 90 min were significantly (P<  0.05) different 
from t = 20 (30 mm Hg), with values of 20.37, 
20.98, and 20.07 mm Hg, respectively. There was
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Table 2. Summary distribution (mean, standard deviation, minimum, 25th percentile [Ql], median, 75th 
percentile [Q3], maximum, 95% confidence interval [Cl) for the median, and number of observations) for each 
cardiopulmonary parameter over the last 80 min (between 20 and 100 min) of the immobilization.*
Estimate
Respiratory rate 
(breaths/min)
Heart rate 
(beats/min)
Rectal
temperature (  Q
BE_
(mmol/L)
HCO, 
(mm Hg)
Mean 5.60 71.40 36.50 13.60 38.77
Standard deviation 2.45 15.53 0.77 4.62 4.28
Minimum 2.00 36.00 35.00 1.00 25.90
Ql 4.00 60.00 36.00 9.00 35.10
Median 5.00 71.00 36.40 14.00 39.60
Q3 6.00 80.00 36.90 17.00 42.20
Maximum 16.00 114.00 38.30 22.00 47.40
Median 95% CI‘ 3.7-6.3 64.1-79.9 36.1-36.7 9.3-18.7 35.8-43.4
ft 94 94 94 93 93
* BEu. base excess; HCO,, bicarbonate; SaOj. arterial hemoglobin ox>gen saturation: PaO,. arterial partial pressure o f  oxygen: 
PaCOj, arterial partial pressure of carbon dioxide: A-a gradient, alveolar -  arterial gradient.
‘ The median 95% CIs were obtained using the bootstrap method to account for lack of independence due to repealed 
measurement in the same rhinoceros over time.
an overall decreasing trend in heart rate, with 
significant differences observed a t t = 50 and t = 
100 (72 and 62 bcats/m in, respectively; P < 
0.003). Median rectal tem perature decreased 
from 36.7°C(t = 20) to 36.4°C (t = 100), although 
this change was not statistically significant (/* = 
0.07).
Median pH values improved from 7.34 (t = 20) 
to 7.37 (t = 90) (P = 0.001). Other significant 
changes in acid-base status between 20 and 100 
min included increases in BE,,, and H C 03 and a 
decrease in lactate. BE,., continued to rise after t = 
20 (11 mM /L), with significant differences ob­
served a tt  = 40 and beyond (17 and 16 m M /L at t = 
80 and t = 100, respectively; P < 0.015). Bicarbon­
ate ions also increased over time, with median 
values at t =  50 and later (41.35 m M /L at t = 100) 
significantly (P < 0.011) higher than values at t =
8 -I .
0 10 20 30 M  50 40 70 80 SO 100
Time (minute?)
Figure I . Distribution of PaCO, values over a 100- 
min immobilization of white rhinoceros.
20 (37.4 mM /L). Lactate values after 20 min 
continued decreasing, and median values were 
significantly different at t = 80 (0.68 mM /L; P  = 
0.033), t=  90 (0.46 m M /L  P=  0.023), and t = 100 
(0.80 mM/L; P -  0.006), compared to the value at t 
= 20 (0.89 mM /L) (Fig. 3). A summary distribution 
for each cardiopulmonary parameter over the last 
80 min of immobilization is shown in Table 2.
DISCUSSION
The purpose of this study was to evaluate the 
cardiorespiratory, blood gas, and lactate values in 
white rhinoceros immobilized for a prolonged 
period of time with a single dose o f butorphanol 
administered intravenously and in the absence of 
supplementary oxygen. Historically, white rhinoc­
eros have only been kept immobilized for short 
time periods (<20 min) as a result of the perceived
8.
0 10 ?0 30 i C  60 60 70 60 90 ICO
Time (minute?)
Figure 2. Distribution of PaO: values over a 100- 
min immobilization of white rhinoceros.
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Fable 2. Extended.
SaO. (% )
Lactate
(mmol/L)
Corrected
pH
Corrected PaOj 
(mm Hg)
Corrected PaCOj 
(mm Hg)
A-a gradient 
(mm Hg)
80.02 1.06 7.35 51.90 69.20 24.70
12.40 0.78 0.04 13.30 7.10 10.40
35.00 0.30 7.25 24.00 45.80 0.16
74.00 0.50 7.33 42.50 65.20 17.30
83.00 0.90 7.36 50.50 68.50 25.60
89.00 1.30 7.38 60.00 72.20 32.80
96.00 4.70 7.41 87.00 89.80 64.10
76.9-89.1 0.6-1.2 7.3-7.4 43.8-58.1 65.3-71.7 21.2-30.0
93 92 92 92 92 91
threats associated with severe opioid-induced 
respiratory depression.'-22 
The initial observations o f hypopnea, hypox­
emia, hypercapnia, and tachycardia are consistent 
with other reports o f immobilized rhinoccr- 
Hypoxemia occurs when PaO, < 80 mm 
Hg; levels reaching 50-60 mm Hg usually require 
corrective action in an anesthetized animal.2' The 
elevated PaCO; (median PaCO; = 60.95; normal 
range = 44.4-53.7 mm Hg1) at the first sampling 
period indicated that the hypoxemia (median 
PaO; = 30 mm Hg; normal range = 90.2-108.6 
mm Hg‘) was, in part, caused by hypoventila­
tion. "•2* Since the PCO; values of alveolar gas and 
arterial blood in healthy individuals are almost 
identical, changes in PaCO; are indicative of 
variations in alveolar ventilation, with hypoventi­
lation resulting in increased arterial carbon diox­
ide values.29 As alveolar ventilation decreases and 
PaCO- increases, there will be a corresponding 
drop in PaO, levels as rates o f alveolar oxygen
0  10 20 30 <0 60 60 10 M  30 100
Time (mins)
Figure 3. D istribution o f lactate values over a 100- 
min immobilization o f white rhinoceros.
replenishment are reduced. Hypoventilation is a 
pronounced side effect associated with the ad ­
ministration of opioids and is mediated by the 
activation of MOP, KOP, and DOP receptors, 
reducing the sensitivity o f carotid and aortic 
bodies to hypoxemia and, more significantly, the 
sensitivity o f brainstem chemosensory neurons to 
increasing carbon dioxide levels.'5 "  In addition, 
opioids have depressant effects on respiratory 
neurons in the brainstem, causing alterations to 
rhythmogcncsis, with resulting hypopnea." 
Opioids can further compromise ventilation 
through increased chest wall rigidity, which limits 
changes in intrathoracic pressure, and the expan­
sion and return to rest of lungs in the immobilized 
animal." Reduced upper airway patency following 
the administration of opioids can further com­
promise alveolar ventilation because of increased 
resistance to air movements through the respira­
tory tree.2*-11
The high A-a gradient (median A-a gradient = 
49.19 mm Hg; normal equine A-a gradient = 
approximately 10 mm Hg5) suggests that vcntila- 
tion/perfusion mismatching (V/Q ratio), a phys­
iologic right-to-left shunt, and diffusion 
impairment may have also contributed to the 
tow oxygen tension. “ •2’ A lower V/Q ratio (pro­
portion o f air to blood reaching an alveoli) for a 
particular lung area will impair pulmonary gas 
exchange and result in a lower PaO;. As a result of 
the "S" shape of the oxygen-hemoglobin dissoci­
ation curve, areas of high V /Q  ratios have limited 
effect on arterial PaO;.29 A shunt (V/Q ratio = 0) 
occurs when blood flows past unventilatcd alveoli 
or in pulmonary tissue not associated with alveoli, 
resulting in no gaseous exchange. This unoxygen­
ated blood flows from the arterial to the venous 
pulmonary circulation, leading to a lower 
PaO ..'5'29 Opioids decrease PaO., through reduced
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alveolar ventilation and by decreasing pulmonary 
perfusion. Pulmonary vasoconstriction occurs 
with opioids because o f both hypoxia and direct 
effects on vasculature.1'  A decreased V/Q ratio, 
including shunts, will also impair carbon dioxide 
excretion; normally this does not result in an 
increased arterial carbon dioxide tension, since as 
PaCO, rises, respiration is stimulated. However, 
in the immobilized animal, because of the opioid- 
induced respiratory inhibition, an increase in 
PaCO, would be expected. The impact of immo­
bilizing drugs used in rhinoceros on the hypoxic 
pulmonary vasom otor response is unknown, 
although injectable anaesthetics, including nar­
cotics, barbiturates, and benzodiazepines, exam­
ined in domestic animals do not have any 
detectable effect.1’-*' Large anesthetized recum­
bent animals are subject to ventilation-perfusion 
disparities due to lung compression by body mass 
and alterations to tidal volume from the abdom­
inal organs impinging on the diaphragm.1’*1 
Diffusion o f  oxygen may be impaired by an 
increase in the physical separation between alve­
olar gas and pulmonary capillary blood (caused by 
interstitial or pulmonary edema) and a shortened 
pulmonary transit time of blood. Since the 
rhinoceros in this study were clinically healthy, it 
is believed they did not have any lung pathology 
that may have reduced diffusion. However, it has 
been demonstrated in goats that etorphine causes 
an increase in the A-a gradient due to pulmonary 
hypertension, and it is proposed that this may 
result in pulmonary edema, which impairs the 
diffusion of oxygen (Meyer, pers. comm.). It may 
also reduce the time for gaseous exchange because 
of a reduced blood transit time through the 
alveolar capillaries.
Arterial oxygen levels (PaO, and SaO,) im­
proved markedly in the first 10 min following 
the administration o f butorphanol in the immo­
bilized white rhinoceros. Significant differences in 
these variables did not occur again until later in 
the immobilization period (t=  50 and beyond) and 
were not as large as the initial change. These 
findings suggest that the initial improvement in 
arterial oxygen tension was due to the adminis­
tration o f butorphanol rather than to an effect of 
tim e reducing the immobilizing drug effects 
through metabolism and redistribution, as likely 
occurred later in the immobilization (Tables 1, 2). 
Improved alveolar ventilation would increase 
PaO; levels; however, there was no evidence to 
indicate an increase in ventilation, since PaCO, 
values did not change significantly during the 
extended immobilization.1’ Increased PaO, with­
out concurrent changes in PaCO; indicates that 
etorphine-induccd respiratory depression was not 
antagonized by the administration of butorpha­
nol. The significant reduction in the A-a gradient 
from t = 0 to t = 10 may also have contributed to 
the increase in PaO. through potential improve­
ments in the V/Q ratio, shunt fraction, diffusion 
o f  oxygen, o r various combinations o f  all three.
Although the results of these clinical observa­
tions do not elucidate the mechanism responsible 
for the improved PaO.-, a number of possibilities 
arc proposed. Butorphanol is reported to reduce 
muscle rigidity and trembling oflim bs in rhinoc­
eros associated with the administration o f ctor- 
phine, which would reduce tissue oxygen 
requirements.21 Decreased tissue oxygen de­
mands, without changes in pulmonary gaseous 
exchange, can lead to increased blood oxygen 
levels.15 Azapcrone, included in the initial immo­
bilizing drug combination, may also have caused 
muscle relaxation, as maximum activity of this 
drug is reached within 20 to  30 min after 
administration.1 However, it has been observed 
by the author (PB) during capture o f large 
numbers o f  rhinoceros (>500) with etorphine 
and azaperonc that muscle tremors and rigidity 
persist through the immobilization period if 
butorphanol is not administered. Recent studies 
in boma-confined white rhinoceros immobilized 
with etorphine and azaperone without butorpha­
nol administration, in which muscle tremors 
persisted, did not show an increase in PaO, over 
20 min." As a partial mixed opioid agonist- 
antagonist, butorphanol may also relieve muscle 
rigidity, which impairs the movement o f the 
thoracic wall and diminishes upper airway paten- 
cy.xn.a cou)(i ajso counteract ctorphinc-associ- 
ated pulmonary vasoconstriction, resulting in 
improved pulmonary gas exchange and, hence, 
blood oxygenation.1'
Despite persistently high PaCO, levels, respira­
tory rate decreased significantly in the first 10 min 
and then remained at this level for the remaining 
90 min. This may have been due to ongoing drug- 
induced respiratory depression by the initial 
immobilizing drugs or the KOP receptor agonist 
effects o f butorphanol.-'' However, the decrease in 
respiratory rate was associated with improved 
blood oxygen values. Possible explanations for this 
change in PaO, include decreased tissue metabo­
lism and oxygen consumption, an increase in tidal 
volume with a fractional decrease in alveolar dead 
space ventilation, an improvement in the A-a 
gradient, or various combinations of all three.
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In the exercising animal, increased lactate 
values are used as a measure of anaerobic 
metabolism due to hypoxia or tissue hypoperfu­
sion. The highest median lactate value (2.48 m M / 
L) occurred at t -  0 but was lower than that 
observed in field-immobilized white rhinoceros.17 
This is not unexpected, as free-ranging animals 
are usually darted from a helicopter and experi­
ence high levels o f  muscle activity prior to and 
during the immobilization induction phase com­
pared to the boma-confincd study animals.■* 
Normal resting lactate values in white rhinoceros 
arc not available in the literature; however, values 
for horses (0.70-2.85 mM/L) suggest the lactate 
levels in these rhinoceros were resting or slightly 
elevated.21 An initial increase in lactate produc­
tion may have occurred as a result of opioid- 
induced localized muscle activity and limb rigid­
ity (tremors) combined with hypoxemia during 
the induction phase.1 A decrease in anaerobic 
metabolism and muscle activity in the immobi­
lized animal would result in progressively de­
creasing lactate levels.
Despite a persistent hypercapnia, lactate levels 
and other acid-base parameters improved over 
time. The initial moderate acidosis improved as a 
result o f increased B E ^and HCOj and decreased 
lactic acid (Fig. 3; Tables 1, 2). These results 
indicate that the improvement in acid-base status 
was metabolic in origin rather than dependent on 
respiratory compensatory mechanisms.
The rhinoceros in this study were tachycardic at 
t = 0 despite minimal exertion associated with 
darting in a confined holding space. Etorphinc is 
reported to cause both tachycardia and bradycar­
dia depending on dose, species, and other con­
currently administered drugs.1’12 Pronounced 
tachycardia and increased blood pressure have 
been reported in elephants after administration of 
ctorphine.’ 10 At t =  20, the median heart rate in 
rhinoceros was reduced by approximately one- 
third from the initial tachycardia (median 120 
beats/m in). This reduction may be due to a 
partially reversed hypoxemic vasodilator effect 
associated with increases in PaO; and SaO, o r a 
decline in the sympathetic response to hypoxia.*-’ 
Another possibility is a direct opioid receptor- 
mediated effect on the heart.* A more complete 
understanding of the observed heart rate changes 
would require measures o f  cardiac output, stroke 
volume, and total peripheral resistance. The an- 
adrenoceptor antagonist activity of azaperonc on 
peripheral vasculature should also be taken into 
account.
There is a paucity of literature regarding the 
effects o f  butorphanol on the cardiovascular 
system. In humans, butorphanol reduces tachy­
cardia in patients under the influence o f cocaine; 
the explanation for this observation has no t been 
elucidated.10
The underlying mechanism for changes in PaO; , 
SaOj, and respiratory and heart rates during the 
first 20 min requires further investigation. A l­
though the timing o f observed changes in this 
report indicates that butorphanol may have con­
tributed to these effects, interpretation is limited 
by the lack of a control group (i.e., animals to 
which no butorphanol was administered), which 
was not included because o f the requirements o f a 
concurrent study using these individual animals. 
Anecdotal observations suggest butorphanol im­
proves immobilization quality and physiologic 
parameters in white rhinoceros.22 However, the 
specific behavioral, pharmacologic, and therapeu­
tic effects o f this mixed opioid agonist-antagonist 
are not clearly defined in complex biological 
systems. The clinical effects o f butorphanol in 
immobilized rhinoceros are further complicated 
by the presence of etorphinc, a potent pure 
agonist at all three opioid peptide receptors.11 In 
humans, the actions of butorphanol are similar to 
those o f pentazocine, which does not antagonize 
the respiratory depression produced by m orphine 
In postoperative patients, 2 to 3 mg of butorpha­
nol produced a respiratory depression equivalent 
to that o f 10 mg of morphine.11 Butorphanol 
administered to rhesus monkeys resulted in a 
dose-dependent decrease in respiratory minute 
volume and behavioral effects consistent with 
MOP receptor activity, which overrides KOP 
receptor-mediated actions.2’-10 The receptor bind­
ing profile o f butorphanol also varies between 
species, and the precise mechanism of action is 
not fully elucidated. Pharmacologic effects in 
rhesus monkeys and pigeons are produced 
through MOP receptors, compared to both 
MOP and KOP receptors in laboratory rodents.10 
It has previously been reported2* that butorphanol 
did not result in any benefits to ventilation in 
immobilized white rhinoceros However, the ef­
fects o f butorphanol may have been dampened in 
this study by the addition of dctomidinc to the 
etorphine and azaperone combination. Dctomi- 
dine, an or.-agonist, can cause significant negative 
respiratory effects, compounding those o f the 
opioids2*
As a result o f the severe hypoxemia that occurs 
in opioid-immobilized white rhinoceros it has 
been suggested that oxygen supplementation
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should be routinely used; however, this can be 
difficult to accomplish. Under extensive condi­
tions, animals are frequently immobilized many 
kilometers from a home base with limited per­
sonnel and equipment associated with helicopter 
capture. Orotracheal intubation can be demand­
ing in white rhinoceros because of the size of the 
head and the muscle rigidity associated with the 
use of etorphine, which makes it difficult to open 
the mouth.: Intermittent positive pressure venti­
lation requires the placement o f a cuffed endo­
tracheal tube and use of high-capacity ventilators 
or a demand valve connected to a large source of 
compressed air.: Oxygen supplementation into 
the trachea using an equine nasogastric tube 
passed through the nasal cavity has also been 
described.2
A recent study" has shown that the oxygen 
supplementation in white rhinoceros immobilized 
with etorphine and azaperone does not improve 
the resulting hypoxemia and causes further in­
creases in PaCOj in animals that are already 
hypercapnic and a severe acidemia with worsen­
ing blood pH. It is hypothesized that these effects 
were due to increased intrapulmonary shunt 
fractions resulting in lung atelectasis. It is also 
possible that the high levels o f hypcrcarbia, which 
result from increasing PaCO: levels in animals 
receiving oxygen, may depress central nervous 
system (CNS) respiratory control." However, if 
butorphanol was administered prior to oxygen 
supplementation, hypoxemia was completely re­
versed, although neither PaCOj nor pH im­
proved." Similar results have been reported2 in 
rhinoceros administered nalorphine (mixed opi­
oid agonist-antagonist) o r doxapram hydrochlo­
ride (CNS stimulant) prior to or during the 
intratracheal adm inistration o f  supplementary 
oxygen to the level of the carina. Oxygen satura­
tion increased to greater than 90%, although 
hypercapnia and academia persisted. In humans, 
supplemental oxygen exacerbates opioid-induced 
ventilatory depression, which may be due to 
decreased output o f the peripheral and ventral 
medulla chemoreceptors, causing a reduced ven­
tilation drive.20
CONCLUSION
Despite the relatively small sample size in this 
report (n = 13 white rhinoceros immobilizations), 
several statistically significant and clinically rele­
vant changes occurred during the immobilization 
period. Initial severe hypoxemia in rhinoceros 
immobilized with etorphine and azaperone and 
administered a single i.v. dose of butorphanol (at
10 times the etorphine dose) at t =  0 improved 
during the first 20 min, as reflected by increased 
PaO, and S a0 2. However, the change in blood 
oxygen tension was limited, and animals remained 
hypoxic. Steadily declining lactate values indicate 
a lack of generalized anaerobic metabolism, which 
suggests that tissue oxygen delivery met metabol­
ic demand or that metabolic rate and oxygen 
consumption was reduced during the first 20 min, 
o r both." PaCOj values did not change signifi­
cantly, and hypercapnia persisted for the entire 
100 min; however, during this time, acidosis was 
corrected by metabolic compensatory mecha­
nisms. A well-designed study with controls is 
required to further investigate these initial results, 
which suggest that butorphanol may improve 
blood oxygen tension and provide some cardio­
vascular and add-base support in immobilized 
rhinoceros. Factors such as body position and 
other potential confounders (e.g., body mass, age, 
drug dosages, and activity levels prior to drug 
administration) should also be considered. Ob­
servations indicate that healthy white rhinoceros 
immobilized with etorphine and azaperone and 
administered a single dose o f butorphanol can 
tolerate prolonged periods (100 min) o f hypox­
emia and hypercapnia.
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Abstract
Objective To investigate the effects of post-induction butorphanoi administration 
in etorphine-immobilized white rhinoceros on respiration and blood gases.
Study design Randomized crossover study.
Animals Six sub-adult male white rhinoceros.
Methods Etorphine, or etorphine followed by butorphanoi 12 minutes after 
recumbency, was administered intramuscularly [2.5 mg etorphine, 25 mg 
butorphanoi (1000 to 1250 kg), or 3.0 mg etorphine, 30 mg butorphanoi (1250 to 
1500 kg)]. Sampling started at 10 minutes after initial recumbency, and was 
repeated at five-minute intervals for 25 minutes. Arterial blood gases, limb muscle 
tremors, expired minute ventilation and respiratory frequency were measured at 
each sampling point. Calculated values included alveolar to arterial oxygen 
gradient, expected respiratory minute volume, tidal volume, physiological 
deadspace, oxygen consumption, and carbon dioxide production.
Results Etorphine administration resulted in an initial hypoxaemia median (range) 
[PaCE 25.0 (23-28) mmElg], hypercapnia [PaCCE 76.2 (67.2-81.2) mmHg], 
increased P(A-a) O2 [41.7 (36.6-45.1) mmHg, VO2 [11.1 (10.0-12.0) L minute'1] 
and muscle tremors. Butorphanoi administration was followed by rapid, although 
moderate, improvements in PaCE [48.5 (42-51) mmHg] and PaCCE [62.8 (57.9- 
75.2) mmHg], In rhinoceros receiving butorphanoi, median VO2 [4.4 (3.6-5.1) L 
minute'1] and [VCCE (4.2 (3.8-4.4) L minute'1] were lower than in those not 
receiving butorphanoi. Increased arterial oxygen tension was associated with 
lower oxygen consumption (p=0.002) which was positively associated with lower 
muscle tremor scores (pO.OOOl).
Conclusion and clinical relevance Hypoxaemia and hypercapnia in etorphine- 
immobilized rhinoceros resulted from an increased alveolar-arterial gradient and 
increased oxygen consumption and carbon dioxide production associated with 
muscle tremors. Rather than being associated with changes in respiratory minute 
ventilation, it appears that improved blood gases following butorphanoi 
administration were a consequence of decreased oxygen consumption associated 
with reduced muscle tremoring.
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Introduction
Chemical capture is an essential tool in the management of free-ranging white 
rhinoceros (Ceratotherium simum) (Wenger et al. 2007). Etorphine, the opioid 
preferentially used in immobilization of rhinoceros, results in areflexia without 
total loss of consciousness, due to central nervous system depression within a few 
minutes following intramuscular (IM) administration (Portas 2004; Swan 1993). 
Etorphine is commonly combined with azaperone, a butyrophenone tranquillizer, 
which reduces induction times and opioid-associated hypertension (Portas 2004). 
Unfortunately, hypoxaemia, hypercapnia and acidaemia are well documented 
adverse effects associated with the use of etorphine and azaperone, and mortalities 
have been associated with immobilization in rhinoceros (Kock et al. 1995; Haw et 
al. 2015). Butorphanol, a mixed opioid agonist - antagonist, is administered 
intravenously (IV) in immobilized rhinoceros to mitigate these adverse 
cardiorespiratory effects. However, inconsistent changes in blood gases following 
butorphanol administration have been reported. Different explanations for the 
effect of butorphanol in white rhinoceros, including improved ventilation or 
possible alterations in metabolic activity, also have been proposed (Miller et al. 
2013; Haw et al. 2014; Boardman et al. 2014; Buss et al. 2015). The objectives of 
this study were to determine the effects of etorphine on respiration in immobilized 
rhinoceros and changes that occur following the intravenous administration of 
butorphanol. Cardiovascular effects of etorphine and intravenous butorphanol in 
these study rhinoceros have been previously reported (Buss et al. 2016).
Materials and methods
The study had ethical approval from SANParks Animal Use and Care Committee 
(Ref. no. 14-2) and University of the Witwatersrand Animal Ethics Screening 
Committee (Ref. no. 2014/15/C). Management of the rhinoceros was conducted 
according to the South African National Parks (SANParks) Standard Operating
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Procedures for the Capture, Transportation and Maintenance in Holding Facilities 
of Wildlife.
Six white rhinoceros, sub-adult (5 to 6 year old) males, were captured in 
Kruger National Park (23° 49’ 60 S, 310 30’ 0 E; alt. 317m), South Africa, and 
habituated to captivity in holding pens over a period of four months. The study 
was a crossover design with two interventions allocated using computer generated 
random numbers with a two week washout period between treatments; I) 
etorphine hydrochloride (9.8 mg mL'1, M99, Elanco, Gauteng, South Africa) plus 
hyaluronidase (5000 i.u., Kyron Laboratories, Gauteng, South Africa), 
administered intramuscularly (IM), and II) etorphine hydrochloride plus 
hyaluronidase administered IM followed by butorphanol (50 mg mL’1, Kyron 
Laboratories) administered IV. Doses were 2.5 mg etorphine, 5000 i.u. 
hyaluronidase, 25 mg butorphanol (1000 to 1250 kg), and 3.0 mg etorphine, 5000 
i.u. hyaluronidase, 30 mg butorphanol (1250 to 1500 kg) (Haw et al. 2014; Buss 
et al. 2015). Azaperone was not included in the immobilizing drug combination 
due to potential confounding respiratory and cardiovascular effects (Portas 2004).
Etorphine plus hyaluronidase were administered using a 3.0 mL plastic 
dart with a 60 mm un-collared needle propelled from a compressed air rifle 
(DAN-INJECT, International S.A., Skukuza 1350, South Africa). Once an animal 
could be safely handled, it was blindfolded and placed in sternal recumbency for 
one minute to facilitate initial instrumentation and subsequently rolled into lateral 
recumbency. The influence of variable induction times on physiological 
measurements was reduced by conducting a trial only if the rhinoceros became 
recumbent and could be safely handled within 15 minutes after darting (Haw et al. 
2014). Recumbency was used as an indicator of immobilization level equivalency 
between trials. Data collection started 10 minutes after initial recumbency (t = 0), 
and was repeated at five-minute intervals over a 25 minutes study period. In those 
rhinoceros receiving treatment II, butorphanol was administered IV at 2 minutes (t 
= 2 ) as this allowed for instrumentation of study animals and most closely 
approximated the time at which butorphanol is administered in field-immobilized 
rhinoceros. In treatment I, rhinoceros were administered sterile saline at t=2. At
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the end of each trial, all rhinoceros were weighed and administered naltrexone (40 
mg mL'1, Kyron laboratories) IV at 20 times the etorphine dose.
Expired minute ventilation (corrected for body temperature and saturated 
pressure) (VEBtps) (L minute'1) was measured via shortened equine endotracheal 
(ET) tubes (V KRUUSE I.D. 28, CAT. No. 282270, Jorgen Kruuse A/S, 
Langeskov, Denmark) inserted into each nostril with the cuffs inflated to create an 
airtight seal. A two-way Y-shape non-rebreathing valve (2730 Series, Hans 
Rudolph, inc, Shawnee, USA) was connected to each ET tube at the nares external 
margin which allowed inspired air to enter the tube and directed expired air to a 
PowerLab Exercise Physiology System (ML870B80, ADInstruments, Castle Hill, 
Australia). Expired minute ventilation (VEBTps) was determined via a respiratory 
flow head (MLT1000L) linked to a spirometer (ML 140) and a gas mixing 
chamber (MLA245). Expired air temperature was recorded by a thermistor pod 
(ML309) in the mixing chamber.
Expired air was collected into a Douglas bag for one minute at the end of 
each sampling interval and analysed using a Cardiocap/5 (Datex-Ohmeda, GE 
Healthcare, Helsinki, Finland) for mixed-expired carbon dioxide pressure 
(PECO2) (mmHg) and expired oxygen fraction (FE02) (%). The same monitor 
was used to analyse expired air from one of the ET tubes to determine end-tidal 
carbon dioxide pressure (PETCO2) (mmHg) and oxygen fraction (FETO2) (%), 
and measure respiratory frequency (fR). Body temperature (TB) (°C) was 
measured using a rectal thermometer (BAT-12, Physitemp Instruments, New 
Jersey, USA).
A 22 gauge intravenous catheter was inserted into an auricular artery and 
blood samples collected into heparinized lmL syringes and immediately analysed 
using a portable blood gas analyser (iSTAT 1 Handheld Clinical Analyzer, Heska 
Corporation, Colorado, USA) and CG4+ cartridge (iSTAT CG4+ cartridges,
Heska Corporation). The alveolar -  arterial oxygen gradient (P(A-a) 0 2) (mmHg) 
was calculated using the formula FI02(PB -  PH20) -  PaCCT -  Pa02, with inspired 
oxygen fraction (FIO2) (%) standardized to 20.9 % and barometric pressure (PB) 
(mmHg) measured by the portable blood gas analyser prior to each 
immobilization. Alveolar vapour pressure of saturated air (PH20 ) (mmHg), at a
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specific TB, was determined using the formula 4.58 exp [(17.27 TB)/(237.3 + 
TB)] (Meyer et al. 2010). The expected respiratory minute ventilation (VEXP) (L 
minute'1) in the rhinoceros prior to immobilization was estimated from body mass 
using the formula 0.518 BM° 802 (Bide et al. 1997). Actual respiratory minute 
ventilation was considered to be equivalent to V E btps, which was divided by fR to 
calculate tidal volume (VT) (L breath"1).
The Enghoff modified Bohr’s equation ((PaCCE -  PEC02)/PaC02)VT was 
used to determine physiological dead space (VDphys) (L breath'1) (Tusman et al. 
2012). The (VDphys) was corrected by 300 mL for the volume of the two ET tubes 
extending beyond the rhinoceros nostrils.
Oxygen consumption (V02) (L minute'1) was calculated as the difference 
between inspired and expired oxygen fractions as a proportion of expired minute 
ventilation at standard temperature and dry pressure (V E stpd), i.e. V0 2 = (FIO2 -  
FE02)/100 x (V E stpd) (McArdle et al. 1986). The V E btps was multiplied by 
(273/310)((PB -47)/760) to convert from BTPS to STPD (West 2008). Since 
inspired and expired minute ventilation were not equivalent (depending on the 
respiratory quotient), and V E stpd was used to determine both FIO2 and FEO2, the 
Haldane transformation was used to correct the inspired oxygen volume, i.e. VC)2 
= V E Stpd(F I0 2( ( 1 -  (FE02 + FEC02)/1 -  (F102 + FIC02)) -  FE02) (McArdle et al. 
1986).
Carbon dioxide production (VC02) (L minute'1) was calculated as the 
product of V E stpd and the difference between expired and inspired carbon dioxide 
fractions. Carbon dioxide production was determined using the formula VC02 = 
V E stpd (FEC02 -  0.03%). Inspired fractions for oxygen and carbon dioxide were 
standardized at FI02 = 20.9% and FIC02 = 0.03% (McArdle et al. 1986).
Skeletal muscle tremors, especially of the limbs, head, and shoulders, in 
the immobilized rhinoceros were subjectively evaluated and scored by a single 
observer at each time point according to criteria in Annexure I. Total muscle 
tremor scores were calculated as the sum of all the scores for that treatment at 
each time point.
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Data analyses
STATA (Stata Statistical Software: Release 14, College Station, Texas, 
USA) was used for statistical analyses. Descriptive statistics were calculated to 
assess data distribution for each treatment at different sampling points. Due to the 
relatively small sample size (n=6), non-parametric statistical tests were used to 
compare median blood gases and respiratory values at specific sampling points 
within each treatment. The Kruskal-Wallis test was used to assess whether 
median values for blood gases and respiratory parameters differed over sampling 
points. Based on these findings, differences in medians between matched pairs of 
values at t=0 to t=10 were compared using the Wilcoxon rank signed test. To 
confirm that no further changes occurred after 10 minutes, linear regression (using 
ranks) was used to assess changes in blood gases and respiratory parameters after 
10 minutes using t=10 as the reference value. Correlations between blood gases, 
respiratory parameters and muscle tremor scores were evaluated using linear 
regression. To evaluate differences in blood gases and respiratory parameters 
between treatment groups, linear regression (using ranks) was used to compare 
median blood gases and respiratory parameters while adjusting for the effect of 
time. Statistical significance was set at p < 0.05 for all statistical tests.
Results
All rhinoceros in both treatments became sternally recumbent within 15 
minutes of etorphine administration, and sample and data collection started 10 
minutes later. All study animals recovered with no ill effects.
Treatment 1: etorphine
Table 1 shows the blood gases and respiratory values for treatment I. 
Median arterial PaC>2 and PaC02 did not change significantly during the first 10 
minutes (t=0 to t=10) or subsequent 15 minutes (t=10 to t =25) (Fig. 1).
The median VEXP (t=0) was 163 L minutes'1. V E btps declined between t= 
0-10 and t=10-25; however, these changes was not statistically significant (Fig.
2). The fR decreased significantly (/;=0.034) over the first ten minutes, but did not
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change between t=l 0-25. No changes over time (t= 0-10, t=10-25) were observed 
in VT, P(A-a) 0 2 and V D PHys-
The V02 decreased between t=0 and t=10 (p=0.046) (Figure 3 A); however 
the decrease in VC02 over the same period was not statistically significant (Figure 
3B). There was a positive correlation between PaC02 and VC02 (p=0.021, r2 
=0.15), and inverse correlations between Pa02and V02 (/>=0.038, r2 =0.12). Both 
V02 and VC02 were associated with muscle tremor scores (p<0.0001, r = 0.52; 
p=0.0001, r=0.57, respectively) which decreased over the study period (Fig. 4).
Treatment 11: etorphine and butorphanol
Table 1 shows the blood gases and respiratory values for treatment II. In 
etorphine-immobilized rhinoceros administered butorphanol IV (t=2), there was a 
significant increase in Pa02 (/?=0.027) and decrease in PaC02 (p=0.046) between 
t=0 and t=10 with no further significant changes (Fig. 1). Between t=0 and t=10, 
V E btps declined (/?=0.03) with a decrease in fR (p=0.032), a reduction in V T 
(p=0.046) and drop in V D PHys (p=0.03), then remained unchanged (t=l 0-25) (Fig. 
2 ). Following butorphanol administration, there was a transient increase in V E btps 
which reached a maximum value at t=3, but returned to pre-injection values at 
t=5. The P(A-a) 0 2 did not change significantly during the trial. The V02 declined 
between t=0 and t=10 (p=0.027) with no further changes over time (Fig. 3A). 
Trends in VC02 were similar to V02 with declines between t=0 and t= 10 
(p=0.027), although there was also a decrease from t= 10 to t=25 (/z=0.014)
(Figure 3B). There was a positive association between PaC02 and VC02 
(p=0.0002; r2=0.34), and inverse correlations between Pa02 and V02 (p=0.002, r2 
=0.25). Both V02 and VC02 were associated with muscle tremor scores 
(p<0.0001, r2 =0.72; p<0.0001, r2=0.65, respectively). Muscle tremors decreased 
rapidly between t=0 and t=5 and remained low for the rest of the trial period (Fig.
4).
Table 1. Distribution of blood gases and respiratory parameters, median and interquartile range (25th to 75th percentile), at sampling periods 0, 5, 10, and 25 minutes in six captive 
male white rhinoceros (5 to 6 year old) for two treatments: I) etorphine IM; and, II) etorphine IM and butorphanol IV.
Treatm ent3 0 min 5 min 10 min 25 min
Pa02 (mmHg) T 25.0 (23-28) 25.0 (23-28) 27.5 (23-29) 26.0 (25-29)
(kPa) 3.3 (3.1-3.7) 3.3 (3.1-3.7) 3.7 (3.1-3.9) 3.5 (3.3-3.9)
25.5 (22-26) 48.0 (42-50) 48.5 (42-51) 43.5 (38-46)
3.4 (2.9-3.5) 6.4 (5.6-6.7) 6.5 (5.6-6.8) 5.8 (5.1-6.1)
PaCCT (mmHg) 76.2 (67.2-81.2) 71.1 (60.9-79.6) 72.3 (66.9-81.8) 78.5 (70.8-82.4)
(kPa) 10.2 (9.0-10.8) 9.5 (8.1-10.6) 9.6 (8.9-10.9) 10.5 (9.4-11.0)
81.7 (76.1-89.3) 58.2 (54.7-68.4) 62.8 (57.9-75.2) 63.7 (62.8-65)
10.9 (10.1-11.9) 7.8 (7.8-9.1) 8.4 (7.7-10.0) 8.5 (8.4-8.7)
VEbtps (L minute'1) I 164.0 (126.6-182.2) 137.6 (102.5-153.7) 118.7 (88.5-130.6) 96.1 (66.8-101.4)
II 151.4 (139.0-172.2) 153.0 (125.7-160.5) 89.5 (85.0-98.5) 83.0 (76.6-86.5)
fR (breaths minute'1) I 9.5 (9-10) 8.5 (8-9) 7.0 (6-7) 5.5 (5-8)
II 9.5 (8-10) 11.0 (10-13) 7.5 (6-8) 6.0 (6-7)
VT (L breath'') I 18.0 (14.1-21.5) 16.1 (14.0-16.7) 18.3 (17.7-18.7) 14.2 (12.7-15.5)
II 16.8 (15.2-20.4) 12.2 (11.7-16.1) 11.9 (11.0-16.9) 13.4 (11.7-14.4)
P(A-a) 0 2 (mmllg) 41.7 (36.6-45.1) 48.9 (39.0-53.3) 44.3 (33.8-46.9) 39.0 (33.6-44.1)
(kPa) 5.6 (4.9-6.1) 6.5 (5.2-7.1) 5.9 (4.5-6.3) 5.2 (4.5-5.9)
37.0 (33.3-41.5) 38.9 (32.9-43.1) 37.0 (30.7-39.3) 36.7 (35.0-39.1)
4.9 (44-5.5) 5.2 (4.4-5.7) 4.9 (4.1-5.2) 4.9 (4.7-5.2)
V D PHYs (L minute'1) I 59.5 (35.8-69.8) 42.1 (19.3-60.5) 39.5 (23.5-43.7) 35.6 (26.4-48.2)
II 47.9 (46.9-50.9) 35.9 (17.5-52.2) 31.4 (21.9-41.2) 29.0 (26.1-34.5)
V 02 (L minute'1) I 11.1 (10.0-12.0) 8.7 (7.7-9.8) 7.8 (5.8-8.6) 6.4 (3.7-7)
11 10.9 (9.1-12.0) 6.8 (5.5-8.0) 4.4 (3.6-5.1) 4.2 (4.0-4.6)
V C02 (L minute'1) 1 8.3 (7.8-11.4) 6.8 (5.9-7.8) 6.0 (4.9-7.1) 4.3 (3.5-5.3)
II 9.3 (7.2-10.4) 6.9 (6.2-7.7) 4.2 (3.8-4.4) 3.7 (2.7-3.8)
aTreatment I, etorphine IM (2.5 mg etorphine, 1000 to 1250 kg; 3.0 mg etorphine, 1250 to 1500 kg); Treatment II, etorphine IM (2.5 mg etorphine 1000 to 1250 kg; 3.0 mg etorphine
1250 to 1500 kg) and butorphanol IV (25 mg butorphanol, 1000 to 1250 kg; 30 mg butorphanol, 1250 to 1500 kg).
Intramuscular (IM), intravenous (IV), arterial partial pressure oxygen (Pa02) and carbon dioxide (PaC02), expired minute ventilation (VEBtps), respiratory rate (fR), tidal volume 
(VT), alveolar -arterial oxygen gradient (P(A-a) 0 2, physiological dead space (V D PHys)> oxygen consumption (V 02), and carbon dioxide production (V C02). OxvO
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Comparison of treatments I and II
Table 2 shows overall distribution of blood gases and respiratory values 
between treatments I and II. The Pa02 was higher (/?<0.001) and PaC02 was 
lower (/?=0.001) when comparing overall median values in treatment II versus 
treatment I (Fig. 1). There were no differences in median values for V E btps or 
VDphys between treatments (Fig. 2). Median fR was statistically higher (p=0.045) 
and Vj significantly lower (/?=0.008) in animals receiving butorphanol. In 
treatment II, median P(A-a) 0 2 values were lower compared to treatment I 
(/?=0.019). Overall V02 and VC02 were lower in treatment II compared to 
treatment I animals (/?=0.001) (Figs. 3A & 3B).
T a b le  2 . O v e ra ll  d is tr ib u tio n  o f  b lo o d  g a s e s  a n d  re sp ira to ry  p a ra m e te rs ,  m e d ia n  a n d  
in te rq u a r t i le  ra n g e  (2 5 th  to  7 5 th  p e rc e n ti le ) ,  o v e r  th e  s a m p lin g  p e r io d  0  to  2 5  m in u te s  in  s ix  
c a p t iv e  m a le  w h ite  rh in o c e ro s  (5  to  6  y e a r  o ld )  fo r  tw o  t re a tm e n ts :  I)  e to rp h in e  IM ; a n d , II)  
e to rp h in e  IM  a n d  b u to rp h a n o l IV .______________________________________________________________
“T rea tm en t I II
P a 0 2 (nim H g) 26 (2 3 -2 9 ) 4 2 .5 (3 0 .5 -4 8 .5 )
(kP a) 3 .5 (3 .1 -3 .9 ) 5 .7 (4 .1 -6 .5 )
P a C 0 2 (m m H g) 75 .5 (6 7 .4 -8 2 .3 ) 64 .3 (6 1 .1 -7 6 .1 )
(kPa) 10.1 (9 .0 -1 1 .0 ) 8 .6 (8 .1 -1 0 .1 )
V E(btps) (L  m in u te '1) 1 0 5 .9 (8 4 .3 -1 3 7 .9 ) 9 0 .0 (8 4 .7 -1 3 7 .9 )
/ R (b re a th s  m in u te '1) 7 .0 (5 -7 ) 7 .0 (6 -9 )
VT (L  m in u te 1) 16.3 (1 4 .0 -1 8 .3 ) 14.1 (1 1 .8 -1 6 .2 )
P(A -a) 0 2 (m m H g) 4 1 .5 (3 4 .1 -4 5 .8 ) 3 6 .8 (3 3 .2 -4 0 .3 )
(kPa) 5.5 (4 .5 -6 .1 ) 4 .9 (4 .4 -5 .4 )
V 0 2 (L  m in u te ') 7.3 (5 .6 -8 .7 ) 4 .8 (4 .1 -6 .8 )
V C 0 2 (L  m in u te '1) 5 .8 (4 .2 -7 .2 ) 4.1 (3 .8 -6 .3 )
“T re a tm e n t  I, e to rp h in e  IM  (2 .5  m g  e to rp h in e , 10 0 0  to  1 2 5 0  kg ; 3 .0  m g  e to rp h in e , 1 2 5 0  to  15 0 0
k g ) ;  T re a tm e n t  II , e to rp h in e  IM  (2 .5  m g  e to rp h in e  10 0 0  to  1250  kg ; 3 .0  m g  e to rp h in e  1 2 5 0  to  
150 0  k g ) a n d  b u to rp h a n o l IV  (2 5  m g  b u to rp h a n o l,  1000  to  1250  kg ; 3 0  m g  b u to rp h a n o l ,  1250 
to  1 5 0 0  kg ).
In tra m u s c u la r  ( IM ), in tr a v e n o u s  ( IV ) , a r te r ia l  p a rtia l p re s su re  o x y g e n  ( P a 0 2) a n d  c a rb o n  
d io x id e  ( P a C 0 2), e x p ire d  m in u te  v e n ti la t io n  (V E BTPS), r e sp ira to ry  ra te  ( fR ) ,  t id a l v o lu m e  (V T ) , 
a lv e o la r  - a r t e r ia l  o x y g e n  g ra d ie n t  (P (A -a )  0 2, p h y s io lo g ic a l  d e a d  sp a c e  ( V D PHys)> o x y g e n  
c o n s u m p tio n  ( V 0 2), a n d  c a rb o n  d io x id e  p ro d u c tio n  ( V C 0 2).
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e t o r p h i n e  I M  e t o r p h i n e  I M  , b u t o r p h a n o l  I V
Figure 1. Median and interquartile range of arterial partial pressures of (A) 
oxygen (Pa02) and (B) carbon dioxide (PaCCF) at sampling periods 0, 5, 10, 
15, 20 and 25 minutes in six captive male white rhinoceros (5 to 6 years old) 
for treatment 1 (etorphine IM) or treatment II (etorphine IM and butorphanol 
IV). The dashed line indicates the time at which butorphanol was 
administered.
*, indicates a significant (p < 0.05) difference within treatment between t = 0 
and t = 10,
+, indicates a significant (p < 0.05) difference within treatment between t =10 
and t = 25,
#, indicates a significant (p < 0.05) difference in overall median values 
between treatments I and II from 5 to 25 minutes.
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Figure 2. Median and interquartile range of expired minute ventilation 
(VEbtps) measured at one minute intervals between 0 and 25 minutes in six 
captive male white rhinoceros (5 to 6 years old) for treatment 1 (etorphine IM) 
or treatment II (etorphine IM and butorphanol IV). The dashed line indicates 
the time at which butorphanol was administered.
*, indicates a significant (p < 0.05) difference within treatment between t = 0 
and t = 10,
+, indicates a significant (p < 0.05) difference within treatment between t =10 
and t = 25,
#, indicates a significant (p < 0.05) difference in overall median values 
between treatments I and II from 5 to 25 minutes.
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e t o r p h i n e  I M  e t o r p h i n e  I M  , b u t o r p h a n o l  I V
Figure 3. Median and interquartile range of (A) oxygen consumption (VO2) 
and (B) carbon dioxide production (VC02) calculated for sampling periods 0, 
5, 10, 15, 20 and 25 minutes in six captive male white rhinoceros (5 to 6 
years old) for treatment I (etorphine IM) or treatment II (etorphine IM and 
butorphanol IV). The dashed line indicates the time at which butorphanol 
was administered.
*, indicates a significant (p < 0.05) difference within treatment between t =
0 and t = 10,
+, indicates a significant (p < 0.05) difference within treatment between t 
= 10 and t = 25,
indicates a significant (p < 0.05) difference in overall median values 
between treatments I and II from 5 to 25 minutes.
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Figure 4. Muscle tremor scores at sampling periods 0, 5, 10, 15, 20 and 25 
minutes were the sum of all the scores (1 to 5) at each time point in six captive 
male white rhinoceros (5 to 6 years old) for treatment 1 (etorphine IM) or 
treatment II (etorphine IM and butorphanol IV).
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Discussion
In this study, immobilization of white rhinoceros with etorphine resulted in 
hypoxaemia and hypercapnia. Contrary to previous reports, these changes were 
not associated with a decrease in respiratory minute ventilation but rather an 
increase in alveolar-arterial oxygen gradient and oxygen consumption. 
Administration of IV butorphanol was followed by improvements in arterial 
oxygen and carbon dioxide tensions, although animals remained hypoxaemic and 
hypercapnic. Improved blood gases appeared to result primarily from a decrease 
in oxygen consumption associated with decreased muscle tremors, rather than 
from changes in ventilation.
The use of only six rhinoceros due to welfare considerations and logistical 
challenges is a study limitation. The small sample size may have resulted in lack 
of statistical differences and masked potentially clinically important physiological 
changes. Inability to determine alveolar ventilation, cardiac output, pulmonary 
artery pressures, shunt fractions and V/Q ratios, in part, limited a comprehensive 
understanding of physiological mechanisms influencing arterial blood gases. 
Physiological differences may exist between free-ranging and captive rhinoceros; 
therefore further studies should compare these conditions.
Hypoxaemia and hypercapnia are frequently reported in etorphine- 
immobilized rhinoceros and extremes of blood gases measured in our study (PaC>2 
of about 25 mmHg and PaCCE of about 80 mmHg) suggest they can be life- 
threatening (Yaksh & Wallace 2011; Haw et al. 2014; Boardman et al. 2014). A 
PaC>2<80 mmHg indicates hypoxaemia in an anaesthetized animal and animals 
with values below 60 mm Hg normally require supportive treatment (Read 2003). 
A PaCC>2>70 mmHg may produce myocardial depression, arrhythmias and 
impaired metabolism due to respiratory acidosis, and ventilator support is 
advocated (Moens 2013). In addition, opioid chemoreceptor depression can 
profoundly depress hypercapnic and hypoxic ventilatory responses (Pattinson 
2008).
In etorphine-immobilized rhinoceros, initial median V E Bt p s  was clinically 
similar to VEXP at rest. These results suggest that the marked hypoxaemia and 
hypercapnia measured in the first arterial sample were not a consequence of a
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reduction in ventilation, as has been previously advocated (Kock et al. 1995; 
Miller et al. 2013; Boardman et al. 2014; Haw et al. 2014). It is unlikely that the 
absence of reduced V E btps was due to a delay in maximum respiratory opioid 
effect as etorphine had caused sufficient central nervous system depression to 
induce a state of immobilization and recumbency for 10 minutes prior to 
sampling. Meyer et al. (2015) reported similar results in that hypoventilation was 
not the primary cause of hypoxaemia and hypercapnia in etorphine-immobilized 
domestic goats.
The initial median fir (9.5 breaths minutes’1) was substantially lower than 
the rate (16 to 23 breaths minutes'1) reported for standing unrestrained captive 
white rhinoceros (Citino et al. 2007). These values suggest that VEbtps was 
maintained by an increase in VT in the immobilized rhinoceros. In the study 
rhinoceros, the increased VT may have been a compensatory response to 
hypoxaemia and, or, hypercapnia. It is also possible that initial sympathetic 
stimulation associated with darting influenced respiratory minute ventilation 
(Heistad et al, 1972).
In rhinoceros immobilized only with etorphine, hypoxaemia and 
hypercapnia did not change significantly over the 25 minute study interval. 
Although median V E btps also did not change significantly, the initial and final 
values of 164 and 96 L minute’1, respectively, may reflect a clinically relevant 
reduction in minute volume. A decrease in V E btps is contradictory to the expected 
response to hypercapnia and hypoxia (Pattinson, 2008). Opioids suppress the 
ventilatory response to hypercapnia and hypoxia through reduced excitation of 
chemosensory neurons and chemoreceptor bodies (Yaksh & Wallace 2011). It is 
possible that etorphine receptor binding increased over time, causing further 
depression of respiratory rhythmogenesis resulting in hypopnoea; however, it is 
likely that peak respiratory perturbations had been reached at initial sample 
collection in the immobilized rhinoceros at approximately 20 minutes post-dart 
(Yaksh & Wallace 2011). The decrease in V E btps may have been due to an 
opioid-induced diminished hypoxic drive associated with a lowered set-point. An 
arterial oxygen tension of 25 mmHg in immobilized rhinoceros should have 
stimulated an increase in ventilation, which was not observed. In opioid-
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immobilized rhinoceros, the hypothetically lowered hypoxic threshold would have 
resulted in a decreased respiratory stimulus at PaC>2 > 25 mmHg with a 
subsequent fall in ventilation and limited changes in Pa02 (Pattinson 2008).
The elevated P(A-a) O2 observed at t=0 may have contributed to decreased 
PaC>2 and increased PaCC>2. The normal resting A-a gradient is unknown for white 
rhinoceros; however, a gradient of 41.7 mmHg in the immobilized rhinoceros, 
compared to 10 mmHg in horses at rest, suggests a clinically relevant finding 
(Doherty & Valverdeis 2008). An elevated A-a gradient is indicative of 
ventilation/perfusion mismatching, a physiologic right-to-left shunt, or impaired 
diffusion of gases between alveoli and perfusing blood (West 2008). A decreased 
V/Q ratio does not usually result in hypercapnia since increasing PaCC>2 stimulates 
respiration. However, this response may be limited in opioid-immobilized 
rhinoceros due to alterations in chemoreceptor sensitivity (Buss et al. 2015). 
Etorphine-induced pulmonary hypertension may contribute to hypoxaemia by 
hindering gas exchange across alveolar-capillary membranes due to pulmonary 
congestion with interstitial oedema or a decrease in blood flow passage time 
through pulmonary vasculature (Meyer et al. 2015).
Oxygen consumption is a measure of metabolic activity and maintenance 
of homeostatic processes in mammals (Porter 1995). The VO2 was elevated in 
etorphine-immobilized rhinoceros (8.23 ml kg’1 minute'1) compared to horses (3 
ml kg'1 minute'1) at rest and may have contributed significantly to hypoxaemia 
(Evans & Rose 1988). The difference in VCE may be due to species differences; 
however, metabolic rate per unit body mass tends to decrease with increased size, 
so a rhinoceros should consume less oxygen per unit body mass than should a 
horse (Porter 1995). Increased skeletal muscle activity may be an important 
contributor to metabolic demands, an idea supported by our findings of a strong 
correlation between VO2 and muscle tremor scores in immobilized rhinoceros.
The overall decrease in V E BTps over time in treatment II supports the 
hypothesis that IV administration of butorphanol in etorphine-immobilized 
rhinoceros does not improve respiratory minute ventilation. The V E Btps increased 
for a few minutes following the administration of butorphanol then subsequently
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decreased, similar to treatment I, so overall there was no significant difference 
between the two treatments. The V D PHys was also similar between treatments, 
suggesting changes in deadspace ventilation did not influence blood gases 
following butorphanol administration. The P(A-a) 0 2 was generally lower in 
treatment II compared to treatment I, but an initial lower value and no significant 
change following butorphanol administration, suggests this finding is of limited 
clinical importance. Further investigations are needed to confirm the consistency 
and significance of this difference between treatments as changes in alveolar 
ventilation: perfusion ratios, shunting, and gas diffusion rates across alveolar­
capillary membranes could alter arterial blood gases (Haw et al. 2014; West, 
2008).
The results of this study suggest that the improvements in Pa02 and PaC02, 
following butorphanol administration in etorphine-immobilized white rhinoceros, 
arose from changes in metabolic oxygen consumption associated with decreased 
muscle tremors. An inverse correlation between Pa02 and V02, and a positive 
correlation between V0 2 and muscle tremor scores, suggest that these three 
variables are interrelated. We propose that an increase in Pa02 following IV 
butorphanol administration is a result of decreased metabolism associated with 
reduced muscle tremors. Carbon dioxide production followed a similar trend to 
that of oxygen consumption which further supports the hypothesis that blood gas 
changes following butorphanol administration result from reduced metabolic 
activity. In shivering humans recovering from induced hypothermia, it has been 
shown that carbon dioxide production and oxygen consumption are positively 
associated with muscular activity and metabolic rate (Ralley et al. 1988). A 
reduction in muscle tremors associated with butorphanol administration may be 
mediated through antagonism of etorphine-induced sympathetic nervous system 
activity. Muscle tremors in immobilized rhinoceros are significantly associated 
with increased plasma catecholamine concentration (de Lange 2015). An 
alternative explanation for the improved arterial blood gases following 
butorphanol administration may be increased pulmonary perfusion and reduction 
in V/Q inequality rather than changes in oxygen consumption (Wagner 2008). 
However, heart rate and systemic blood pressure decreased in etorphine-
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immobilized rhinoceros following butorphanol administration, suggesting a 
decrease in cardiac output (Buss et al. 2016).
The transient increase in ventilation following the administration o f 
butorphanol is of clinical significance in that it has the potential to mislead the 
uninformed observer. It may appear that butorphanol administration improves 
ventilation by increasing respiratory rate; however, within a few minutes, 
respiratory minute ventilation was the same as in opioid-immobilized rhinoceros 
that did not receive butorphanol.
Conclusion
Our findings support the hypothesis that butorphanol does not improve respiratory 
minute ventilation in etorphine-immobilized white rhinoceros. However, 
butorphanol did improve arterial oxygen and carbon dioxide tensions, likely as a 
consequence of reduced metabolism and muscle tremors. We also showed that 
hypoxaemia and hypercapnia following etorphine administration were not a result 
of decreased respiratory minute ventilation. An increase in the alveolar-arterial 
oxygen gradient likely contributed to hypoxia in immobilized white rhinoceros. 
However, the impact of and underlying physiological processes leading to 
changes in A-a gradient require further elucidation. Our findings provide evidence 
that hypoxia and hypercapnia in immobilized rhinoceros result also from increases 
in metabolic oxygen consumption and carbon dioxide production with inadequate 
ventilatory compensation.
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Annexure I: Muscle tremor scores
Criteria for subjectively scoring muscle tremors.
Degree of Muscle Tremor
Level 5: Severe Tremors -  resulting in whole body and head 
movement
Level 4: Moderate Tremors -  resulting in severe shoulder, chest, leg 
and foot movement
Level 3: Slight Tremors -  resulting in minor shoulder, chest and severe 
leg and foot movement
Level 2: Mild Tremors -  resulting in minor leg and foot movement
Level 1: No Visible Tremors
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Cardiovascular effects of etorphine, azaperone, and butorphanol 
combinations in chemically immobilized captive white rhinoceros 
(Ceratotherium simum).
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CARDIOVASCULAR EFFECTS OF ETORPHINE, AZAPERONE, AND 
BUTORPHANOL COMBINATIONS IN CHEMICALLY 
IMMOBILIZED CAPTIVE WHITE RHINOCEROS 
(C E R A T O T H E R IU M  SIM U M )
Peter Buss, B.V.Sc., M.MctLVet., Michele Miller, D.V.M., Hh.D., Andrea Fuller, IkSc. (Hons.), Ph.D., 
Anna I law, B.V.Sc., Rachel Wanly, B.Sc., Francisco Olea-Popelka, D.V.M., Pli.I)., and Leith Meyer, 
B.V.Sc., Hh.D.
Abstract: Chemical capture is an essential tool in the management and conservation o f  white rhinoceros
(Ccraiothcrium simum ); however, cardiovascular responses in immobilized mcgaherbivorcs arc poorly understood. 
Blood pressure and heart rate responses in rhinoceros immobilized with ctorphinc o r  ctorphine plus azaperone, 
and the effects o f subsequent i.v. butorphanol adm inistration were investigated. Six white rhinoceros were used in 
a random ized crossover study design with four interventions: 1) ctorphinc i.m.; 2) ctorphinc plus azaperone i.m.; 
3) ctorphinc i.m. and butorphanol i.v.; and 4) ctorphinc plus azaperone i.m., and butorphanol i.v. E torphinc 
resulted in hypertension and tachycardia in immobilized rhinoceros on initial measurements. O ver the 25-min 
study period, blood pressures and heart rate declined. Heart rates were slower, although the rhinoceros were still 
tachycardic, and blood pressures lower during the whole study period in animals immobilized with ctorphinc and 
azaperone com pared with those that received only ctorphinc. Butorphanol adm inistration resulted in  lower 
arterial blood pressures and heart ratos in ctorphinc-immobilizcd rhinoceros In rhinoceros immobilized with 
ctorphinc and azaperone, heart rate slowed following administration o f  butorphanol i.v., although blood pressures 
remained unchanged. Azaperone reduced hypertension associated with ctorphinc immobilization, but animals 
remained tachycardia Administration o f butorphanol to ctorphine/azapcronc-im m oblizcd rhinoceros lowered 
heart rate to values approaching normal resting levels without altering blood pressure 
K ey words: Blood pressure, cardiovascular, Ccraiothcrium simum , heart rate, white rhinoceros.
INTRODUCTION
Chemical immobilization is an essential man­
agement tool for moving white rhinoceros (Cera- 
totherium simum) between isolated populations to 
maintain genetic diversity, collecting biological
From the Veterinary Wildlife Services, South African 
National Parks, Kruger National Park. Private Bag X402. 
Skukuza 1350, South Africa (Buss); Department of 
Science and Technology,'National Research Foundation 
Centre of Excellence for Biomedical Tuberculosis Re­
search, Medicine Research Council of South Africa 
Centre for Tuberculosis Research. Faculty of Medicine 
and Health Sciences. Stellenbosch University, P.O. Box 
241, Cape Town 8000, South Africa (Miller); Brain 
Function Research Group. School of Physiology. Faculty 
of Health Scienoes. University of the Witwatersrand, 
Medical School, 7 York Road, Parktown 2193, South 
Africa (Fuller. Haw); Department of Clinical Scienoes. 
College o f Veterinary Medicine and Biomedical Science, 
Colorado State University, Fort Collins, Colorado 80523, 
USA (Olea-Popelka. Wanty); Department o f Paraclinical 
Sciences, Faculty of Veterinary Science, University of 
Pretoria. Private Bag \'(W. Onderstepoort 0110, South 
Africa (Meyer). Correspondence should be addressed to 
Michele Miller (michelemillcrl 28(ii gmail.com).
samples, attaching radio-tracking devices, facili­
tating dehorning procedures, and treating injured 
individuals.22' 2 Etorphine plus azaperone, the 
preferred immobilizing drug combination, causes 
significant respiratory depression in immobilized 
white rhinoceros and butorphanol is commonly 
administered to counteract these effects.2-1-22-2’ 
Alterations in respiratory function have been 
extensively studied in white rhinoceros; however, 
there are only a few reports on the cardiovascular 
effects o f these drugs.IOU5-u The pressor effects 
of etorphine, and etorphinc plus fentanyl, have 
been described in captive and free-ranging rhi­
noceros, respectively.1 Alterations to heart 
rate and blood pressure, measured noninvasivcly, 
also have been described briefly in game-ranched 
rhinoceros chemically captured utilizing etor­
phine, azaperone, and butorphanol.2 Clinical 
observations following the administration of 
butorphanol in immobilized free-ranging rhinoc­
eros suggest that it results in a substantial 
reduction in heart rates (Buss, pers. comm.).
The purpose of this study was to determine and 
compare the cardiovascular effects of ctorphine 
or ctorphine plus azaperone in boma-adapted
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white rhinoceros, and to evaluate how i.v. butor- 
phanol administration influences these effects.
MATERIALS AND M ETHODS
Six subadult (5-6 yr) male white rhinoceros, 
weighing between 1,194 and 1,420 kg, were 
captured in Kruger National Park (23a49’60 S, 
31“30'0 E; alt. 317 m). South Africa, and habitu­
ated to captivity over a period of 4 mo. The 
animals were housed individually in rhinoceros- 
specific holding pens. Water and a 50: 50 mix of 
Lucerne (Medicago saliva) and Tef (Eragrostis tef) 
hay were provided ad libitum. Feces were re­
moved from the enclosures, water troughs 
cleaned, and food replaced daily.
A randomized crossover study design was used 
with a  2-wk washout period between each o f four 
treatm ents: treatment 1: etorphine (Elanco, 
Kempton Park 1619, South Africa: 9.8 mg/ml) 
plus hyaluronidasc (Kyron Laboratories, Benrose 
2094, South Africa; 5000 i.u./vial) i.m.; treatment 
2: etorphine and azaperone (Janssen Pharmaceu­
tical Ltd., Halfway House 1685, South Africa; 40 
m g/m l) plus hyaluronidase i.m.; treatment 3: 
etorphine plus hyaluronidase i.m. followed by 
butorphanol (Kyron Laboratories; 50 mg/ml) i.v.; 
and treatm ent 4: etorphine and azaperone plus 
hyaluronidase im . followed by butorphanol i.v. 
Doses were based on two standardized body mass 
categories: 1,000 to 1,250 kg received 2.5 mg 
etorphine, 37.5 mg azaperone, 5,000 i.u. hyaluron­
idase, and 25 mg butorphanol; and 1,250 to 1,500 
kg received 3.0 mg etorphine, 45 mg azaperone, 
5,000 i.u. hyaluronidasc, and 30 mg butorphanol. 
Hyaluronidase (5,000 i.u.) was included in the 
immobilizing drug mixture as it facilitates drug 
absorption and reduces induction time.10
The immobilizing drugs were delivered into the 
muscles o f the nuchal hump using a 3.0-ml plastic 
dart with a 60-mm uncollared needle using a 
compressed air rifle (DAN-INJECT International 
S.A., Skukuza 1350, South Africa). Once a darted 
animal could be safely approached, it was blind­
folded and placed into lateral recumbency. Trials 
were conducted only if the animal was recumbent, 
could be safely handled within 15 min of darting, 
and instrumented within a further 10 min. A 22 G 
x  1-inch catheter (Nipro Safelcl Cath, Nipro 
Medical Corporation, Bridgewater, New Jersey 
08807, USA) was placed into a medial auricular 
artery. Arterial blood pressures were recorded 
using a transducer (TranStar 60-inch Single 
Monitoring Kit, Ref MX950T, Smiths Medical 
ASD, Inc., Dublin, Ohio 43017, USA) secured at 
the level o f the heart and zeroed prior to
connecting to a precalibrated Cardiocap/5 phys­
iological monitor (Datcx-Ohmeda, G E Health­
care, Helsinki 00510, Finland). Heart ra te  was 
determined by chest auscultation and confirmed 
using the physiological monitor.
Systolic, diastolic, and mean arterial blood 
pressures, and heart rate were initially recorded 
at 10 min after the animal became recumbent (/ = 
0) and at each subsequent 5-min interval for a 
total o f 25 min. Butorphanol (at 10 x the 
etorphine dose in mg) was administered i.v. into 
an auricular vein at 2 min (/ = 2) after the first 
measurement (/ =0) to rhinoceros in treatm ents 3 
and 4. An equivalent volume o f sterile saline was 
administered i.v. as a control at /  =  2 to  those 
animals not receiving butorphanol.
At the end of each procedure, butorphanol was 
administered i.v. (at 10 x  the etorphine dose mg) 
to animals in treatments 1 and 2 after the last 
sample a t / -2 5  min. All animals were walked into 
a crate o f known weight and weighed by suspend­
ing the crate from a scale. Naltrexone (Kyron 
laboratories; 40 mg/ml) was administered i.v. (at 
20 x  the etorphine dose in mg). Rhinoceros were 
kept under observation until fully recovered.
Data analysis
STATA (Stata Statistical Software: Release 14, 
College Station, Texas 77840, USA) was used for 
the statistical analysis. Descriptive statistics 
(means, standard deviations, medians, and 1st 
[Ql] and 3rd [Q3] quartile) were calculated to 
assess the data distribution for each treatment at 
different sampling points. Due to the relatively 
small sample size used for this study (n =  6), 
nonparametric statistical tests were used to com­
pare median cardiovascular values at different 
sampling points within each treatment. Initially 
the data was screened using the Kruskal-Wallis 
test to assess if median values for different 
cardiovascular parameters differed over sampling 
points. Subsequently, we formally tested the hy­
pothesis that cardiovascular values changed at /  -  
10 as compared with /=  0. To compare differences 
in medians between matched pairs o f cardiovascu­
lar values at / =- 0 with / = 10, the Wilcoxon signed 
ranks test was used to account for repeated 
measurements over time in the same individual. 
The data distribution indicated that after /  = 10, 
cardiovascular values tended to stabilize; thus, and 
to confirm that no further changes occurred after 
10 min, we used linear regression (using ranks) 
with sampling points as fixed effects to formally 
assess changes on cardiovascular parameters after 
10 min, using / =  10 as the reference value. To
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Table I. D istribution o f cardiovascular parameters (median and interquartile range [IQRI) in six captive white 
rhinoceros (n = 6) for four treatm ents a t sampling periods 0, 5, 10, 15, 20, and 25 min.
blood
pressures
Treatment* 0 min 
IQR*
5 min 
IQR
10 min 
IQR
15 min 
IQR
20 min 
IQR
25 min 
IQR
Overall
IQR
Mean 1 174 157 131 131 122 122 133
(mm Hg) (155-187) (143-169) (129-144) (121-142) (112-129) (112-129) (124-150.5)
2 111 93 92 93 90 94 94
(91-120) (80-111) (84-103) (81-112) (83-102) (81-106) (83-110.5)
3 180 131 110 111 112 103 117
(171-188) (110-136) (96-116) (92-122) (95-128) (90-114) (99.5-142)
4 131 81 77 80 83 88 87
(98-146) (63-112) (74-86) (68-89 (72-87) (77-97) (725-99)
Systolic 1 192 173 154 155 146 144 158
(mm Hg) (175-209) (164-190) (146158) (141-162) (134-152) (136155) (144-167.5)
2 123 112 112 112 110 114 114
(110-141) (92-135) (101-121) (91-132) (101-124) (90-130) (97.5-130.5)
3 211 155 138 141 140 135 146
(196-226) (130-173) (121-144) (113-148) (119-157) (116140) (124.5-179.5)
4 145 101 100 104 102 110 106
(115-169) (73-120) (96-114) (91-111) (92-114) (92-119) (92-120)
Diastolic 1 160 139 123 113 104 105 119
(mm Hg) (136-169) (129-151) (107-129) (103-125) (97-111) (94-112) (104-132.5)
2 97 76 78 81 75 79 79
(81-106) (73-94) (68-88) (67-90) (71-79) (7 6 8 5 ) (71.5-90)
3 161 116 93 96 98 85 101
(151-166) (93-121) (82-99) (79-106) (78-112) (7 6 9 7 ) (83.5-124)
4 117 67 65 67 72 76 74
(84-129) (53-105) (62-72) (58-74) (63-77) (7 6 8 3 ) (60-85)
H eart rate 1 136 141 134 125 120 114 127
(bcats/m in) (130-144) (124-144) (112-136) (114-128) (112-128) (101-124) (114-139)
2 120 116 110 n o 108 104 112
(112-132) (104-124) (92-116) (92-116) (88-116) (84-112) (96-120)
3 139 89 65 63 60 68 68
(122-148) (82-114) (58-68) (52-64) (48-68) (48-69) (60-111)
4 134 68 54 52 49 58 56
( I 14-140) (58-80) (4 6 5 6 ) (45-56) (48-56) (5 6 6 1 ) (48-69)
■Treatments: 1) Morphine; 2)etorphine plus uzaperone; 3) Morphine and butorphanol i.v.; and 4) ctorphinc plus uzaperone, and 
butorphano! i.v.
* IQR indicates interquartile range (25th to 75th percentile).
evaluate differences on cardiovascular parameters 
between treatment groups, we used linear regres­
sion (using ranks) to compare median cardiovas­
cular parameters while adjusting for the effect o f 
time, including sampling time points, as a fixed 
effect in the model. Statistical significance was set 
at P < 0.05 for all statistical tests.
RESULTS
T rea tm en t I: c to rp h in e
A t first sampling (I -  0), the median values for 
arterial blood pressures were: mean 174 mm Hg, 
systolic 192 mm Hg and diastolic 160 mm Hg 
(Table 1). These arterial pressures decreased 
significantly over time to 131 mm Hg (P —
0.028), 154 mm Hg (/> = 0.028), and 123 mm Hg 
{P -  0.028), respectively, at t -  10. Between /=  10 
and / = 25, mean and diastolic arterial blood 
pressures decreased further to 122 mm Hg (P = 
0.017) and 105 mm Hg (T -0 .012), although there 
was no significant change in systolic blood 
pressure (Table 1; Fig. 1). Heart rate decreased 
from 136 bcats/min to 114 bcats/m in over the 
immobilization period (r = 0 to r = 25); however, 
changes were not statistically significant between t 
= 0 and /=  10 (/> = 0.059), and t = 10 and / = 25 (7>= 
0.442) (Table 1; Fig. 2).
T rea tm en t 2: e lo rp h in c  p lu s uzaperone
A t t -  0, the median values for arterial blood 
pressures in rhinoceros immobilized with clor-
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Figure I. A rterial blood pressures: (A) M can,(B) Systolic, (C) Diastolic. N ote: Median and interquartile range 
of m ean, systolic, and diastolic arterial blood pressures at sampling periods 0, S, 10, IS, 20, and 2S min in six 
captive white rhinoceros (n =  6) for four treatments: 1) etorphinc; 2) ctorphinc plus azaperone; 3) ctorphine and 
butorphanol i.v.; 4) ctorphinc plus azaperone and butorphanol i.v. The black arrow  indicates the time at which 
butorphanol was adm inistered. *, indicates a  significant (P  <  0.05) difference within treatm ent between 1=0 and / 
- 10. **.indicates a  significant (P <  0.05) difference within treatm ent between t ~  10 a n d /= 25. the same letter 
indicates a  significant (P  <  0.05) difference in overall median values between treatments.
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Figure 2. Heart rates. Note: Median and interquartile range of heart rates at sampling periods 0. S, 10, IS, 20, 
and 25 min in six captive white rhinoceros (n -  6) for four treatments: l)ctorphine; 2)etorphine plus azaperone; 3) 
ctorphinc and butorphanol i.v.; 4) ctorphinc phis azaperone and butorphanol i.v. The black arrow indicates the 
time at which butorphanol was administered. *, indicates a significant (P < 0.05) difference within treatment 
between r=0 and/=  10. **, indicates a significant (P < 0.05) difference within treatment between /=  10 andr = 25. 
•-«, the same letter indicates a significant (P < 0.05) difference in overall median values between treatments.
phine and azaperone were: mean 111 mm Hg, 
systolic 123 mm Hg, diastolic 97 mm Hg, and 
heart rate was 120 beats/m in (Table 1). Signifi­
cant decreases occurred between f= 0 an d  I -  10 in 
mean (111 mm Hg to 92 mm Hg, P -  0.046) and 
diastolic (97 mm Hg to 78 mm Hg, P — 0.046) 
arterial blood pressures: however, the decrease in 
systolic blood pressure (123 mm Hg to 112 
mmHg) during the same period was not statisti­
cally significant (P — 0.075). Heart rate decreased 
significantly from 120 beats/m in to llO bcats/m in 
over the first 10 min of the study (P = 0.028) 
(Table 1; Figs. 1, 2). No further statistically 
significant changes were observed in mean, sys­
tolic, and diastolic arterial blood pressures and 
heart rate after 10 min.
Overall, during the 25-min immobilization 
period, arterial blood pressure measurements 
were significantly (P < 0.001) lower in rhinoceros 
immobilized with ctorphinc and azaperone com­
pared with those that received only ctorphine 
(differences in blood pressures were mean 39 mm 
Hg, systolic 45 mm Hg, and diastolic 40 mm Hg) 
(Table 1; Fig. 1). Median heart rates were also 
significantly different between the two treatments 
(15 beats/m in, P < 0.001) (Table 1; Fig. 2).
Treatment 3: ctorphine and butorphanol
After the administration of butorphanol i.v. (/ = 
2) in rhinoceros immobilized with etorphine, 
blood pressures decreased significantly (P -
0.028) between t = 0 and t -  10 (mean 180 mm 
Hg to 110 mm Hg, systolic 211 mm Hg to 138,
and diastolic 161 mm Hg to 93 mm Hg (Table 1; 
Fig. 1). Heart ralealso decreased significantly (F=  
0.028) by 74 beats/min (139 beats/min to 65 
beats/min) between l -  0 and /=  10. After r=  10, 
arterial blood pressures and heart rate did not 
change significantly over the rest o f the immobi­
lization period (Table 1; Fig. 2).
Generally and when controlling for the effect o f 
time, cardiovascular parameters and heart rate 
were significantly lower in etorphine-immobilized 
rhinoceros that received butorphanol compared 
with those given sterile saline (decreases in 
arterial blood pressures were mean 15 mm Hg, P 
=  0.001; systolic 12.5 mm Hg, P = 0.019; and 
diastolic 18.5 mm Hg, P < 0.001; and heart rate 59 
beats/min, P < 0.001) (Table 1; Figs. 1, 2).
Treatment 4: ctorphine plus azaperone, and 
butorplianol
The administration of butorphanol at t -  2 to 
rhinoceros immobilized with a combination of 
etorphine and azaperone resulted in significant 
changes in arterial blood pressures between / =  0 
to / = 10 (mean 131 mm Hg to 77 mm Hg, P — 
0.028; systolic 145 mm Hg to 100 mm Hg, P = 
0.046; diastolic 117 mm Hg to 65 mm Hg, P -  
0.028). Between / = 10 and I =  25, there were no 
significant changes in blood pressures (Table 1; 
Fig. 1). Heart rate slowed significantly between/ = 
0 and I — 10 (134 beats/m in to 54 beats/min, P -  
0.028) and remained unchanged for the rest of the 
immobilization beyond r=  10 ( P - 0.442) (Table 1; 
Tig. 2).
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Overall in rhinoceros immobilized with etor- 
phine and azaperone, there were no significant 
differences in arterial blood pressures between 
those administered i.v. butorphanol and those 
that did not receive butorphanol (Table I; Fig. 1). 
H eart rate was significantly (P < 0.001) lower in 
rhinoceros administered butorphanol, compared 
with no butorphanol (56 beats/min compared 
with 112 beats/min) (Table 1; Fig. 2).
DISCUSSION
Immobilization of white rhinoceros with ctor- 
phine results in hypertension and tachycardia. 
The inclusion o f azaperone with etorphinc in the 
immobilizing drug combination reduces blood 
pressure associated with etorphinc administration 
to  values lower than those reported for unre­
strained zoo animals.4 Heart rates were also lower 
with this combination o f opioid and tranquillizer 
compared with animals induced with only ctor- 
phinc; however, the animals remained tachycardic 
with heart rates (>100 beats/m in) more than 
double those of normal values in unrestrained 
awake animals (32 to 42 beats/min).4 Intravenous 
administration of butorphanol to rhinoceros im­
mobilized with only etorphine resulted in some 
reduction in arterial blood pressure and no 
significant change in animals that were induced 
with both etorphine and azaperone. However, in 
both of these treatments, butorphanol adminis­
tration resulted in significant reductions in heart 
rate.
The rhinoceros in this study, when immobilized 
with etorphine, were hypertensive at i - O  (10 min 
after becoming immobilized) compared with 
standing unrestrained captive white rhinoceros 
(mean arterial blood pressure 173.5 mm Hg vs. 
124 mm Hg, systolic 192 mm Hg vs. 160 mm Hg, 
diastolic 160 mm Hg vs. 104 mm Hg).‘ In 
addition, animals that received etorphinc were 
tachycardic compared with standing unrestrained 
animals (heart rate 136 beats/m in vs. 39 beats/ 
min).4 Hypertension and tachycardia have been 
previously reported in a small number of captive 
white rhinoceros immobilized with etorphinc.
A mean intra-arterial blood pressure of 183 mm 
Hg was recorded in free-ranging animals chemi­
cally captured with an opioid combination of 
etorphine and fentanyl.1' This blood pressure is 
similar to values of animals in the study, but the 
influences of combining fentanyl with etorphine 
or a potential adrenergic response induced by a 
chase and darting from a helicopter are un­
known.11
The underlying mechanisms for increased arte­
rial blood pressures and tachycardia in rhinoceros 
immobilized with etorphinc arc not fully under­
stood. The cardiovascular response observed in 
the study may, in part, result from hypoxia caused 
by drug-induced respiratory depression, a  com­
mon finding in immobilized white rhinoceros.4,1’ 
Hypoxia in humans resulted in increased heart 
rate, cardiac output, and systolic blood pressure, 
although mean and diastolic arterial pressures 
remained constant or fell slightly.11 Hypoxemic 
activation o f arterial chcmoreceptors increases 
both sympathetic vasoconstrictor outflow to vas­
cular beds and cardiac sympathetic activity in­
creasing heart rate.17 In domestic horses 
administered etorphine and acepromazine, a sim­
ilar cardiovascular outcome was hypothesized to 
result from an etorphine-induccd sympathetic 
response through the release o f catecholamines 
from postganglionic neurons.'-24 Cardiovascular 
pressor effects arc consistent findings in opioid- 
immobilized perissodactyls, and have been re­
ported in domestic and Mongolian horses, and 
Grcvy’s zebra.12 Opioid receptors have been 
identified in rodent myocardial tissue prepara­
tions. If these myocardial receptors are ubiqui­
tous in mammals, then activation o f these 
receptors by etorphine could result in tachycardia 
with a potential increase in cardiac output."
The initial hypertension in rhinoceros immobi­
lized with etorphine had resolved at / =  25 to 
values similar to those in standing unrestrained 
zoo animals (arterial blood pressures were mean 
122 mm Hg vs. 124 mm Hg, systolic 154 mm Hg 
vs. 160 mm Hg, and diastolic 105 mm Hg vs. 104 
mm Hg).4 Although the change in heart rate from 
13 6 beats/min to 114 beats/min between / = 0 and 
I -  25 was not statistically significant, it may 
reflect a clinically relevant reduction in rate. 
However, rhinoceros remained tachycardic at /  = 
25 compared with unrestrained animals (heart 
rate 114 beats/min vs. 39 beats/min).4 A decrease 
in blood pressures with a persistent tachycardia at 
the end o f the immobilization is an unexpected 
result A decreased drug effect due to redistribu­
tion and metabolism o f etorphine would account 
for decreasing blood pressure over time but not 
the elevated heart rate. A possible explanation is 
an increase in heart rate to maintain cardiac 
output and arterial blood pressures in the pres­
ence of a reduced stroke volume and/or total 
peripheral resistance. In a recumbent immobi­
lized animal, stroke volume may be reduced due 
to limited limb skeletal muscle activity causing 
blood pooling and decreased venous return to the
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heart. Blood pooling may also occur due to an 
opioid-induced venous dilation, as has been 
reported in humans.1 Respiratory depression and 
chest wall rigidity, which commonly occurs in 
immobilized rhinoceros, can also potentially de­
crease cardiac venous return by limiting the 
negative intrathoracic pressure that develops in 
association with inspiration and usually assists 
blood flow through the chest.*-'*-34 Severe hypoxia 
associated with opioid immobilization o f rhinoc­
eros may also be implicated in a local vasodilation 
in response to tissue hypoxia, a fundamental 
physiological response to ensure adequate oxygen 
supply-demand balance in metabolically active 
tissues. '*■*'
A persistent tachycardia with potential in­
creased myocardial oxygen consumption is of 
clinical concern due to limited anaerobic capacity 
o f the myocardium and pronounced hypoxia 
commonly associated with etorphinc-induccd re­
spiratory depression.I, M It is also unknown how 
immobilizing drugs may influence the mecha­
nisms that match coronary blood flow with 
myocardial oxygen requirements.*0 No obvious 
adverse effects associated with the persistent 
tachycardia were observed in the study animals; 
however, a negative outcom e may occur in 
rhinoceros compromised due to age, disease, or 
poor nutrition.
Overall, arterial blood pressures in lhe study 
animals were significantly lower during the entire 
study period when azaperonc was included with 
ctorphinc compared with ctorphine only. A t / -  0, 
rhinoceros had lower blood pressures compared 
with resting values in standing unrestrained 
captive animals. Heart rate decreased significantly 
over the first 10 min and was also clinically slower 
with the inclusion o f azaperonc; however rhinoc­
eros were still tachycardic compared with values 
in standing resting animals (110 bcats/min vs. 39 
beats/m in).‘ By comparison, Boardman et al. 
(2014) reported similar heart rates (118 beats/ 
min), but higher blood pressures (systolic 162 mm 
Hg and diastolic 104 mm Hg) in white rhinoceros 
immobilized with similar doses of ctorphinc and 
azaperonc.2 Those rhinoceros were free-ranging 
and darted from a vehicle, which may have a 
caused a greater sympathetic response and hyper­
tension than in the boma-acclimalcd rhinoceros.
Azaperonc is advocated for rhinoceros immo­
bilization to counteract etorphine-induccd hyper­
tension by antagonizing i,-receptors in peripheral 
arterioles thus limiting vasoconstriction.2-'4-2* The 
hypotensive effects o f azaperonc have been de­
scribed in domestic horses; azaperone can reduce
mean arterial pressure by approximately a third 
from resting levels, for up to 4 hr.30
Potential mechanisms for tachycardia in etor- 
phine/azaperone-immobilizcd rhinoceros could 
be related to a baroreoeptor reflex induced by 
the hypotensive effects o f azaperone, the sympa­
thomimetic effects of etorphinc and associated 
hypoxia, and possible direct opioid effects on the 
myocardium."•I4"‘ However, these explanations 
for the cardiovascular effects may be incomplete 
due to a limited understanding of receptor 
(opioid, dopamine, and adrenergic) distributions 
and associated functions within rhinoceros organ 
system s.5-3
While inclusion of azaperone reversed hyper­
tension associated with etorphine immobilization, 
the lower than normal blood pressure that result­
ed in the rhinoceros also could be o f clinical 
concern. A low mean arterial blood pressure can 
reduce blood flow through skeletal muscles, 
especially o f the limbs, causing a buildup of 
metabolic waste products and a persistent hypox­
ia with possible myopathy and irreversible muscle 
damage.3’-34 Increased muscle activity from run­
ning prior to immobilization, and compression of 
muscles with occlusion of blood vessels in limbs 
positioned underneath a recumbent animal can 
further increase the risk of tissue injury.3’ A 
normal pressure response in other conscious 
megaherbivores is an increase in blood pressure 
when animals move from standing to lateral 
recumbency.'* This compensatory response in 
the rhinoceros appeared to be prevented by the 
etorphinc and azaperone combination.
Administering butorphanol to etorphinc-im- 
mobilized rhinoceros resulted in rapid reductions 
in both arterial blood pressures and heart rate, 
reaching maximum changes within 10 min. Blood 
pressure values did not decrease to values ob­
served in rhinoceros immobilized with etorphine 
and azaperone; however, heart rate was markedly 
slower in animals receiving butorphanol (65 
bcats/m in compared with 110 bcats/min at t -  
10). In horses and humans, butorphanol adminis­
tered alone did not significantly alter heart rate or 
blood pressure.31-" Due to a limited understand­
ing of the complex pharmacology of butorphanol 
and its interactions with potent opioids like 
ctorphinc, it is difficult to definitively explain 
the mechanisms that result in these cardiovascu­
lar e f fe c ts .E to rp h in e  is a potent pure opioid 
agonist at p-, 6-, and x-receptors, while butorpha­
nol is a synthetic agonist-antagonist opioid that 
acts as a partial agonist at p-, a pure agonist at 
and mainly as an antagonist at 6-receptors.u *
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Pharmacological responses resulting from butor- 
phanol activity at p-rcceptors frequently over­
shadow those o f the v-receptors.1 Apart from the 
potential interactions of these two drugs at 
multiple opioid receptor types, pretreatment with 
etorphinc can alter the binding o f p-reccptors 
with o ther specific agonists.1 It is therefore 
plausible that butorphanol's partial agonist ef­
fects on p-receptors partly antagonize some of 
etorphine’s p-agonist effects, like tachycardia.
Butorphanol administration in etorphinc- plus 
azaperone-immobilized rhinoceros did not alter 
blood pressures, but heart rates decreased to 
values clinically comparable to those recorded in 
unrestrained zoo rhinoceros.* Boardman et al. 
(2014) reported a  decrease in both heart rate and 
blood pressure following the administration of 
butorphanol in rhinoceros immobilized with ctor- 
phine and azaperone.2 The reason for the differ­
ence in blood pressure response is unknown, but 
may arise from the difference in the initial flight 
response in game-ranched animals darted from 
vehicles compared with boma-adapted rhinoceros 
darted from the ground.2 Despite the difference in 
blood pressure responses between the two stud­
ies, rhinoceros in both groups had low blood 
pressures with a normal resting heart rate follow­
ing butorphanol administration.
Since arterial blood pressures didn't change but 
heart rate slowed in etorphinc- plus azaperone- 
immobilized rhinoceros following the administra­
tion of butorphanol, it is likely that the falling 
heart rate was associated with an increase in 
stroke volume, ejection fraction, or a combination 
of both to maintain cardiac output. Azaperone 
antagonizes peripheral vascular a ,-receptors so it 
is unlikely that an increased total peripheral 
resistance contributed to maintaining blood pres­
sure. I<,•2, The reduction in heart rate may result not 
only from a barometric response to an increase in 
cardiac output, but could also be related to a 
decrease in sympathetic response due to partial 
antagonism of ctorphinc’s effects or an improve­
ment in arterial oxygen tension. Buss ct al. (2015) 
found that arterial oxygen partial pressures in­
creased, from very low values, after the adminis­
tration o f butorphanol in boma-habiluated 
rhinoceros immobilized with a combination of 
etorphine and azaperone.* A reduction in heart 
rate subsequent to improved blood oxygen levels 
would be expected if the original tachycardia was 
caused by hypoxia.2'
Irrespective o f immobilizing drug combination 
used, administration of butorphanol in boma- 
adapted white rhinoceros reduced heart rate. As
previously mentioned, a potential benefit o f  
decreased heart rate is a  reduction in myocardial 
oxygen requirements in animals experiencing a 
marked hypoxia.
The mechanisms resulting in the cardiovascular 
changes recorded in this study can be elucidated 
further by developing a validated technique for 
determining cardiac output and through molecu­
lar investigation of drug-receptor interactions in 
rhinoceros. Cardiovascular changes associated 
with the use of etorphine, azaperone, and butor­
phanol should also be investigated in free-ranging 
rhinoceros as they are usually captured by darting 
from a helicopter, which induces a significant 
sympathetic response that may further alter 
cardiovascular function.2’
CONCLUSION
Hypertension and tachycardia, which occurred 
in rhinoceros immobilized with etorphinc, were 
reduced by both including azaperone in the 
immobilizing drug combination and administer­
ing butorphanol i.v. shortly after the animal had 
become recumbenL Inclusion of azaperone in the 
dart reduced etorphine-induced hypertension but 
did not correct tachycardia. Intravenous admin­
istration o f butorphanol reduced the heart rate to 
values reported for resting unrestrained animals, 
but did not alter blood pressure further. This 
reduction may be due to an improvement in 
hypoxemia. A decreased heart rate may have a 
beneficial oxygen sparing effect on the myocardi­
um. Similarly, a reduction in peripheral resistance 
and blood pressure by azaperone will reduce 
cardiac workload and hence oxygen requirements. 
However, o f clinical concern, is that a profound 
decrease in blood pressure associated with the use 
of azaperone could cause adverse consequences 
due to reduced tissue perfusion, especially in 
compressed skeletal muscle groups in recumbent 
animals. Whether a lower azaperone dose than the 
one used may reverse the etorphine-induced 
hypertension without causing hypotension re­
quires further investigation. In summary, azaper­
one reduced the hypertensive effects and 
butorphanol reduced the tachyeardic effects of 
etorphine in immobilized white rhinoceros, there­
by reducing potential risks associated with etor- 
phinc immobilization.
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CHAPTER 5
Discussion
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White rhinoceros immobilization is a fundamental procedure used in the 
conservation of this endangered megaherbivore and allows for the capture, 
translocation and treatment of individuals. Immobilization also promotes 
scientific investigation which facilitates protection of this species. The potent 
opioids, including etorphine, are the only class of drugs which provide a rapid and 
reversible immobilization in rhinoceros (Haw et al. 2015). Opioids are essential in 
the capture of free-ranging rhinoceros as they allow for effective immobilizing- 
dose administration using low-volume darting systems (Burroughs et al. 2012a). 
However, immobilization is associated with significant changes in rhinoceros 
respiratory and cardiovascular physiology, which may result in high morbidity 
rates and mortalities (Boardman et al. 2014; Haw et al. 2014, Kock et al. 1995; 
Miller etal. 2013; Wenger et al. 2007).
The objectives of my studies were to investigate the cardiorespiratory 
pathophysiological effects of etorphine and azaperone, pharmacological agents 
most often used in white rhinoceros immobilization, and to examine the 
effectiveness of post-induction butorphanol IV in limiting these adverse effects. 
Reducing the risk of morbidity and mortality through an increased understanding 
and moderation of drug-induced cardiorespiratory changes in immobilized white 
rhinoceros will contribute to future successes in managing this species.
5.1 Respiratory effects in etorphine-immobilized white rhinoceros and the 
impact of post-induction butorphanol administration.
My studies described in chapters 2 & 3 confirmed that severe hypoxaemia and 
hypercapnia occur in white rhinoceros during immobilization with etorphine and 
azaperone. Similar changes in blood gases were also evident in rhinoceros 
immobilized with etorphine only. The initial, widely accepted, hypothesis was 
that opioids cause hypoventilation through depression of respiratory rhythm 
generating neurons, central and peripheral chemoreceptors, increased chest wall 
rigidity, and reduced airway patency. The resulting hypoventilation was suggested 
as the primary cause of the low oxygen and high carbon dioxide arterial pressures 
measured. However, the results of my study did not reveal a decrease in
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ventilation as the primary cause of hypoxaemia but rather indentified increased 
metabolic oxygen consumption as a significant contributor in immobilized 
rhinoceros. Muscle tremors were positively associated with oxygen consumption 
and carbon dioxide production, leading to hypoxaemia and hypercapnia. 
Additionally, my results support the idea that abnormal blood gas values in 
immobilized-rhinoceros were also a consequence of an increase in the alveolar- 
arterial oxygen gradient.
My study results were consistent with literature reports that opioid-immobilized 
white rhinoceros experience life-threatening hypoxaemia and hypercapnia 
(Boardman et al. 2014; Haw et al. 2014; Kock et al. 1995; Miller et al. 2013; 
Wenger et al. 2007). However, early studies attributed these changes to hypopnea 
(Bush et al. 2004; Heard et al. 1992; Keep 1971; West 2008). Hypopnea leads to 
decreased minute ventilation, which has never been measured in immobilized 
white rhinoceros. Therefore, my results reported here are the first to show that 
hypoventilation does not predominantly contribute to the compromised blood 
gases observed in immobilized-rhinoceros. Respiratory minute ventilation at the 
first sampling period (10 minutes into the immobilization) was not significantly 
different from the expected value at rest, based on body mass. Although 
respiratory minute ventilation declined over the immobilization period, there were 
no significant changes in blood gases. Therefore, increased oxygen consumption 
and carbon dioxide production associated with an elevated metabolism is a more 
plausible explanation for the blood gas changes attributed to hypoventilation in 
earlier studies.
The idea that metabolic oxygen consumption and carbon dioxide production are 
increased in opioid-immobilized rhinoceros was first postulated by Miller et al. 
(2013) to explain arterial oxygen and carbon dioxide tensions, measured in field- 
immobilized white rhinoceros, which were not associated with hypoventilation. 
Oxygen consumption in our study animals was found to be inversely correlated 
with arterial oxygen partial pressure which, in turn, was significantly associated 
with increased muscle tremors. These results suggest that muscle tremoring in
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etorphine-immobilized rhinoceros increased oxygen consumption through 
elevated metabolic activity and, consequently, increased carbon dioxide 
production. Although, not evaluated in my study, several reports suggest 
increased muscle tremoring is driven by a rise in plasma catecholamine levels 
associated with either a direct etorphine effect or opioid-induced hypoxia (Carter 
et al. 2002; Daniel & Ling 1972; De Lange et al. 2015; Schlarmann et al. 1973).
Another possible cause of observed hypoxaemia and hypercapnia in opioid 
immobilized rhinoceros was the increased P(A-a)C>2 gradient found in my studies 
(Chapter 2 & 3), as previously suggested by Wenger et al. (2007). Although the 
normal resting alveolar-arterial gradient is unknown for white rhinoceros, the 
value in our etorphine-immobilized rhinoceros was approximately four times 
higher when compared to a horse at rest (Doherty & Valverdeis 2008). The P(A- 
a)C>2 gradient is a non-specific measure of respiratory function and can be 
influenced by ventilation/perfusion mismatching, a physiological right-to-left 
shunt, or impaired alveoli-blood gas diffusion (West 2008). Studies in goats show 
that opioids cause pulmonary hypertension as a result of increased pulmonary 
vascular resistance (Meyer et al. 2015). Similar vascular changes in etorphine- 
immobilized rhinoceros may lead to an increased P(A-a)C>2 gradient, as observed 
in my study animals, due to hydrostatic fluid shifts resulting in pulmonary oedema 
or decreased pulmonary vascular red blood cell transit times, thereby reducing 
respiratory gas transfers. Further investigations are required to confirm the 
increased P(A-a)C>2 gradient in opioid-immobilized rhinoceros and determine the 
underlying cardiopulmonary physiological anomalies.
Apart from an increase in P(A-a)02 gradient and metabolic oxygen consumption 
in immobilized rhinoceros, our results indicate that the respiratory system’s ability 
to respond to hypoxaemia and hypercapnia was inhibited. Initial PaC>2 (25 mm 
Hg) and PaCC>2 (76 mm Hg) values did not change significantly over the 
immobilization period in rhinoceros that only received etorphine and no 
butorphanol, although ventilation declined (Chapter 3). This result was 
unexpected as hypoxaemia and hypercapnia are drivers of increased respiration
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(Pattinson 2008). There was also a 40% decline in oxygen consumption 
associated with a reduction in muscle tremoring by the end of the immobilization 
period. Assuming no other compensatory changes in respiratory function, this 
decrease in oxygen consumption should have resulted in an increase in PaOj; 
however this increase was not observed. A possible explanation is that etorphine 
reduces chemosensory neuron and chemoreceptor excitability, and lowered the 
threshold at which hypoxaemia stimulates ventilation (Yaksh & Wallace 2011) to 
about 25 mm Hg. The normal threshold for rhinoceros at rest is unknown, but in 
humans, it is approximately 55 mm Hg (Kim et al. 2008). We propose that as 
oxygen consumption decreased over time, a PaC>2 value above 25 mm Hg would 
be associated with an etorphine-induced reduced hypoxic respiratory drive. With 
reduced stimulus, there would be a decrease in ventilation, as we observed, and 
arterial oxygen tension would remain static. Similarly, a PaCCb value above 70 
mm Hg would not increase ventilation due to opioid chemoreceptor blockade. 
Opioids have been shown to block central chemosensitivity to hypercapnia and 
hypoxaemia (Koo & Eikermann 2011). Likewise, the response of peripheral 
carotid chemoreceptors to hypoxaemia, and possibly hypercapnia, would also be 
suppressed by opioids (McDonald & Lambert 2005; Pattinson 2008).
My results in chapter 2 & 3, suggest that azaperone causes limited respiratory 
effects when combined with etorphine to immobilize white rhinoceros. The PaCh 
and PaCCL in rhinoceros immobilized with etorphine or etorphine plus azaperone 
(prior to the administration of butorphanol) were very similar. Respiratory effects 
of azaperone are equivocal; increased and decreased respiratory rate in horses, 
improved ventilation in domestic animals and humans, and inhibition of opioid- 
induced respiratory depression have been reported (Lees & Serrano 1976; 
Radcliffe et al. 2000; Serrano & Lees 1976). It is possible that variable azaperone- 
associated respiratory outcomes are due to the distribution of dopamine receptor 
sub-types in respiratory regulatory structures, both centrally and peripherally 
(Lalley 2008; Tsuchiya et al. 2011). Azaperone binding at receptor types other 
than dopamine may also modulate respiration (Ahmed et al. 1980; Armtjo & 
Florez 1974; Fryer & Jacoby 1998; Lemke 2007; Olson et al. 1979). Predicting
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respiratory effects of azaperone in immobilized rhinoceros is further complicated 
by concurrent potent opioid respiratory influences. Additional studies are required 
to further investigate azaperone’s respiratory effects in opioid-immobilized 
rhinoceros. Blood gases should be compared between etorphine and etorphine and 
azaperone immobilized-rhinoceros and the pathophysiology of differences 
investigated.
One drug that is increasingly being used in immobilized rhinoceros to purportedly 
improve ventilation is butorphanol. However, the reported effects on ventilation, 
reflected by changes in blood gas values, are variable and contradictory 
(Boardman et al. 2014; Haw et al. 2014; Miller et al. 2013; Wenger et al. 2007). 
These inconsistent findings were the impetus for my study to further investigate 
the cardiorespiratory effects of butorphanol.
In the study described in chapter 2, butorphanol (at 10 times the etorphine dose) 
administered IV to white rhinoceros immobilized with etorphine and azaperone 
resulted in improvements in PaCT and SaOo, and no change to PaC02, at 10 and 
20 min after administration. There were also improvements in the A-a gradient 
and arterial pH, and a decrease in respiratory rate. Despite the improvement in 
blood gases, the rhinoceros remained hypoxaemic and hypercapnic for the 
remainder of the 100 minute immobilization period. These results suggest that 
although butorphanol improved blood oxygenation, it was not due to improved 
ventilation as elevated arterial carbon dioxide levels remained unchanged. One of 
the explanations we proposed for improved oxygen values was a decrease in 
oxygen consumption which resulted in a relative improvement in Pa02. A 
decrease in the initial moderate acidosis over time due to increases in base excess 
and bicarbonate ions, and a decrease in lactic acid, further supports our hypothesis 
that the changes in blood gases were influenced by metabolic changes. We also 
noted anecdotally in this study that muscle trembling and limb movements in the 
immobilized rhinoceros decreased following butorphanol administration, which 
may be associated with a change in metabolism. The design of this initial 
observational study, compared to the later randomized cross-over study, prevented
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rigorous evaluation of butorphanol effects. However, the results highlighted the 
importance of further studies to investigate the causes of hypoxaemia and 
hypercapnia, and pathophysiological changes after butorphanol administration. 
The results also demonstrated that healthy white rhinoceros immobilized with 
etorphine and azaperone and administered a single dose of butorphanol, can 
tolerate prolonged periods of hypoxaemia and hypercapnia. This finding has had 
significant clinical consequences in managing free-ranging rhinoceros as it allows 
for prolonged immobilization and procedures not thought possible prior to this 
study.
In order to confirm that the blood gas changes observed in the initial study were a 
result of butorphanol administration and to elucidate the physiological 
mechanisms underlying these changes, we performed a cross-over study (chapter 
3). We compared two interventions, etorphine-immobilization with post-induction 
butorphanol administration or etorphine with no butorphanol treatment, allowing 
us to rigorously evaluate butorphanol effects. Our results showed that 
butorphanol, administered IV, resulted in rapid, although limited, improvements 
in the markedly depressed oxygen and elevated carbon dioxide arterial tensions. 
However, rhinoceros remained hypoxaemic and hypercapnic over the entire 
immobilization period. Expired minute ventilation improved transiently for three 
minutes following butorphanol administration, then for the remainder of the study 
period, it was not significantly different from that in the rhinoceros that did not 
receive butorphanol. These findings support the hypothesis that butorphanol does 
not consistently change ventilation in etorphine-immobilized white rhinoceros. 
Other measured respiratory parameters, including P(A-a)02, were also not 
modified by butorphanol administration. However, butorphanol did result in a 
rapid decrease in muscle tremor scores. A significant inverse correlation between 
Pa02 and V02, a positive correlation between PaC02 and VCO2, and significant 
associations of both Vo2 and Vco2 with muscle tremor scores support the theory 
that improvements in PaCT and PaCC>2 values were due to a reduction in 
metabolic activity.
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Respiratory function depression is a significant adverse outcome in etorphine- 
immobilized white rhinoceroses and it has been proposed that butorphanol may 
limit this side-effect. Butorphanol has varied opioid receptor activities, including 
being an antagonist at MOR and agonist at KOR. It has been suggested that 
administration of butorphanol would limit etorphine-associated respiratory 
depression at MOR2 without significantly reversing opioid-induced sedation in 
immobilized rhinoceros (McCrackin et al. 1994; Wenger et al. 2007; Yaksh & 
Wallace 2011). Anecdotal evidence from my own unpublished clinical work 
supports this hypothesis. However, variable respiratory outcomes have been 
reported in immobilized rhinoceros administered butorphanol (Boardman et al. 
2014; Haw et al. 2014; Haw et al. 2015; Miller et al. 2013; Van Zijll Langhout et 
al. 2016; Wenger et al. 2007). These different outcomes may arise from 
differences in immobilizing drug combinations, different butorphanol dosages, 
routes and times of administration, use of captive or free-ranging study animals, 
and results based on cross-over or observational studies (Boardman et al. 2014; 
Haw et al. 2014; Haw et al. 2015; Miller et al. 2013; Van Zijll Langhout et al. 
2016; Wenger et al. 2007). In studies by Wenger et al. (2007) and Miller et al. 
(2013), butorphanol was added to the immobilizing drug combination 
administered to free-ranging rhinoceros located and darted using a helicopter. 
Wenger et al. (2007) concluded that inclusion of butorphanol in the dart did not 
result in any observed respiratory benefits. The lack of effects may be explained 
by an inadequate butorphanol dose or the inclusion of detomidine as well as 
azaperone in etorphine-immobilizing combinations. Miller et al. (2013) reported 
that 78% of the rhinoceros receiving butorphanol in the dart remained standing 
and had higher Pa02 and lower PaC02 compared to recumbent animals. This 
result suggests that butorphanol had an indirect respiratory benefit as immobilized 
rhinoceros tended to remain on their feet, a position which favours respiratory 
function compared to lateral recumbency (Morkel et al. 2010). However, results 
from this study did not support the hypothesis that the respiratory inhibitory 
effects of etorphine were antagonized by butorphanol at the opioid receptor level 
(Miller et al. 2013). Moreover, both of these studies were observational which 
limits the conclusion that can be made about individual drug effects (Miller et al.
1 0 2
2013; Wenger et al. 2007). In addition, drug dosages based on estimated body 
masses, variable drug delivery depending on the anatomical site and angle at 
which the dart struck the rhinoceros, gender differences including pregnancy 
status, and subjective distance estimates of distances traveled by a rhinoceros 
prior to and after darting may have affected results in these studies. The extent 
and variability of the adrenergic stress-response in rhinoceros associated with 
helicopter-darting, and how this response might influence drug effects and 
respiration were also not evaluated. These factors are all potential confounders, 
impacting results of field studies involving free-ranging rhinoceros located and 
darted using a helicopter.
As a result of the influence of multiple variables associated with field- 
immobilization, discussed above, it is difficult to definitively compare 
butorphanol-linked respiratory effects between studies. Two projects have 
reported arterial blood gas values prior to and following intravenous butorphanol 
administration in rhinoceros immobilized with etorphine plus azaperone 
(Boardman et al. 2014; Miller et al. 2013). Miller et al. (2013) found decreased 
PaCC>2 and no change in Pa02 and suggested that these blood gas changes were 
linked to butorphanol-induced muscle relaxation. In contrast, findings of 
decreased PaCCb with increased PaC>2 supports the hypothesis that butorphanol 
antagonizes etorphine-induced ventilation depression in immobilized rhinoceros 
(Boardman et al. 2014).
My observational study results, described in chapter 2, in etorphine-azaperone 
immobilized boma-adapted rhinoceros administered butorphanol post-induction, 
suggested ventilation did not improve, since there was no change in PaC02, 
although PaC>2 increased. However, in a cross-over study performed in a similar 
controlled environment, the findings supported the improved ventilation 
hypothesis (Haw et al. 2014). It is difficult to explain why these two trials 
conducted under similar circumstances gave conflicting results. The different 
outcomes may be due to differences in age, gender and body mass between 
rhinoceros in my study compared to Haw et al. (2014). The dose of IV
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butorphanol also differed between the two studies (15 times etorphine dose for 
Haw et al. (2014) and 10 times in my study). The differences in study outcomes 
highlight the influence that variation in study design and implementation 
methodology can have on interpreting effects of butorphanol administration on 
changes in ventilation or metabolic activity in immobilized rhinoceros.
In order to assess both respiratory and metabolic effects of butorphanol, we 
evaluated respiratory function and muscular activity in etorphine-immobilized 
boma-adapted rhinoceros. Azaperone was not included as an immobilizing drug 
as this eliminated another variable when investigating the interaction of the 
opioids. The study design incorporated the measurement of expired minute 
ventilation, mixed-expired and end-tidal carbon dioxide pressures, and expired 
and end-tidal oxygen fractions; it is the first time these variables had been 
measured in immobilized white rhinoceros. Using these parameters, we were able 
to calculate oxygen consumption as a measure of metabolic activity. Muscle 
tremoring, especially of limbs, was also scored as an indicator of activity. The 
results of this study supported the hypothesis that butorphanol increases PaCT and 
decreases PaCC>2 in immobilized rhinoceros through reducing metabolic oxygen 
consumption and carbon dioxide production. My findings also showed that 
rhinoceros remain severely hypoxaemic and hypercapnic, even though oxygen 
and carbon dioxide blood gas values were improved after butorphanol 
administration.
Oxygen insufflation in carfentanil-xylazine immobilized elk {Cervus Canadensis 
manitobensis) increased Pa02 and reduced body and limb rigidity, suggesting that 
hypoxaemia contributed to muscle rigidity (Paterson, Caulkett & Woodbury 
2009).These results support an alternative explanation for the improved blood 
gases and decrease in muscle tremoring observed in the etorphine-immobilized 
rhinoceros following butorphanol administration. The decrease in muscle activity 
may have been the result of an increase in arterial oxygen tension. Although, the 
rhinoceros did not receive supplementary oxygen as did the elk, there was an 
initial improvement in PaC>2 associated with a temporary increase in ventilation
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immediately after the IV butorphanol was given. It is possible the acute increase 
in PaC>2 initiated a decrease in hypoxaemia-induced muscle tremors, which may 
have reduced oxygen consumption and carbon dioxide production.
In summary, my results support the concept that beneficial respiratory effects 
from butorphanol administration in etorphine-immobilized rhinoceros arise 
predominantly from a reduction in metabolic demands, not improvements in 
ventilation. These findings also offer an alternative explanation for blood gas 
changes reported by Haw et al. (2014) and Boardman et al. (2014) which were 
attributed to ventilation improvements. In my study, butorphanol IV resulted in an 
increase in PaC>2 and decrease in PaCC>2 due to an alteration in metabolism; 
however, these changes in both oxygen and carbon dioxide tensions mimic those 
associate with improved ventilation (West 2008).
Based on my findings, it is suggested that IV butorphanol administration 
improves the risk-profile and reduces the mortality potential associated with 
rhinoceros immobilization using opioids. Young healthy rhinoceros, as discussed 
above, appear to tolerate severe hypoxaemia and hypercapnia. However, 
butorphanol-associated improvements in arterial oxygen and carbon dioxide are 
expected to reduce the risk of immobilization-associated deaths, especially in 
compromised individuals. Although butorphanol does not return blood gas values 
to normal levels, it does increase PaC>2 by limiting skeletal muscle oxygen 
consumption, which makes more blood oxygen available for essential organ 
functions such as those in the brain and heart. Studies by Haw et al. (2014,2015) 
indicated that the risks can be further reduced by intranasal oxygen insufflation in 
immobilized-rhinoceros following a single dose of butorphanol IV.
Supplementary oxygen improves PaC>2 but does not influence PaCC>2, which 
continued to climb over time in the immobilized rhinoceros and potentially 
resulted in a worsening acidaemia. This risk may be higher in immobilized free- 
ranging rhinoceros which develop an initial metabolic acidosis due to 
physiological and psychological stress associated with dart-delivery from a 
helicopter (Haw et al. 2015).
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Haw et al. (2014), reported unchanged low PaC>2 values over a 20 minute study 
period in etorphine-immobilized rhinoceros (no butorphanol was administered) 
under almost identical research conditions compared to my study. These authors 
also reported that critically low PaCK values did not improve with intranasal 
supplementary oxygen administration. This finding was unexpected as earlier 
reports indicated that tracheal oxygen insufflation in immobilized rhinoceros 
improved arterial oxygen tensions (Bush et al. 2004). Although ventilation was 
not measured (Haw et al. 2014), respiratory rates did decline in those immobilized 
rhinoceros administered oxygen. Proposed reasons for the adverse oxygen 
supplementation response included alveolar denitrogenation absorption 
atelectasis, intra-pulmonary shunt fractions caused by abdominal organ pressure 
on the lungs, and hypercapnia-induced central respiratory depression (Haw et al. 
2014). My findings suggest an alternative explanation; supplementary oxygen 
may temporarily increase PaC>2 to above the decreased hypoxic threshold which 
was stimulating respiration, thereby removing the hypoxic ventilator drive. This 
effect would result in reduced respiratory minute ventilation associated with the 
decreased respiratory rate similar to what has been found in humans (Niesters et 
al. 2013).
5.2 Cardiovascular effects in etorphine-immobilized white rhinoceros and the 
impact of post-induction butorphanol administration
There is a paucity of information on the cardiovascular effects of etorphine 
administered on its own or with azaperone in immobilized rhinoceros. Therefore, 
we assessed these effects by measuring heart rate and arterial blood pressures in 
animals that had been given etorphine only and those administered etorphine with 
azaperone (Chapter 4). Rhinoceros immobilized with etorphine were initially 
tachycardic and hypertensive. The underlying mechanisms resulting in these 
outcomes were not investigated but a sympathetic pressor effect due to opioid- 
induced hypoxia or a direct stimulation of myocardial opioid receptors was 
proposed as the potential cause. Unexpectedly, during the immobilization period, 
blood pressures decreased to values observed in rhinoceros standing at rest,
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although heart rate did not change significantly. A possible reason for heart rate 
not changing was a requirement to maintain cardiac output and arterial pressure 
due to a reduction in stroke volume and, or, total peripheral resistance. Rhinoceros 
immobilized with etorphine and azaperone had lower blood pressures than those 
in individuals administered only etorphine, and compared to standing awake 
rhinoceros. Heart rates, which were slower than those in etorphine-immobilized 
rhinoceros, were still considered tachycardic. We proposed that the arteriole ai- 
blocking effect of azaperone may have countered etorphine-induced hypertension 
by preventing vasoconstriction and reducing peripheral resistance. We also 
suggested that the tachycardia was a baroreceptor response initiated by the lower 
blood pressure, sympathomimetic effects of etorphine, hypoxia, a direct 
myocardial opioid effect, or a combination of these factors.
My results, showing increased blood pressure and heart rate in etorphine- 
immobilized rhinoceros confirm earlier reports of etorphine-associated 
tachycardia and hypertension in captive rhinoceros, and tachycardia in wild- 
caught individuals (Heard et al. 1992; Kock et al. 1995; LeBlanc el al. 1987). The 
pathophysiological mechanisms resulting in these cardiovascular changes in 
rhinoceroses are unknown. Etorphine-induced circulatory system alterations vary 
between species; however, in perissodactyls (which include white rhinoceros), 
increased cardiac output, total peripheral resistance, and arterial blood pressure 
are consistent findings (Haigh 1982; Haigh 1990; Heard et al. 1992; Lees & 
Hillidge 1975). Proposed explanations for these cardiovascular outcomes include 
increased sympathetic activity and a response to opioid-induced hypoxaemia and 
hypercapnia (Heard et al. 1992; Kock et al. 1995; LeBlanc et al. 1987). Severe 
hypoxaemia and hypercapnia, commonly found in immobilized rhinoceros, may 
activate peripheral and possibly central chemoreceptors, increasing sympathetic 
heart and blood vessel stimulation, leading to a sympathetic chemoreflex (i.e., 
increased heart rate and blood pressure) (Guyenet 2006). It has been suggested 
that hypertension in carfentanil-xylazine immobilized bongo (Tragelaphus 
eurycerus isaaci) was as a result of increased blood nor-adrenalin concentrations 
caused by hypercapnia (Schumacher, Citino & Dawson 1997).
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Etorphine may also have direct inotropic and chronotropic effects, depending on 
distribution of opioid receptor types within the rhinoceros myocardium (Headrick 
et al. 2012; Pugsley 2002, 2004; Yaksh & Wallace 2011). Additionally, etorphine 
may interact directly with myocardial cells and blood vessel smooth muscle, 
especially at higher doses, influencing ion-channel function and depolarization of 
these cells (Pugsley 2002, 2004). Opioid receptors within the sympathetic and 
parasympathetic nervous systems may also influence cardiovascular function 
(Feuerstein & Siren 1987). In rats, MOR and DOR-specific agonists increase 
heart rate and blood pressure, most likely due to activation of the 
sympathoadrenamedullary axis (Feuerstein & Siren 1987). Heart rate may also 
increase due to inhibition of vagal activity and baroreflex-mediated bradycardia, 
associated with either central or peripheral opioid effects (Headrick et al. 2012). 
Central MOR activation in rats has been shown to reduce baroreceptor control 
(Gordon 1986; Gordon 1990). Cardiovascular functions may also be changed by 
central opioid effects in immobilized rhinoceros; however, it is difficult to provide 
more definitive clarification since study results can be influenced by species, 
opioid type and site of administration (Feuerstein 1985; Feuerstein & Siren 1987).
Moderation of blood pressure by azaperone in etorphine-immobilized 
megaherbivores is thought to be due to blocking at peripheral vascular cti- 
receptors (Burroughs et al. 2012a). In horses, azaperone resulted in a decrease in 
total peripheral resistance and mean arterial blood pressure for up to four hours 
(Lees & Serrano 1976; Serrano & Lees 1976). However, azaperone also has 
antagonist activity at multiple additional receptors, including D r  and D2-like, 5- 
HT-, M3- and Hi-receptors, which may influence cardiovascular outcomes, 
although our understanding of these effects is limited, especially in the presence 
of etorphine (Lemke 2007; Missale et al. 1998). Both D|- and D2-like receptors 
occur in the epicardium, myocardium, and endocardium of the human heart and 
exogenous dopamine administration increases cardiac contractility (Cavallotti et 
al. 2010; Pivonello et al. 2007). 5-HT-cardiomyocyte receptor activation has 
positive chronotropic and inotropic effects, and stimulation of blood vessel
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receptors can result in either vasoconstriction or vasodilation, depending on the 
species (Ni & Watts 2006). Activation of Hr  and Ho-receptors results in 
vasoconstriction and vasodilation, respectively (Ebeigbe & Talabi, 2014). 
Stimulation of these histamine receptors in the heart can result in positive 
inotropic and chronotropic effects (Krzan 1996). Therefore, the observed 
cardiovascular effects of azaperone are the outcome of complex interactions with 
multiple receptors.
My results in chapter 4 show that tachycardia in rhinoceros immobilized with 
etorphine only and etorphine plus azaperone was reduced following 
administration of butorphanol IV. Butorphanol also reduced arterial blood 
pressures; however azaperone in the darting drug combination appeared to have a 
greater anti-etorphine-induced-hypertensive effect than did butorphanol in 
etorphine-immobilized rhinoceros. When butorphanol was administered to 
rhinoceros immobilized with etorphine plus azaperone. it did not significantly 
change arterial blood pressures, which were already lower than those in standing 
conscious rhinoceros. The cardiovascular effects attributed to butorphanol, 
observed in rhinoceros immobilized with etorphine plus azaperone, suggest that 
blood pressure was maintained by increased cardiac output rather than increased 
total peripheral resistance, since peripheral vasoconstriction is inhibited by the ap  
antagonist effects of azaperone. A number of scenarios can be proposed to explain 
the heart rate reduction following post-induction butorphanol administration. 
These include a baroreceptor response to increased cardiac output, decreased 
sympathetic response due to partial antagonism of etorphine effects, or an 
improvement in arterial oxygen tension associated with butorphanol 
administration.
My findings showed that hypertension was reduced by azaperone and tachycardia 
by butorphanol in etorphine-immobilized white rhinoceros. These findings are 
consistent with various reports of the cardiovascular effects following butorphanol 
administration in immobilized free-ranging rhinoceros, including a significant 
reduction in tachycardia and a lowering of blood pressure (Boardman et al. 2014;
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Haw et al. 2015; Miller et al. 2013). However, my studies represent the first time 
that the cardiovascular effects of azaperone and butorphanol have been examined 
independently and in combination in etorphine-immobilized rhinoceros.
5.3 Clinical implications of findings
My research suggests that opioid-immobilized rhinoceros experience life- 
threatening side-effects, associated with low PaC>2 (25 to 31 mm Hg) and high 
PaCCT (65 to 76 mm Hg). Hypoxaemia in anaesthetized animals, with values less 
than 60 mm Hg, usually requires supportive interventions, and a hypercapnia 
greater than 70 mm Hg results in respiratory acidosis which can depress 
myocardial and CNS functions (Haw et al. 2014; Moens 2013; Read 2003). The 
young healthy rhinoceros used in our studies did not apparently experience short 
or long-term organ damage due to extremely low oxygen and high carbon dioxide 
arterial tensions resulting from immobilization. The reasons for these outcomes 
are unknown and may be related to the high oxygen affinity of rhinoceros 
haemoglobin and a lower tissue metabolic rate compared to smaller mammals 
(Baumann, Mazur & Braunitzer 1984; Heard et al. 1992). The degree to which 
rhinoceros can modulate neural breathing control may also play an essential role 
in individuals adapting to acute severe hypoxaemia and hypercapnia associated 
with opioid immobilization (Mitchell & Johnson 2003). Modulation of respiratory 
control is defined by Mitchell & Johnson (2003) as “neurochemically induced 
alteration in synaptic strength or cellular properties, adjusting or even 
transforming neural network function”. My study animals were healthy sub-adult 
rhinoceros, a demographic which may have aided in compensating for severe 
physiological stresses, reducing potential negative outcomes. However, 
mortalities in rhinoceros due to immobilization have been reported (Kock et al. 
1995), and, in my clinical experience, deaths can occur in immobilized free- 
ranging rhinoceros that do not receive adequate cardiorespiratory support and are 
compromised due to severe infections, poor nutritional status or advanced age.
Future studies should investigate the possibility of sub-clinical organ damage 
induced by hypoxaemia and, or, hypercapnia in immobilized rhinoceros. A
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cardiac-specific troponin isoform (cTnl) is used in the detection of myocardial 
injury in humans (Babulin & Jaffe 2005). Central spinal fluid brain-specific 
creatine kinase isoenzyme and neuron-specific enolase are useful prognostic 
indicators of hypoxic brain injury (Karkela, Bock & Kaukinen 1993). Serum 
creatine kinase isoenzyme (CK-MB and CK-MM) concentrations provide a 
measure of cardiac and, or, skeletal muscle injury (Apple 1999).
As a consequence of high morbidity rates from hypoxaemia and hypercapnia, and 
potential for mortalities, respiratory support interventions are required for opioid- 
immobilized free-ranging white rhinoceros. Providing intranasal supplementary 
oxygen has been proposed as a potential support strategy. However, giving 
additional oxygen can further compound high carbon dioxide blood levels without 
improving blood oxygenation in immobilized rhinoceros, unless an intravenous 
dose of butorphanol is administered prior to commencing insufflation (Haw et al. 
2014). A combination of butorphanol, followed by oxygen administered 
intranasally, corrected hypoxia in immobilized rhinoceros, although the animals 
remained hypercapnic. The physiological changes induced by butorphanol which 
facilitated the increase in PaC>2 are not known and further studies are required to 
elucidate these. Bush et al. (2004) also advocated nasal tracheal insufflation as a 
means of improving safety for field-immobilized rhinoceros. They found that the 
technique improved PaC>2 and SaC>2 without changing PaCC>2. These results 
appear contradictory to those reported by Haw et al. (2014) since butorphanol was 
not administered to the rhinoceros. However, nalorphine (mixed opioid agonist- 
antagonist (Swan 1993)) and, or, doxapram (nonspecific respiratory stimulant 
(Swan 1993)) were given prior to or in conjunction with the supplementary 
oxygen. The outcomes of this study suggest that nalorphine and, or, doxapram 
may also facilitate an increase in PaC>2 during oxygen insufflation. As the study 
design used by Bush et al. (2004) was observational, it is not possible to confirm 
this recommendation based on the results provided.
My study in etorphine-azaperone-immobilized rhinoceros confirmed that young 
healthy rhinoceros can be kept safely immobilized for up to 100 min following a
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single butorphanol IV dose (chapter 2). Prior to my study, the duration of white 
rhinoceros immobilization has been kept to a minimum to limit potential adverse 
effects associated with depressed respiratory function (Burroughs et al. 2012b). 
My results and subsequent clinical experience indicate that rhinoceros can be kept 
immobilized for extended periods to facilitate prolonged procedures including 
surgical treatment of snaring or bullet injuries resulting from poaching. Orphaned 
white rhinoceros calves immobilized with etorphine plus azaperone and 
administered a single butorphanol IV dose (5 to 10 times etorphine dose) have 
been safely airlifted for up to 50 min suspended by their feet under a helicopter. 
Free-ranging rhinoceros calves orphaned as a result of poaching also can now be 
recovered and stabilized with intravenous fluids administered for up to three hours 
using this immobilization regime.
My results have shown that muscle tremoring and limb shaking in etorphine- 
immobilized rhinoceros decreased rapidly (within three minutes) after 
butorphanol IV administration and was associated with an increase in PaC>2 and 
decrease in PaCCL (chapter 3). This observable change in muscle activity provides 
a mechanism by which butorphanol effects can be easily evaluated by a clinician. 
In immobilized wild-caught rhinoceros, it is costly and not always logistically 
practical to routinely monitor blood gases, and the value of using pulse oximetry, 
capnography, and other measures of blood gas levels still need to be validated in 
immobilized rhinoceros. The results from this study suggest an alternative indirect 
and subjective measure. Assessing the decrease in muscle tremoring following 
butorphanol IV administration may provide a measure of the improvements in 
arterial blood gases
The persistent tachycardia in rhinoceros immobilized with etorphine or etorphine 
plus azaperone raises concerns of possible hypoxic cardiac failure (chapter 4). As 
heart rate increases, there is a linear increase in myocardial oxygen consumption 
per beat and per minute (Boerth et al. 1969). There may also be a reduction in 
myocardial perfusion as heart rate increases (Mosley & Gunkel, 2007). Low 
arterial oxygen partial pressures are well documented in immobilized rhinoceros
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(Buss et a/. 2015). A combination of these factors may result in insufficient 
oxygen delivery to the myocardium to support aerobic ATP production required 
for contraction. In my study animals, there was no evidence of cardiac failure 
caused by hypoxia, although this may be due to limited cardiac functional 
assessment. However, the risk of cardiac failure may increase in rhinoceros 
compromised due to age, disease or poor nutrition. The potential for myocardial 
hypoxia also supports the administration of supplementary oxygen in immobilized 
rhinoceros as advocated by Haw et al. (2014 & 2015).
The decrease in heart rate following butorphanol administration provides a 
clinical measure of effect of this drug under field conditions. Since the dose of 
etorphine used to immobilize free-ranging rhinoceros is usually based on a 
combination of estimated body size and age, this estimate can result in significant 
variations in drug responses. Administering butorphanol to effect by monitoring 
the decrease in heart rate may permit tailoring of the dose for individual 
cardiovascular responses in etorphine-immobilized rhinoceros.
A word of caution: butorphanol administration in etorphine-immobilized 
rhinoceros results in an initial improvement in ventilation due to an increase in 
respiratory rate; however, this change in ventilation is transient and within a few 
minutes returns to pre-butorphanol levels. Therefore, to the casual observer, it 
may appear that butorphanol administration improves respiration; however, 
ventilation remains unchanged or progressively declines overtime. Butorphanol 
also reduces the depth of immobilization in rhinoceros and an excess dose or 
incorrectly titrated doses may result in an animal becoming insufficiently 
immobilized and dangerous to personnel handling them.
5.4 Project limitations
As a consequence of the logistical challenges and welfare considerations 
associated with my research, small numbers of animals were used in each study. 
The small sample size likely results in greater variability in measured parameters 
which can influence detection of clinically important physiological changes using
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statistical analyses. However, the use of a randomized crossover study design 
limited the influence of physiological variability between the individual 
rhinoceros and the outcome of comparisons between different drug combinations.
All of the rhinoceros used for these studies were boma-adapted and maintained 
under captive conditions for the duration of the research project. For the cross­
over study, male rhinoceros of similar age and body mass were the study subjects. 
All animals were healthy and in apparently optimal body condition. Therefore, 
the impact of age, gender, nutritional status, and concurrent disease could not be 
evaluated. However, we suspect that the severe physiological changes observed in 
these healthy animals may lead to greater complications, and increase the risk of 
morbidity and mortality in compromised white rhinoceros.
In my studies, rhinoceros conditioned to captivity were used to limit the influence 
of potential confounders associated with immobilizing free-ranging animals. 
Rhinoceros captured in the field are typically approached and darted from a 
helicopter, which can influence arterial blood pressures, heart rate and metabolism 
as a result of increased physical exertion and an adrenergic stress response 
(Radcliffe & Morkel 2007). Age, body mass, and health status, which are usually 
unknown prior to darting in free-ranging rhinoceros, also influence 
cardiorespiratory responses to immobilizing drugs. Field drug dosages are based 
on an estimated body mass, and may vary significantly based on operator 
experience. All of these factors influence cardiorespiratory responses to drugs, 
limit comparison of results between studies, and understanding of underlying 
physiological mechanisms. Since physiological differences likely exist between 
free-ranging and captive rhinoceros, the results from this research may not be 
translatable to what occurs in field-immobilized white rhinoceros.
Although we were able to evaluate the effect of etorphine, azaperone, and 
butorphanol on blood pressures and heart rate in immobilized rhinoceros, due to 
technical limitations, it was not possible to evaluate changes in stoke volume or 
total peripheral resistance. The determination of cardiac output would allow for
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the calculation of these cardiovascular parameters; however this measurement 
requires insertion of a catheter into the pulmonary artery, which is challenging 
due to the large body size, lack of easily accessible peripheral veins, and 
inadequate length of available catheters for rhinoceros. Inability to determine 
alveolar ventilation, cardiac output, pulmonary artery pressures, shunt fractions 
and ventilation-perfusion ratios, in part, limited a comprehensive understanding of 
physiological mechanisms influencing arterial blood gases and cardiorespiratory 
responses to these drugs.
5.5 Future research directions.
As discussed above, there are numerous factors that may impact physiological 
responses in field compared to boma-confined white rhinoceros. Haw et al. (2015) 
have indicated that respiration rate is higher and PaCC>2 lower in helicopter-darted 
immobilized free-ranging rhinoceros compared to boma-adapted individuals 
darted from foot with equivalent immobilizing-drug dosages. Our study results 
should be compared with those from field studies using similar drug combinations 
and doses. Pathophysiological influences of an increased sympathetic response, 
increased exertion and rise in body temperature associated with helicopter-based 
white rhinoceros immobilization could be evaluated with such studies.
Volumetric capnography should be used in the evaluation of immobilized- 
rhinoceros ventilation in the future. It will allow for the calculation and more 
comprehensive evaluation of respiratory dead space using either Bohr's formula 
or Enghoff s modification. Physiological dead space determination (chapter 3) 
required the collection and evaluation of mixed expired CO2 of exhaled air 
collected in a Douglas bag. Physiological dead space was calculated using the 
Enghoff s modification of Bohr’s formula (Tusman et al. 2012). Although dead 
space was determined relatively easily using this technique, it was not possible to 
determine alveolar deadspace ventilation as airway dead space ventilation was not 
known. Volumetric capnography has the potential to overcome this limitation 
(Tusman et al. 2012). As Enghoff s formula uses PaCCE, it provides an overall 
measure of ventilation/perfusion mismatching and includes both wasted
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ventilation (true dead space with alveoli of high ventilation/perfusion ratios) and 
wasted perfusion (shunt plus alveoli of low ventilation/perfusion ratios) (Tusman 
et al. 2012). Bohr's formula by comparison is considered a measure of wasted 
ventilation. Volume capnography allows for direct alveoli carbon dioxide tension 
determination which is required for Bohr’s dead space calculation (Tusman et al. 
2012).
The pulmonary and systemic circulatory structures are different in that they are 
considered low- and high-pressure systems, respectively. Pulmonary vascular 
resistance is low with little impedance of blood flow, even with increases in 
cardiac output and pulmonary artery pressures, which occurs in exercising 
animals (Robinson 2007). Although systemic arterial pressures were increased in 
my etorphine-immobilized study rhinoceros, pulmonary artery pressure effects are 
unknown and require further investigation. Meyer et al. (2015) have shown that 
etorphine-immobilized goats develop pulmonary hypertension which is thought to 
alter pulmonary gas exchanges as a result of interstitial and possibly alveolar 
oedema. The most likely cause of increased pulmonary hypertension was a 
pulmonary vasoconstriction and an increase in pulmonary vascular resistance 
following etorphine administration (Meyer et al. 2015). The increase in P(A-a)C>2 
gradient observed in my study rhinoceros supports the idea that similar pulmonary 
vascular changes may occur in immobilized rhinoceros and requires further 
investigation.
Azaperone is frequently administered in combination with etorphine as it reduces 
induction time in white rhinoceros (Burroughs et al. 2012b). A number of 
investigators report that azaperone reduces opioid-associated hypertension and 
can result in normotension in immobilized free-ranging rhinoceros (Citino &
Bush 2007; Bush et al. 2004; Hattingh et al. 1994). My study results in chapter 4 
support the idea that azaperone reduces blood pressure in etorphine-immobilized 
rhinoceros. Arterial blood pressures were reduced to values lower than those 
recorded in captive rhinoceros standing at rest. This decrease in systemic blood 
pressure may have significant clinical implications in immobilized-rhinoceros as
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the risk of compromised perfusion of oxygen-depleted dependent limbs in 
recumbent animals is possibly increased. Limited oxygen supply to and metabolic 
waste removal from limb skeletal muscle could result in a rhinoceros having 
difficulty rising from a recumbent to standing position. The capture of free- 
ranging rhinoceros usually involves partial etorphine-effects reversal using a 
mixed opioid agonist-antagonist so that the rhinoceros is able to rise to its feet and 
walk into a crate (Burroughs et al. 2012b). However, I have found that some 
etorphine/azaperone-immobilized white rhinoceros, especially large bulls, have 
difficulty standing due to an apparent proprioceptive deficit and limited weight­
bearing capability of the dependent limbs. Cases have occurred in which 
immobilized rhinoceros are unable to stand on their hindlimbs following 
immobilization, despite the opioid effects being completely antagonized, and have 
subsequently required euthanasia. The importance of blood pressure effects of 
azaperone on limb perfusion in recumbent rhinoceros requires further 
investigation. A recommendation for reducing the azaperone dose in 
immobilization combinations should also be considered.
In my cardiovascular study, butorphanol decreased heart rate in boma-adapted 
rhinoceros immobilized with either etorphine or etorphine and azaperone which 
were initially tachycardic. Similar findings have been reported in free-ranging 
rhinoceros immobilized with etorphine plus azaperone that received butorphanol 
(Boardman et al. 2014; Haw et al. 2015; Miller et al. 2013). These findings 
suggest that etorphine, as the common factor between these various scenarios, is 
responsible for the tachycardia observed in the immobilized rhinoceros. However, 
further studies are required to test this hypothesis under different immobilizing 
conditions and with the inclusion of other drugs such as azaperone.
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CHAPTER 6
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My study results confirmed that the use of etorphine or etorphine with azaperone, 
results in severe hypoxaemia and hypercapnia in immobilized captive white 
rhinoceros. The severity of these abnormal blood gases normally requires 
cardiorespiratory support to prevent mortalities in anaesthetized domestic species. 
However, mortalities or clinically apparent organ damage did not occur in the 
healthy young adult white rhinoceros used in my studies. These results do not 
exclude the possibility of death in compromised rhinoceros or individuals 
immobilized under different circumstances.
Hypoxaemia and hypercapnia in etorphine-immobilized rhinoceros are not a 
consequence of reduced minute ventilation as has been proposed in previous 
studies. My findings suggest the primary cause is an increase in metabolic oxygen 
consumption and carbon dioxide production associated with increased muscle 
tremors. The cause of muscle tremors in immobilized rhinoceros is unknown but 
they likely result from direct or indirect sympathomimetic drug effects. The 
pathophysiology causing an increased calculated alveolar-arterial oxygen gradient 
seems to contribute to hypoxaemia in immobilized rhinoceros; however, the 
significance of and cardiopulmonary pathophysiology influencing the 
development of this gradient require further elucidation. Azaperone appears to 
have limited respiratory effects in immobilized rhinoceros but also requires more 
thorough investigation. Our studies suggest that although a decrease in minute 
ventilation may not be the fundamental cause of hypoxaemia and hypercapnia in 
etorphine-immobilized rhinoceros, low Pa02 and high PaC02 also do not result in 
stimulation of ventilation as etorphine appears to reduce hypoxic and hypercapnic 
drive thresholds by depressing central and peripheral chemoreceptors.
Butorphanol administered post-induction in etorphine-immobilized rhinoceros 
resulted in moderate improvement in blood gases; although, hypoxaemia and 
hypercapnia persisted. My results support the idea that butorphanol reduces 
metabolic oxygen consumption rather than improving ventilation. Although 
hypoxaemia and hypercapnia persist following butorphanol administration, we 
believe its improvement in PaC>2 and availability of oxygen for essential organ
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functions reduces hypoxic mortality risk in immobilized rhinoceros. This risk can 
be further mitigated by provision of intranasal supplementary oxygen (Haw et al. 
2014). My results suggest rhinoceros that receive butorphanol post-induction can 
be kept immobilized for longer periods than was thought possible in the past. An 
increase in immobilization duration has clinical advantages in the treatment of 
injured rhinoceros and management of calves orphaned due to poaching.
Cardiovascular changes in our etorphine-immobilized rhinoceros included 
hypertension and tachycardia. Causes of these opioid-induced cardiovascular 
effects are unknown and may include direct myocardial drug effects, sympathetic 
system activation or a sympathetic chemoreflex due to opioid-induced hypoxia.
A persistent hypertension and tachycardia in etorphine-immobilized rhinoceros 
raises concerns of potential increased cardiac workload and hypoxic cardiac 
failure. The inclusion of azaperone with etorphine in the immobilizing drug 
combination reduced blood pressure to below values for rhinoceros at rest; 
however, heart rate was still significantly elevated. The lower blood pressure in 
these individuals has been attributed by various authors to the ai-blocking effects 
of azaperone. Azaperone is a multi-receptor antagonist and may influence blood 
pressure through activity at a variety of receptors. Low blood pressure associated 
with azaperone in immobilized rhinoceros can result in reduced dependent limb 
perfusion in recumbent animals. This concern should be further investigated and 
an azaperone dose reduction should be considered for the immobilization of 
rhinoceros.
Post-induction butorphanol administered IV reduced tachycardia, with a limited 
reduction in blood pressure in etorphine-immobilized rhinoceros. Butorphanol did 
not influence blood pressures but reduced tachycardia in individuals immobilized 
with etorphine plus azaperone. Determining cardiac output in immobilized 
rhinoceros would allow further investigation of these variable cardiovascular 
results. The reduction in tachycardia suggests butorphanol IV may have a 
myocardial oxygen sparing effect. A reduction in heart rate and limb tremoring in 
immobilized white rhinoceros provide subjective monitoring techniques by which
1 2 0
multiple butorphanol doses can be administered to achieve preferred 
cardiorespiratory outcomes.
My research has significantly advanced the understanding of the 
pathophysiological effects of immobilizing drugs and potential mechanisms that 
cause tachycardia, hypertension, hypoxaemia and hypercapnia in chemically- 
immobilized white rhinoceros. These findings have clinical applications in that 
they can be applied to reduce the morbidity and mortality risks associated with 
white rhinoceros immobilization, especially in compromised individuals. The 
study results also suggest that future research on interventions to counter opioid- 
induced respiratory depression and cardiovascular alterations should focus more 
on improving alveoli gas exchange and reducing the sympathomimetic and 
hypermetabolic effects of the potent opioids, rather than just focusing on 
improving ventilation and blood pressure.
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